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Introduction 
 1
1 Introduction 
 
1.1 General 
 
Small bioactive molecules are of always of great interest for any discovery research, 
be it drug discovery/medicinal chemistry research or a chemical biology/chemical 
genetics investigation [1]. As complementary method to genetic approaches, the use of 
small molecules as highly specific modulators (i.e., inhibitors or activators) of protein 
functions is a powerful approach which is frequently applied e.g. for the study of 
dynamic processes in cells. Due to the irreversible effects of genetic manipulations, 
such biological methods may be of limited use for this purpose [2]. For the success of 
chemical genetics/genomics-based research programs, efficient and rapid access to 
diverse sets of biologically relevant small molecules is mandatory [3]. Combinatorial 
chemistry and compound library synthesis along with developments in both solid- and 
solution-phase organic synthesis have emerged as important technologies to provide 
compound collections in an efficient manner. After an initial phase of development in 
which accessibility and size of compound collections gained a major share of 
attention, the ´quality´ of compound libraries, in particular their resemblance to 
natural products structural features has become the key criterion in design and 
synthesis [4, 5]. Compound collections enriched in diversity, complexity and of 
biological relevance, the inherent characteristics of natural products, generally 
provide hits in biochemical and biological investigations with higher success rate than 
collections designed on the basis of chemical accessibility [6].   
 
In the last six decades, synthetic organic chemistry has witnessed immense 
developments [7-8]. So much that, often the key question today in a target synthesis 
endeavor is not about what molecule to synthesize but how to make it more efficiently. 
However, how to create bioactive molecules remains in the realm of mysterious 
mother nature and chemists have to uncover a lot of truth to understand the natures 
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magic hands [9,10]. Indeed, half of all therapeutic drugs, and an even greater proportion 
of narcotics, are based on natural compounds. However, the concerns for their feeble 
availability from natural resources by extraction and/or by expensive and inefficient 
semi-synthetic or synthetic means were always pushing the chemists especially in 
pharmaceutical industry to find alternatives to these secondary metabolites and 
therefore no surprise that a major decline in NP research has been around since early 
1990s. However, the idea of accessing the large chemical space with combichem 
approaches combined with in silico methods though initially appeared very appealing 
for drug discovery, proved to be a false lead. The large numbers of compounds 
created through these efforts still represent only a fraction of the total number of 
compounds that could theoretically exist (in excess of 1060) and could not provide any 
significant hit and lead structures [11]. This period of 10-15 years also witnessed a 
steady decline in the output of new active substances or NCEs [12]. It was being 
realized that combinatorial and NP chemistry should complement on a synergistic 
form to provide molecules with features of NPs and yet completely synthetic in nature 
[13].  
 
Targeting this synergistic approach to create moelcules resembling natural products, 
chemists had developed synthesis concepts that could enrich a given compound 
collection with biological activities. Diversity oriented synthesis (DOS) and biology 
oriented synthesis (BIOS) have emerged as two guiding principles for the design and 
synthesis of compound collections for chemical biology and medicinal chemistry 
research. Among other less explored strategies include [14, 15] “molecular editing” 
(Danishefsky) [16], “libraries-from-libraries” (Houghten) [17], function-oreineted 
synthesis (FOS) by Wender [18]. 
 
The non-focused nature of the concept Diversity-oriented synthesis (DOS) enables it 
to induce a vast range of physical and consequently biological properties to the library 
members and therefore can be useful to identify novel lead compounds [18-20]. The goal 
of DOS is to discover the novel small molecules with appealing biological properties 
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and spanking new structure [14, 15].  
 
1.2  Diversity Oriented Synthesis 
 
Diversity oriented syntheses (DOS), as the name suggests is an approach to synthesize 
diverse molecular classes including natural products based molecules and spanning 
large areas of unexplored chemical space. To achieve that goal, DOS methods must 
be sufficiently robust and efficient to produce complex and diverse and natural 
product-like compounds combinatorial. DOS approach is therefore different to that of 
target-oriented synthesis (TOS), where often the target is one complex NP and 
chemistry is designed and developed with that focus only. TOS is thus a linear and 
convergent strategy, and follows a planned retrosynthesis which considers the logical 
breaking of complex molecule to the simpler substrates. DOS on the other hand 
targets the collections of structurally complex and diverse molecules from simple 
substrates [21-22]. DOS approach has thus developed a different divergent planning 
strategy termed as forward synthetic analysis. This planning involves and employs the 
complexity generating reactions of the relatively simple and easily accessible 
substrates in the direction of products (Fig. 1-1) [1, 14, 23]. 
 
Figure. 1-1 Comparison of Target Oriented Synthesis and Diversity Oriented Synthesis 
 
In order to gain quantity and quality of molecules by DOS, the molecules generated at 
one point of library synthesis should have functional sites that can be modified to 
yield more diverse structures that show a superior biological activity and selectivity 
characteristic. In this feature, DOS remarkably differs from TOS (Figure 1-2) [1, 14]. 
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While TOS provides just a few analogues of a complex natural product, [1, 14, 24, 25] 
DOS can maximize the structural complexity of every compound and consequently of 
the entire compound library [26, 27]. 
 
DOS synthetic methods are branched and forky; they are schemed as mentioned 
before by using forward-synthetic analysis to design targets [28]. The most significant 
feature of this ‘forward’ synthesis [29] is the ability to propagate the functional and 
skeletal transformations to the next stages of the synthesis to cover large areas of 
chemical space [30]. In the forward-synthetic strategy one target product is transformed 
into a collection of compounds by wide range of possible chemical transformations. 
Thus, in DOS a set of products are transformed into another set of new molecules by 
one common transformation on the common functionalities present in any set of 
molecules [31].  
 
1.3 Generating molecular complexity in DOS 
 
One of the features of NPs that possibly imparts the biological activity to this class of 
molecules in their relatively complex frameworks. Their continuous good record of 
providing hits and that too for difficult biological targets, e.g. to disrupt 
protein–protein interactions [32-33] clearly suggest to induce their structural features to 
compound collections. It is thus an aim of DOS to prepare small molecules with 
complex molecular skeletons and in combination with forward-synthetic strategy to 
generate the compounds from simple to complex molecular scaffolds [1, 14, 34, 35]. The 
structural complexity includes not only the ring- or architectural complexity but an 
overall three-dimensional complexity that includes diverse stereo-chemical properties 
[36-38]. In order to enhance the efficiency of the whole DOS process in yielding diverse 
and complex molecules, the strategy should make the complex building blocks 
quickly (by not more than three to five steps) and if possible, without the use of 
protecting groups. For instance, Shair and co-workers synthesized a DOS based 
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library based on the natural product, galanthamine (Scheme. 1-1) commencing with 
imine formation by reaction of the aldehydes (2) and resin bound amine (1). A 
reductive amination and protecting-group adjustments later yielded 3. Treatment of 
the latter with PhI (OAc)2 afforded 4 which was transformed to 5 via Pd- mediated 
deprotection and spontaneous cyclization. Resin bound 5 was used as a template for 
generation of further diversity and complexity by means of different reactions 
(Scheme. 1-1). Finally cleavage of the products from the solid support yielded a 
galantamine-inspired library of ca. 2500 molecules [39]. 
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Scheme 1-1: Galanthamine based compound library synthesis. 
 
To efficiently generate complex molecules, multi-component, Domino or cascade 
reactions wherein more than one reaction happens consecutively and molecular 
complexity is rapidly built up, have been employed in the DOS processes [1, 14, 40, 41]. 
For instance, Martin and co-workers used the classic Ugi reaction to generate 
collection of complex scaffolds [42-44]. In the Ugi four component reaction (Ugi-4CR) 
each of its four components has the function, which can be used in subsequent 
transformations. Thus it can generate a number of cyclization manifolds. A graph 
showing diversity of some of the post-condensation cyclizations by the U-4CR is 
presented in (Scheme 1-2). 
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Scheme 1-2. An overview of the U-4CR post condensation cyclizations. (a) S. Marcaccini, R. 
Pepino, M. C. Pozo, S. Basurto, M. Garc_a- Valverde, T. Torroba, Tetrahedron Lett. 2004, 45, 
3999 – 4001; (b) T. P. Ribelin, A. S. Judd, I. Akritopoulou-Zanze, R. F. Henry, J. L. Cross, D. N. 
Whittern, S. W. Djuric, Org. Lett. 2007, 9, 5119 – 5122; (c) L. El Kaim, M. Gageat, L. Gaultier, L. 
Grimaud, Synlett 2007, 0500 – 0502; (d) V. Gracias, S. W. Djuric, Tetrahedron Lett. 2004, 45, 
417 – 420; (e) P. Tempest, L. Pettus, V. Gore, C. Hulme, Tetrahedron Lett. 2003, 44, 1947 –1950; 
(f) Z. Ma, Z. Xiang, T. Luo, K. Lu, Z. Xu, J. Chen, Z. Yang, J. Comb. Chem. 2006, 8, 696 – 704; 
(g) K. Paulvannan, Tetrahedron Lett. 1999, 40, 1851 – 1854; (h) I. Akritopoulou-Zanze, A. 
Whitehead, J. E. Waters, R. F. Henry, S. W. Djuric, Org. Lett. 2007, 9, 1299 –1302.—Depicted by 
Martin´s group [34] 
 
1.4 Generating Diversity in DOS (Similar→Diverse) 
 
Structural diversity in a compound collection can be following ways; by a) generating 
diverse scaffolds or skeletons supporting functionalities that could further provide 
skeletal modification; b) incorporating elements of functional group diversity around 
the given cores structures; c) generating different stereoisomers to access different 
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binding patterns with protein targets (stereochemical diversity) [39]. To achieve these 
goals in DOS, the basic element in forward synthetic planning is the transformation of 
a collection of substrates into a collection of products by performing a number of 
common chemical transformations. The key to success in this strategy is the inherent 
reactivity of common sites available in all the substrates which not only transforms all 
of them to the products but also ensures their further possible common 
transformations by generating a new set of common reactive sites. [1, 14, 45]. 
 
1.4.1 Appendages diversity 
 
The most feasible of all diversity generating possibilities is to cause ´Appendage 
diversity´ and is the central diversity-generating process. It involves the use of 
coupling reactions to attach different appendages to a common molecular skeleton. If 
a molecular scaffold has multiple reactive sites with potential for orthogonal 
functionalization, then the split pool synthesis can be used to generate all possible 
combinations of appendages efficiently. This one-synthesis/one-skeleton approach has 
proven to be highly general and capable of generating hundreds, thousands, or even 
millions of distinct small molecules [39, 46].  For example, a complexity-generating, 
consecutive transesterification-cycloaddition sequence was used to generate, in one 
step, the tetracyclic skeleton 26 with potential for functionalization through a series of 
diversity-generating appending processes (Scheme 1-3) [46]. A Songashira coupling 
reaction was then used to append a collection of alkynes to the idolatry moiety of 26 
and generated a collection of more diverse products 27. The common lactones moiety 
27 was transformed to a collection of new amide products 28. Similarly, members of 
this new collection 28 share a common nucleophilic secondary hydroxyl group, thus 
making them all substrates for a third appending process i.e. coupling with a 
collection of carboxylic acid building blocks. This series of products-equals-substrates 
relationships made it possible to generate the complex arrangement of building blocks 
found in 29 in a highly efficient manner by using split pool synthesis. 
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24
25
26 27
28 29  
Scheme 1-3. Appending processes in DOS 
 
1.4.2 Stereochemical diversity 
 
Stereochemical diversity provides diverse possible three dimensional and 
conformationals possibilities of the elements in small molecules that interact with 
macromolecules. The best way to achieve this diversity is through reactions that 
proceed with enantio- or diastereoselectivity and are capable of generating all possible 
isomers in a selective manner. These collective asymmetric transformations of chiral 
substrates into products having enhanced stereochemical diversity require powerful 
reagents that can overcome any substrate bias and yield the highly diastereoselective 
product profiles [39, 47]. There are ample evidence to the fact that altering the relative 
stereochemistry of a given molecule can drastically change its overall shape, and 
consequently its biological profile and these calls for developments in asymmetric 
synthesis providing efficient access to all stereoisomers in a compound collection.  
Some examples of stereochemically diverse library generation are shown in Scheme 
1-4. A novel conformational restriction approach was used by Schreieber and 
co-workers to favor macrocyclization, via strategic placement of ester and amide 
functionalities in a linear precursor. The macrocyclization also provided further 
diversity points for structural modifications (Scheme 1-4, IV) [48].  Panek et al 
synthesized 14-, 16- and 22 member macrodiolides bearing up to six stereogenic 
centers (Scheme 1-4, IV) [49]. Oteras distannoxane transesterification catalysts were 
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employed to effect solution-phase cyclohomodimerization of -hydroxyesters. The 
products were obtained in high yields with limited trimer formation. Again, the 
products could be diversified further using substrate-controlled stereoselective 
reactions. 
 
Verdine and co-workers used the concept of stereochemical variation and acyclic 
stereocontrol to generate non-peptides ligands for peptide receptors (Scheme 1-4. III) 
[50]. Inspired by an endogenous ligand for mu opoid receptor, endomorphin-2 (Scheme 
1-4, III 34) a stereodiverse collection of nonpeptide compounds 35, was generated 
where the N-terminal tripeptide unit of 34 has been replaced by a nonpeptidic, 
stereodiverse unit incorporating a 1,5-enediol moiety. The dense array of 
stereocenters combined with the rigidifying olefin in 35 was intended to generate 
geometric diversity. 
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Scheme 1-4: Stereochemically diverse compound collections 
 
1.4.3 Skeletal diversity 
 
DOS pathways that yield collections of products with many distinct molecular 
frameworks are particularly effective at achieving a diverse display of chemical 
functionality in three dimensional spaces. There are, at present, two different 
strategies for planning DOS pathways that generate skeletal diversity. The first 
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strategy involves using different reagents to transform a common substrate with the 
potential for diverse reactivity into a collection of products having distinct molecular 
skeletons (Figure 1-3). [1, 14, 51-56]. 
Substrate-based approach / folding process 
 
Reagent-based approach / branching pathway 
 
Figure 1-3. Two general approaches for planning synthesis pathways that generate skeletal 
diversity [42]. 
 
a) The first approach is termed as ‘folding pathway’ and  uses a common set of 
reaction conditions to transform a range of substrates into products with distinct and 
diverse molecular skeletons (Figure. 1-3). The substrates are encoded to ‘fold’ into the 
alternative scaffolds through strategically embodied functionalities, known as 
‘-elements’. Each -element thus dictates the formation of diverse molecular 
framework.  order to achieve the skeletal diversity efficiently and yielding wide 
range of distinct scaffolds, different precursors has been proposed to be explored for 
this cause, for instance, (1) the use of pluripotent functionality; (2) use of densely 
functionalized molecules and (3) the use of folding processes [1, 14, 45].  
 
Exploring the radical cyclizations Panek and Porco designed a folding approach to 
generate skeletal diversity (Scheme. 1-5) employing a set of tetrahydropyridines as 
substrates [50]. The skeletons of the products 41-43 were pre-encoded in the substrates 
38-40 by the location of the radical-initiating sites and the unsaturated groups. The 
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folding processes were triggered by treatment of the tetrahydropyridines 38-40 with 
tributyltin hydride and a substoichiometric amount of AIBN at 80°C. The bromine 
atom on the phenyl group was strategically placed in substrates in order to generate 
the site-specific radical and consequently selective cyclization reaction to yield a 
range of distinct polycyclic alkaloid like frameworks. 
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Scheme 1-5: Folding Pathways in DOS 
 
Schreiber´s group has developed a folding pathway by using multiple modes of 
intermolecular reactions in a systematic fashion to generate the indole alkaloid-like 
skeletons, which have elaborate substrates and a versatile scaffold (Scheme 1-6) [57]. 
A mode C→A reaction sequence using Schreiber’s general protocol possessed 
R-diazoketocarbonyl and indole groups at sites C and A [58], respectively start with the 
installation of the alkyl linker on site B, via C-alkylation producing ester to be 
activate, the α-ketoester is installed on site C by a coupling reaction with a 
magnesium enolate [59]. Treatment of the R-diazo ketoester with a catalytic amount of 
rhodium(II) octanoate dimer in benzene at 80 °C results in the formation of a 
presumed carbonyl ylide intermediate that undergoes cycloaddition to afford 
hexacyclic 47 in 74% yield as a single isomer [58]. The pathway for the mode A→B, 
C-Alkylation that have an indole group at site B [60] and installing a linker having a 
terminal silyl ester, are treated with toluene to give N-acetoacetylated product which 
are converted into the α-diazoimide, then treated the α-diazoimide with rhodium (II) 
catalyst in benzene at 50 °C to generate hexacyclic 48 in good yield (74%) with 
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complete diastereoselectivity [59, 61]. The pathway A →C is expected to provide an 
approach to generate diverse indole alkaloid-like compounds in only four steps, 
including a pair of complexity generating processes [62], a Ugi four-component 
condensation reaction and a Rh-catalyzed tandem reaction. 
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Scheme 1-6. Folding strategy yielding a collection of products having diverse indole alkaloid-like 
skeletons—Depicted by Schreiber´s group [57] 
 
b) The ‘branching pathway’ strategy involves the conversion of common 
precursors into a range of distinct molecular scaffolds (Figure. 1-3). This strategy is 
little more challenging and one needs to design the substrates which can be flexibly 
transformed into distinct molecular scaffolds. However, the synthesis of the molecules 
should remain combinatorial. 
 
A branching pathway based on the chemistry of the Michael adducts 85 was 
developed by Porco (Scheme 1-7) [62]. Reduction of the nitro group triggered 
lactamisation to yield -lactams such as 51. In contrast, with appropriately positioned 
alkenyl and alkynyl substituent, cyclization via ring-closing metathesis or 
Pauson–Khand reaction was possible. With R1 = allyl and R2 = C≡CCH2OMe, enyne 
metathesis yielded the cyclic diene 52. In contrast, with R1 = C≡CH and R2 = allyl, a 
Pauson–Khand reaction allowed the remarkable bridged cyclopentenone 53 to be 
obtained. 
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Scheme 1-7: Porco´s Branching Pathway; a) Zn, AcOH-THF, then Na2CO3 (aq.)[R1 = C≡CMe, R2 
= H]; b) Grubb´s Ist gen. cat., ethylene, MW, 150 W, 50° C, CH2Cl2 [R1 = allyl, R2 = 
C≡CMCH2OMe],; c) Co2(CO)8, MW, 150 W, 80° C, CH2Cl2 [R1 = C≡CH, R2 = allyl]. 
 
In another case of branching pathway approach inspired by the nature, Spring´s et. al. 
used the fluorous tagged α-diazoacetate ‘two-carbon’ unit 54 as starting to create 
diverse scaffolds [63]. The molecular complexity was generated in the second step of 
the synthesis as shown in Scheme 1-8 and Scheme 1-9 below [64-66] . 
O
RFO
N2
54
C6F13H2CH2CRF=
CO2RF
CO2RF
R
CO2RF
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N
CO2RF
H
CO2RF
H
H CO2R
CO2R
R
CO2RF
a
b
56
55
57
58
59
60
c
d
e
Step 2
Step 1
 
Scheme 1-8 Example of diversity-oriented synthesis with fluorous-tagged diazoacetate (1). (a) 
C6H6, Rh2(O2CCF3)4, 70%; (b) RCCH, Rh2(OAc)4, [BuCCH, 57%]; (c) RNH2, NaOH then MeOH, 
H2SO4, [MeNH2, 35%]; (d) dienophile [dimethyl acetylenedicarb- oxylate, 59%]; (e) C5H6, 
92%.—Depicted by Spring´s group [58b] 
 
Thus, in the first step of the DOS, multi-functional group 54 follows the following 
reactions to yield skeletally diverse molecules: (1) three member ring formation 
(shown in Scheme 1-8); (2) 1,3-dipolar cycloadditions (b and d, Scheme 1-8); and (3) 
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α-deprotonation and subsequent quenching with an electrophile and carbenoid 
formation (c, Scheme 1-8). 
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Scheme 1-9 Divergent reaction pathways lead to skeletal diversity. (a) Rh2(OAc)4, furan, then I2, 
60%(91%). (b) DMAD, 84% (88%). (c) LDA, RCOR9, then Rh2(OAc)4; 8: 49%(90%); 9: 
68%(97%). (d) PhCHO, PhNH2, then DMAD, Rh2(OAc)4, d.r. 5 20 : 1, 51%(80%). (e) Guanidine 
carbonate 62%(96%). (f) Resorcinol, H2SO4, 74%(95%). (g) NH2OH, 77%(89%). (h) 
Thiophene-2-carboxaldehyde, guanidine carbonate, then 3-formylchromone, 43%(98%). Yields 
and purity (in brackets) of the product example following generic purification using (reverse) 
fluorous SPE or precipitation shown. Purity determined by HPLC, LCMS or 1H NMR. DMAD 5 
dimethyl acetylenedicarboxylate.—Depicted by Spring´s group [63] 
 
The divergent chemistry of the fluorous-tagged diazoacetate explained above thus, 
yielded 223 small molecules, which are divided into 30 discrete molecular 
frameworks with unique structural features (Scheme 1-4).   
 
In a typical example of reagent-based approach, Fallis´s group exploited the triene [1, 
67] 69 which due to characterisitic functionalization of dienes undergo tandem 
Diels-Alder reactions with various dienophiles to generate diverse building blocks 
(Scheme 1-5) [68]. Thus, the reaction of triene 69 with N-phenylmaleimide 70 and 
triazole 71 separately afford one Diels-Alder reaction in situ followed by another one 
with a second molecule of the dienophile 70 or 71 to give tetracyclic product (81%). 
In the same way, benzoquinone 72 or 73 are added to the starting compound triene 69 
at 21 °C to yield the bicyclic skeletons in a single cycloaddition reaction and obtain 
functionalized cyclohexene derivatives.[68]. Thus, by using tandem cycloadditions 
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complex multicyclic skeletons were easily and efficiently built up. 
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Scheme 1-10 DA reactions generate diverse compounds 
 
Schreiber´s group reported concise and efficient synthesis process, which used the 
succinct intermolecular cyclization reactions and densely functionalized amino 
alcohols [14, 69]. The complete synthesis of a compound collection which has more than 
15 different types of skeleton used only three to five steps. They used the Petasis 
three-component and boronic acid Mannich reactions, later an amine propargylation 
to generate ß-amino alcohols. These compounds undertook polar (amino, hydroxy, 
ester) and nonpolar (alkene, alkyne, cyclopropane) functionalities to generate densely 
functionalized template, and then came to the skeletal diversification reactions 
(Scheme 1-11). 
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Scheme 1-11. The Petasis reaction followed by amine propargylation to yield ß –amino 
alcohols.—Depicted by Schreiber´s group [69] 
 
A series of skeletal diversification reactions with 78 (Scheme 1-12) were then 
explored. For instance, while the cycloisomerization catalyzed by [Pd(PPh3)2(OAc)2] 
resulted in opening of the cyclopropyl ring to afford triene; cycloisomerization 
catalyzed by [CpRu(CH3CN)3PF6] (Cp=cyclopentadienyl) resulted in a [5+2] reaction 
to afford cyclic diene. A Pauson–Khand reaction, in which the starting compound 78, 
[Co2(CO)8] and trimethylamine N-oxide were mixed efficiently yielded azabicyclo- 
[3.3.0] ring-system diastereoselectively (>10:1 d.r.). Enyne metathesis of starting 
compound 91 using the Hoveyda–Grubbs catalyst provided diene, then followed 
Diels–Alder reaction with 4-methyl- 1,2,4-triazolin-3,5-dione at room temperature to 
afford tricyclic building block 93. Further reactions of selected skeletons generated a 
second generations of compounds. For example, the lactone 85 was subjected to the 
same reaction conditions as those for template 78 to well afford the corresponding 
bicyclic triene 86, fused tricyclic [5+2] product 87, fused tricyclic enone 88 and 
bicyclic diene 89. Diene 89 was further converted into fused tetracyclic compound 90 
by a Diels–Alder reaction using the same conditions. The transformations of lactone 
85 also proceeded with high diastereoselectivity to generate each product as a single 
detectable diastereomer [1, 69]. 
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Scheme 1-12. a) [Pd(PPh3)2(OAc)2] (10 mol%), benzene, 80
OC; b) [CpRu(CH3CN)3PF6] (10 
mol%), acetone, RT; c’) [Co2(CO)8], trimethylamine Noxide, NH4Cl (for conditions c), benzene, 
RT; d) Hoveyda–Grubbs second-generation catalyst (10 mol%), CH2Cl2, reflux; e) 
4-methyl-1,2,4-triazoline-3,5-dione, CH2Cl2, RT; f) NaAuCl4 (10 mol%), MeOH, RT; g) NaH, 
toluene, RT; h) mCPBA, THF, -78-0OC. [a] Single diastereomer; [b] >10:1 d.r.; [c] trans/cis=6.7:1; 
[d] trans/cis=6.4:1; [e] from trans diene; [f ] trans/cis=3:1; [g] combined yield from the trans and 
cis dienes. mCPBA=m-chloroperbenzoic acid.—Depicted by Schreiber´s group [65] 
 
Design of the common substrate which can be transformed into skeletally diverse 
molecules is obviously dictated by the nature of chemistry one plans to execute. An 
intelligent design can provide an easy access to numerous small molecular scaffolds 
in a very quick and efficient manner. One notable example is the preparation of a 
complex and highly diverse library by the group of Nelson [70] using ruthenium 
metathesis reactions as key transformations. This approach relies on the quick and 
efficient generation of simple scaffolds suitable for a series of cascading ring closing 
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and ring opening or ene-yne metathesis reactions (Scheme 1-13). The precursors 
consist of three parts, a constant fluorinated tag, to simplify the purification step using 
fluorous solid-phase extraction; a propagating core of cyclic nature or containing 
alkynes, which allows the cascade propagation through ring-closing-ring-opening 
metathesis while the alkyne containing propagating unit allows for the propagation 
through ring-closing ene-yne metathesis cascade and a capping group, where the 
reaction sequences are initiated. With this approach, Nelson et al could generate more 
than 84 different molecular frameworks. 
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Scheme 1-13. Efficient generation of complexity using Grubbs ruthenium catalysts [71]. 
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1.5 Biology Oriented Synthesis (BIOS) 
 
BIOS is another concept that leads to the synthesis planning and takes into account 
the biological relevance as a major prerequisite for design and synthesis of compound 
libraries [72]. The core-structures of bioactive molecules like natural products or drugs 
form the basis for design of compound libraries. The concept of BIOS further exploits 
the evolutionary link between the protein and the natural products world. The 
typically targets for natural products and other bioactive molecules are the 
three-dimensional folds of proteins. These folds have been well conserved during and 
over the evolution than their underlying amino acid sequences.[73] Similarly, the 
frameworks of different natural product classes exhibit a kind of conservatism. Thus, 
these two classes of molecules that often are ligand and receptors for each other do 
complement the elements of conservatism. On the basis of these facts, Waldmann et al 
developed the guidelines for compound library development and termed BIOS.[72] 
Thus, the scaffolds of either natural products or medicinally important molecular 
classes are used as starting points for the design and synthesis of small focused 
libraries. In the first concept of BIOS i.e. “structural classification of natural 
products” (SCONP),[74] a “natural product scaffold tree” was generated to correlate the 
scaffolds of natural products in a hierarchical manner thus allowing simplification of 
complex frameworks to simple ring systems that could be taken as starting points for 
the library synthesis (Figure 1-4) [75].   
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Figure 1-4: Tree-like graphical representation of natural-product scaffolds. For clarity, only 
scaffolds that cumulatively represent at least 0.2% of the natural products in the DNP are shown. 
 
Thus, it would be of significant interest to find the structural motifs of natural 
products which could retain or improve the kind of biological activity of the parent 
natural product. For instance, Waldmann et al synthesized a compound library based 
on a simple spiroketal motif to determine if the spiroacetal moiety which is part of 
extraordinarily potent tubulin polymerization-inhibiting complex natural product 
spongistatins, could retain this bioactivity (Scheme 1-14).[76] 
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Scheme 1-14. Solid phase asymmetric synthesis of a spiroacetal collection. 
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An aldol reaction of the resin-bound aldehyde 94 with the preformed Z-boron enolate 
95 provided the enantioenriched aldol adduct 96. An anti-selective aldol reaction of 
an E-boron enolate (generated on the solid phase) with a set of aldehydes provided the 
protected bis (-hydroxy) ketone 97. Simultaneous removal of the PMB group and 
acetalization was performed by oxidative cleavage using DDQ, thereby releasing the 
spiroketals 98 from the resin.. Interestingly, compound 99 (Scheme 1-14) obtained 
from this collection was found to be an inhibitor of the phosphatases VHR and Ptp1b 
with IC50 values of 6 and 39 M respectively and also could distort the correct 
organization of the tubulin network in a human carcinoma cell line.    
 
Thus, BIOS may help identify structurally simpler starting points for library design 
and provide high hit rates in yielding desired inhibitor/activator molecules. In yet 
another example from the same group, structurally complex alkaloids – yohimbine 
and ajmalicine – were identified as inhibitors of the protein phosphatase Cdc25A. 
SCONP analysis and brachiation simplification led to tetracyclic indolo[2,3-a]- 
quinolizidines. A library based on the indoloquinolizidine scaffold yielded two 
compounds with IC50 values comparable to the natural products. By extending the 
screen to other phosphatases, structurally new inhibitors of the Mycobacterium 
tuberculosis phosphatase MptpB could be identified.[77] In a similar manner, BIOS of 
a focused library of macroline analogs yielded several new inhibitors of the 
Mycobacterium tuberculosis phosphatase MptpB [78]. Interestingly, further simplified 
compounds with three- and two-membered rings also yielded one inhibitor of Cdc25A 
with an IC50 value similar to the value recorded for the pentacyclic molecule. The 
compound collection also contained inhibitors of protein tyrosine phosphatase 1B and 
MptpB including eight inhibitors with sub-micromolar IC50 values. 
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Scheme 1-15. Natural product alkaloids inspired compound libraries. 
 
In the second concept incorporated in BIOS i.e. “protein structure similarity 
clustering” (PSSC), the biological protein targets of small molecules are classified 
into clusters according to structural similarity in their ligand binding cores.[79] The 
inhibitor of one of the proteins of such clusters could represent a class of potential 
inhibitors for all other proteins in that cluster. For instance, an example from a 
retrospective analysis of literature data using the PSSC concept would have suggested 
the development of ligands for the farnesoid X receptor. 
 
Scheme 1-16. A BIOS approach to identify synthetic ligands for farnesoid X receptor.  
 
The farnesoid X receptor is a member of the class of nuclear hormone receptors, 
which have key roles in development and homeostasis, as well as in many diseases 
like obesity, diabetes and cancer.[80] The ligand sensing domain of the farnesoid X 
receptor was found to be structurally similar to the cores of the estrogen receptor β 
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(ERβ)[81] and the peroxisome proliferation-activated receptor γ (PPARγ)[82] This 
cluster of proteins exhibits a similar fold pattern but with less than 20% sequence 
similarities. The natural product genistein (Scheme 1-16) is an inhibitor for both the 
ERβ and PPARγ receptor.[83] Also, troglitazone, a benzopyrane drug modulates the 
activity of the PPARγ receptor.[84]  In a retrospective analysis, a BIOS approach 
would have taken the benzopyran scaffold which is common to both ligands as 
starting point for the library to identify farnesoid X inhibitors. The benzopyran library 
synthesized by Nicolaou et al. indeed yielded such ligands [85] for the other members 
of this PSSC (Scheme 1-16).. 
 
The BIOS approach thus not only provides simplified biologically relevant starting 
points for compound library synthesis but also opportunities for medicinal chemistry 
research by unraveling unprecedented classes of protein inhibitors. In another 
example dehydrodecalins were identified as potent inhibitors for 11HSDs. 
Glycyrrhetinic acid (Figure 1-5), a structurally complex natural product is a ligand of 
the enzyme 11βHSD1. On simplification by SCONP analysis, the parent structure of 
glycyrrhetinic acid led to two decalin motifs as starting points for library synthesis. 
The critical decision for the right decalin scaffold as core structure was taken by 
considering a natural ligand for the Cdc25A protein which is a member of the protein 
cluster along with 11HSDs and AChE. Dysidiolide is a NP ligand for Cdc25A[86] and 
also embody a dehydrodecalin motif and thus this scaffold was chosen as starting 
point for a collection of ca. 500 dehydrodecalins. These were synthesized using an 
asymmetric Robinson annulation as the key transformation [87]. Biochemical screening 
of 162 compounds from this collection for inhibitory activity on 11βHSD yielded 30 
inhibitors with IC50 values below 10 μM; 4 of them even showed IC50 values between 
310 and 740 nM.  
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Figure 1-5. A BIOS approach to develop inhibitor classes for a cluster of proteins. 
 
1.6 Summary and future perspectives 
 
Progress in the biological sciences, in particular, the deciphering of the genomes of 
various organisms including man during the last decades has led to a steep increase in 
knowledge about basic biological processes as well as the factors leading to their 
misregulation and ultimately the establishment of disease. Small bioactive molecules 
can provide immensely important insights in chemical biology research, where they 
are used to perturb a given biological system followed by analysis of  the difference 
between perturbed and non-perturbed state. In a drug discovery or medicinal 
chemistry research, small bioactive molecules as ´hit and lead compounds are 
prerequisites to progress them to the lead and development candidate stage in order to 
modify disease states. These two approaches differ from each other in their goals, 
although the initial steps and milestones to discover biologically active molecules are 
very similar. In both cases the chemist faces the same question as to which 
compounds to synthesize and use in biochemical or biological screen medium or high 
through-put screen? An answer to this question is not readily given and the selection 
is even made more complicated by the diverse criteria to be met in the subsequent 
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optimization steps. Given this uncertainty, one always desires to enrich the initial 
compound collections that undergo screening with biological activities in order to 
obtain certain number of starting hits which can be evolved into either chemical 
probes or drug candidates. Both DOS and BIOS are chemists’ endeavors to enrich the 
collections with functional characteristics including biological activity.  
 
In order to meet this goal, compound collections should incorporate both diversity and 
molecular complexity into their compound classes. That definitely calls for 
developing efficient synthesis strategies that can generate skeletally diverse and 
complex molecules rapidly and in a combinatorial fashion. In particular, synthesis 
planning should develop new complexity generating reactions that yield molecules 
embodying scaffolds of natural products in a concise and efficient manner. 
 
1.7 The aim of this work 
 
Recent years have witnessed chemists’ endeavors targeting bioactive small molecules 
shaping up different hypothesis, for instance DOS and BIOS [89]. It would however be 
enlightening to understand the way nature targets bioactive regions of vast chemical 
space while creating diverse natural products [90]. Adapting similar strategies in 
compound library syntheses might enrich them with desired and interesting biological 
activities. In a prominent biosynthetic strategy, primary metabolites or derivatives 
would build up an intermediate scaffold which is later transformed into diverse 
secondary metabolites, often retaining the molecular framework of intermediate [91].  
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Figure 1-6 Biosynthetic and Cascade reaction strategies 
 
Figure 1-6. A) Biosynthetic strategies leading to diverse secondary metabolites, B) 
Cascade reactions based strategy to transform a common multi-functional substrate 
into diverse scaffolds. For instance, in indole alkaloid biosynthesis [92], tryptamine is 
converted into a template structure, Strictosidine, which is further transformed into a 
variety of monoterpene indole alkaloids (Figure 1-6, A). Similarly, in the Gibberellin 
biosynthesis pathway geranylgeranyl diphosphate (GGDP) is cyclized to form a 
template scaffold ent-kaurene, which undergoes skeletal and functional group 
transformations to at least 136 products with only few of them displaying biological 
activities (Figure 1-6, A).  [93]. A different cyclization of GGPP catalyzed by 
taxadiene syntheses forms another common intermediate taxadiene which later 
elaborates into taxol and related natural products [94]. Nature, thus exploits branching 
pathway strategy in transforming the common intermediate into diverse and complex 
secondary metabolites to provide the required diversity in the secondary metabolites 
to achieve the desired biological activities [90, 95]. On this inspiration, it could be 
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possible to design the common substrates decorated with required functional groups 
that can facilitate chemical transformations providing different scaffolds under 
different conditions. The better would be if these transformations happen in a one-pot 
strategy or in a domino reaction sequence fashion to yield complex and diverse 
molecular architectures.  
 
Thus in our approach, which is based on branching pathway strategy and is termed as 
branching cascades for it exploits the cascade/domino reaction sequences, a common 
precursor follows different domino or cascade reaction sequences that are triggered by 
different reagents by exploiting diversely reactive multiple functionalities on the 
common substrates in our case (Figure 1-6, B). Every cascade reaction sequence 
could in principle lead to a different scaffold formation. The mode of triggering these 
cascades can be controlled by both adding non-addundant reagents that only activate 
and push a domino reaction. In this case, different intermolecular transformations 
would yield diverse molecules without addition in the overall molecular weight of the 
molecules. In the second approach, addition cascade triggering substrates could be 
employed that follow different cascade reaction owing to their diverse inherent 
chemical relativities and also add to the overall complexity of the final products. In 
the later case, therefore numerous variations in the inter- and intermolecular chemical 
transformations are possible and thereby far more skeletal diversity and complexity 
can be accessed. In addition, the branching cascade strategy would yield molecules 
that are already functionalized because out of much functionality in the common 
substrates only few would be exploited in every cascade reactions. Therefore, 
synthesis of analogues of the branching cascade products should be much easy and 
efficient and so should be the generation of focused compound collections.  
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2. Reagent Controlled Branching Cascades  
2.1 Introduction 
The use of diverse sets of small molecules in chemical biology studies has led to 
many new insights into various biological phenomena [96-98]. For the development of 
compounds that help elucidate the mysteries of life processes, DOS and BIOS have 
proven to be useful approaches [99-101]. In both of these approaches, structural 
complexity and diversity is often generated by means of multi-step sequences 
employing skeletally-differentiating transformations on common precursors. 
Development of synthetic methods that allow rapid and systematic variation of 
molecular scaffolds has proven to be extremely challenging [99]. Not surprising, often 
it is impossible to avoid tedious and multistep synthesis to access different scaffold 
structures. Further, addition of functionalities and modifications thereof require more 
efforts with each and every synthetic step reducing the yield of the desired molecules. 
Targeting a cascade reaction sequence based concise synthesis strategy, we 
envisioned that branching cascade strategy could provide complex, diverse and 
functionalized scaffold structures and thereby small focused libraries in an efficient 
manner [100]. Substrates capable of entering cascade/domino reaction sequences must 
have diverse reactive sites, at which different chemical reactions can take place in a 
sequential manner. Therefore, a key to successful branching cascade strategy would 
require an elegant design of the common precursors. In the following section, the 
reagent controlled branching cascade strategy is detailed wherein a common precursor 
is activated by different reagents and thus pushed into different domino reaction 
sequences [101]. Every domino reaction sequence transforms the precursor into 
skeletally different scaffolds that comes out suitably functionalized. 
 
The chemical functionalities on a common precursor (Figure 1-5) can be 
activated/modified in number of ways in order to trigger a cascade reaction sequence 
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that might include inter- and intermolecular transformations  leading to a new 
complex scaffold. As depicted in the figure 2-1below, different functionalities FA, FB 
or FC on the common substrates can be modulated by different reagents RA, RB and 
RC. A treatment with each reagent thus would trigger a cascade reaction wherein 
activation of one functional group pushes the reaction sequence involving other 
functional group(s) and leading to diverse scaffolds (Figure 2-1).  
 
Figure 2-1: Reagents controlled branching cascades 
 
2.2 Design and synthesis of Common Precursor 
 
Appropriately substituted 3-chromanylidene--ketoesters (Figure 2-2) were 
envisioned as the key precursors  for the establishment of new cascade or domino 
reaction sequences. If appropriately substituted with reactive functionalities that can 
be activated by different reagents, diverse inter- and intra-molecular chemical 
reactions would be plausible on these common substrates. The presence of reactive 
functionality (RF) along with an ,-unsaturated moiety (blue), a vinylogous ester 
(grey), and a ketone (green) would bring numerous opportunities for performing 
different sequences of cascade reactions (Figure 2-2).  
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Figure 2-2: Substrate design for Branching Cascades; RF = reactive function, EWG = 
electron-withdrawing group. 
 
Precisely, β-ketoesters a1 with TBS protected group the common substrate 1 was 
planned. These compounds contain electrophilic centers, e.g. C2 and C10, where 
nucleophiles can attack, and also nucleophilic centers such as C4´ and OH (after 
deprotection). Furthermore, the C3´ ketone provides an entry into imine–enamine 
chemistry. Finally, the variable alkyl chain supports a terminal silylated alcohol. Thus, 
desilylating the alcohol at C7´ could possibly induce the formation of six-membered 
hemiacetals. It was expected that different desilylating regents might trigger different 
cascade reaction sequences and yield different molecules.  
 
O
O
O
RO
O
OTBS
3' 4'
7'
1'
2
4
R1a1  
Figure 2-3: Common substrate for reagent controlled branching cascade. 
 
Synthesis of a1 and analogues commenced by condensing the substituted 
3-formylchromones with ethyl 3-oxobutanoate in the acetic anhydride/acetic acid 
(Scheme 2-1). The reaction mixture was stirred in a preheated 145oC oil-bath under 
argon atmosphere which results in product formation within 5 minutes. After 
quenching the reaction mixture with water under argon, the mixture was kept for 2-3 
hours when the suspending oil changed into transparent brown solution which was 
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extracted with ethyl acetate and dried over Na2SO4. A4 was formed as 1:1 mixture of 
E/Z-isomers, identified by two sets of peaks according to 1H-NMR spectra. These two 
isomers were very difficult to isolate by silica gel column chromatographic 
purifications. 
O
O
O R2 O
O O
+
R1
Ac2O/AcOH=1:4
O
O
R2
O
O
OR1
ratio 1:1
R1= Me, iPr, Br, Cl, H, NO2 .....
R2=Me, Et, n-Pr
reflux, 5min
a2 a3 a4
 
Scheme 2-1. Synthesis of chromen-methylene-anoate. 
 
2.3 Reagent controlled branching cascades 
 
In order to induce a cascade reaction sequence on common substrates, it was planned 
to desilylate the alcohol by different desilylating reagent and determine if the 
formation of a possible hemiacetals or any other intermediate is followed by further 
reactions at the different electrophilic centers available in these molecules and result 
in transformation of common substrates into different ring systems. 
 
2.3.1 Synthesis of functionalized phenols 
 
Initially the standard desilylating reagent tetrabutylammoniumfluoride (TBAF) was 
employed. However to our disappointment the reaction led to a retro-aldol reaction, 
thereby hydrolyzing a1 to form chromone and -ketoesters. 
 
In the next case, cesium fluoride as desilylating regents was used. The common 
precursor beholds many electrophillic centers, especially highly electrophilic C2 
(Figure 2-3), that can be easily attacked by nucleophiles. The chromanylidene 
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intermediates a5 were treated with CsF in DMF at 80° C. Interestingly, the formation 
of substituted phenols a6 was observed under these reaction conditions in moderate to 
good yields (Scheme 2-2). The reaction yields were much better using at least two 
equivalents of CsF. With these reaction conditions, differently substituted substrates 
a5 were efficiently converted into the corresponding phenols a6 in acceptable to good 
yields. 
 
O
O
RO
O
R3
O
R1
R2
O
R2
OH
R1
R3
CO2R
OH
CsF (2.0eq), DMF
80oC, 2-4h
R1 = H, Me, iPr, Cl
R2 = H, Cl
R3 =
OTBS OTBS Me
a5 a6
 
Scheme 2-2: Synthesis of functionalized phenols 
 
COMPOUNDS R1 R2 R3 R4 YIELD(%) 
a7 iPr H H Me 83% 
a8 Me H H Me 89% 
a9 NO2 H H Me 81% 
a10 F H NO2 Et 79% 
a11 Cl Me H Me 82% 
a12 Br H H Me 84% 
Table 2-1 the results of functionalized phenols 
 
Mechanistically, it is proposed that this cascade reaction sequence commences with 
the removal of the TBS group by CsF.  
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While the products lack the -keto-CH2 of the substrate a15, it is possible thata 
cesium enolate might have formed after desilylation reaction in this domino process 
and its addition C2 of the chromone ring generates the tricyclic intermediate a16. 
Isomerization and ring-opening of chromone would form a17 that aromatize to 
generate the functionalized phenols a17.  
EtO
R2
O O
O
O
R1
CsF
DMF,80oC
O
OH
CO2Et
R2
OH
R1
EtO
R2
O O
O
O
R1
Cs
EtO
R2
O O
O
O
R1
Cs
EtO
R2
O O
O
O
R1
H
HH
R1= Me, iPr, Br, Cl, H, NO2 .....
R2=Me, Et, n-Pr
a13
a14 a15 a16
a17
 
Scheme 2-3. Domino synthesis of substituted phenols. 
 
2.3.2 Synthesis of functionalized pyridines 
 
In the second case, ammonium fluoride was employed as desilylating reagent at room 
temperature (Scheme 2-4). Interestingly, the reaction provided single products (TLC 
control) within an hour, which after purification (silica gel column chromatography) 
were identified by spectroscopic techniques (NMR, DEPT, HRMS) to be pyridines 
a21 (Scheme 2-4). However, under these reaction conditions, the TBS ether remained 
intact. Extending the reaction time and raising the temperature (60 oC) led to clean 
removal of the protecting group (Scheme 2-4). Chromanylidene--ketoesters a20 with 
short alkyl chains (R4 = Me or H) were also cleanly transformed to the corresponding 
substituted pyridines a21 by means of the this branching cascade (Scheme 2-4).   
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EtO
R2
O O
O
O
R1
NH4F (10.0 eq)
MeOH, 60oC
O
N
CO2Et
OH
R1
R2
a20 a21  
Scheme 2-4: synthesis of functionalized pyridines 
 
Mechanistically, formation of the pyridine ring proceeded, most likely, by means of 
the initial conversion of e.g. -ketoester a20 into enamine a22, which then attacks the 
activated C-2 position in the chromone (a23, Scheme 2-5). Rearrangement was 
accompanied by opening of the chromone, and aromatization resulted in the formation 
of pyridine a21. Overall, this domino sequence provided high yields of substituted 
pyridines [102]. 
EtO
R2
O O
O
O
R1
NH4F (10.0 eq)
MeOH, 60oC
O
N
CO2Et
OH
R1
R1= Me, iPr, Br, Cl, H, NO2 .....
R2=Me, Et, n-Pr
EtO
R2
O NH2
O
O
R1
EtO NH
O
O
O
R1
R2
EtO N
O
O
O
R1
R2
H
R2
a20
a22 a23 a24
a21
 
Scheme 2-5. Domino synthesis of substituted pyridine. 
 
These two domino processes provided highly substituted phenols and pyridines, 
which could be further diversified for compound collection synthesis (Scheme 2-2 
and Scheme 2-4).  
 
Reagent Controlled Branching Cascades 
 
 
35
2.3.3 Synthesis of functionalized benzopyrans 
 
One of the expected reaction pathway after desilylation of the TBS ether on common 
substrate was the formation of hemiacetal by addition of alcohol to ketone. However, 
in the two branching cascades described above, no reagent could induce this 
transformation. In order to realize this possibility that could lead to a different cascade 
reaction sequence, a desilylating reagent supporting the acetal formation reaction 
conditions is required. Based on this assumption, pyridinium para-toluene sulfonate 
(PPTS) was used as the desilylating reagent. Pleasingly, treatment of silyl ethers with 
PPTS in methanol at 65oC for 36 h led to the formation of benzopyrans (Scheme 2-6). 
During this reaction course, transesterification of the substrates was observed which 
could be successfully avoided by reducing the reaction time to 24 h.  
R2O
O O
O
O
R1
PPTS (8.0 eq), MeOH
24h, 65oC
OTBS
R3
R2O
O
O
R1
O
R3
HO
a25 a26  
Scheme 2-6: Synthesis of functionalized benzopyrans 
 
The PPTS controlled branching cascade operates by removal of the TBS group. The 
liberated alcohol cyclizes to generate the expected hemiacetal (Scheme 2-7). Removal 
of water molecule leads to the dihydropyran a28. An intermolecular cyclization 
followed by aromatization thus produces the benzopyrans a29. This domino sequence 
provided an obvious advantage on the reported multi-step synthesis of similar 
molecules [102]. 
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R2O
O O
O
O
R1
PPTS (8.0 eq), MeOH
24h, 65oC
OTBS
R3
R2O
O O
O
O
R1
OH
R3
R2O
O
O
O
R1
O
R3
OH
R2O
O
O
O
R1
O
R3
R2O
O
O
R1
O
R3
R3= (S)-Me, (R)-Me, H
R2=Me, Et
R1= H, Me, iPr, Cl, Br
HO
a25
a27 a28 a29
a26
- H2O
 
Scheme 2-7. Domino synthesis of benzopyrans. 
 
In order to have more insight into the reaction mechanism of this domino process, the 
reaction between building block a25 and PPTS in methanol was stopped after 1 h, and 
the major product was quickly purified by flash column chromatography. We were 
pleased to find that this was not the final product—benzopyran but one of the 
expected intermediate i.e. chromanomethylidene- substituted dihydropyran a30 
(Scheme 2-8). Stirring the compound a30 under the same reaction conditions—with 
PPTS in methanol at 65oC for 24 h, generated the corresponding benzopyran a31 in 
almost quantitative yield was completely supporting the proposed cascade reaction 
mechanism in Scheme 2-8 [102]. 
MeO
O
O
O
R1
O
PPTS (8.0 eq), MeOH
24h, 65oC
OH O
O
O
O
98%
a30 a31  
Scheme 2-8. The reaction of dihydropyran to benzopyran. 
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In order to introduce hydrophobic alkyl chain which a stereoelement. The common 
substrates a32 and a33 were synthesis and employed in branching cascades. (Figure 
2-4).  
EtO
O O
O
O
OTBS
Me
a32
EtO
O O
O
O
OTBS
Me
a33  
Figure 2-4. Silyl ester (offered by Francisca Martín Gálvez) 
 
Indeed, expectedly and pleasingly, CsF and NH4F induced their respective cascade 
reaction sequences. These substrates yield corresponding phenols and pyridine in 
good yield (Scheme 2-9).  
EtO
O O
O
O
OTBS
Me
CsF (2.0 eq)
DMF, 80oC
NH4F (10.0 eq)
MeOH, rt
O
N
CO2Et
OH
O
OH
CO2Et
OH
Me
HO
EtO
O O
O
O
OTBS
Me
CsF (2.0 eq)
DMF, 80oC
O
OH
CO2Et
OH
Me
HO
EtO
O O
O
O
OTBS
Me
OH
Me
NH4F (10.0 eq)
MeOH, rt
O
N
CO2Et
OH
EtO
O O
O
O
OTBS
Me
OH
Me
a34 a36
a35 a37
a34 a38
a35 a39  
Scheme 2-9. Silyl esters react with different regents. 
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The hydrolysis of the ester groups with sodium hydroxide provided the corresponding 
carboxylic acids in good yields. 
 
2.4 Functional group modification of the cascade products 
 
The reaction product obtained in above cascade sequences are well functionalized and 
therefore can be further modification to provide functional group diversity is the 
compound collection. 
 
2.4.1 Synthesis of oximes, oxazole and isoxazole derivatives of 
pyridines and phenols 
 
So as to combine the scaffold of the molecular architecture of the library with 
multiple biological properties and introduce special structure that were explored to 
add further diversity in three-dimension compounds space, synthesizing derivatives of 
building blocks are necessary. The structure of oximes, oxazole and isoxazole are 
similar with our building block and the building block can be easily converted into 
oxazole. 
 
2.4.1.1 Synthesis of oximes 
 
The presence of hydroxybenzoyl moiety in the cascade products, pyridines and 
phenols a40, suggest to covert the ketones to the corresponding oximes which can be 
transformed into the medicinally useful isoxazoles (Scheme 2-10) .  
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OH O
X
OEt
R2
R1
O
OH N
X
OEt
R2
R1
O
O
N
X
R2
R1
O
OEt
R3 R3
starting structure target structure
OH
R3 X = N,  no R1, R2= Me, Et, iPr
X = C,  R1= Me, Et, iPr, R2= OH
R3 = Cl, Br, Me, NO2, H...
Step 1 Step 2
a40 a41
a42  
Scheme 2-11: Synthesis design the oxazole in our case. 
  
A similar synthesis route from literature is presented in Scheme 2-11 [103].  In this 
case, benzophenone a45 was prepared from benzoyl chloride a43 and 
1,4-dimethoxybenzene a44 in the presence of aluminum chloride and 
1,2-dichloroethane. The demethylation of benzophenone with pyridine hydrochloride 
at high temperatures (200 °C) produced benzophenone a45. This building was 
converted into benzisoxazole a46 in two steps. First, oxime a46 formation was 
accomplished with hydroxylamine in ethanol followed by dehydration of oxime a46 
under Mitsunobu condition—DIAD and PPh3, yielded benzisoxazole a47. 
COCl
OMe
R1 +
OMe
OMe
(a) AlCl3, ClCH2CH2Cl
(b) pyridineaHCl
OR
OR
O
R1
OR
(c) NH2OHaHCl, EtOH
OH
OH
N
R1
OH
OH
(d) diethylazodicarboxylate, PPh3, THF
O
N
R1
HO
OH
a43 a44 a45 a46
a47  
Scheme 2-11: The synthesis of oxazole in literature 
 
The corresponding oximes of the cascade products, pyridines and phenols were also 
of interest because  they can modulate the bioactivity of the precursor ketones [104-105]. 
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For instance, it was proved that enones were easily converted into oximes and oxime 
hydrolysis was described as a substantial metabolic pathway. Oxime was regarded as 
useful prodrugs to develop more analogues (Figure 2-5) [106-107]. 
 
N
RO
In vivo
hydrolysis
O OH
HO
In vivo
oxidation
a48
a49 a50  
Figure 2-5. An oxime acting as a ‘cascade’ prodrug.—depicted by Wikstro¨m’s group. [107]  
 
Thus, in order to access oxime formation of the phenols obtained in the branching 
cascade strategy, a mixture of hydroxyphenyl-benzoate, hydroxylamine hydrochloride 
(10.0 eq), pyridine (5 mL), and EtOH (30 mL) was heated to reflux. The solvent was 
removed under vacuum, after adding excess aqueous Na2CO3, it was extracted with 
EtOAc. The organic layer was dried over MgSO4 and concentrated to give a yellow 
solid. This solid was purified by column chromatography (30% EtOAc/hexane) to 
give two white solids in the 1:1 ratio. The two products appear very close on the TLC 
but could be purified by repeated chromatographic purifications (Table 2-2). These 
two products had the same molecular weight and the NMR spectra looked very 
similar, thus suggesting them to be the E- and Z- isomers of oximes (Figure 2-6).[103] 
Differently functionalized phenols were thus converted into their oximes in acceptable 
yields.  
 
OH O
OR5
OH
R4
O
NH3OHCl
Py/EtOH = 1/6
R1
R2
R3
OH N
OR5
OH
R4
O
R1
R2
R3
OH N
OR5
OH
R4
O
R1
R2
R3
+
OH HO
 
 
compounds R1 R2 R3 R4 R5 CONF. Yield (%) 
a51 Me H H Me Et E 48% 
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a52 Me H H Me Me Z 48% 
a53 Br H H Me Et E 47% 
a54 Br H H Me Et Z 47% 
a55 i-Pr H H Me Et Z 48% 
a56 F H NO2 Me Et Z 45% 
a57 NO2 H H Me Et E 47% 
a58 NO2 H H Me Et Z 47% 
a59 Cl Me H Me Et E 47% 
a60 Cl Me H Me Et Z 47% 
a61 H H H Me Et E 49% 
a62 Me H H Me Et E 48% 
a63 H H H H Et E 48% 
a64 H H H H Et Z 48% 
a65 Me H H Et Et E 46% 
a66 Br H H Et Et E 47% 
a67 Br H H Et Et Z 47% 
a68 H H H Et Et E 48% 
a69 H H H Et Et Z 48% 
a70 Cl H H Me Et Z 44% 
a71 H H H Me Me E 49% 
a72 H H H Me Me Z 49% 
Table 2-2: The synthesis of oxime. 
 
OH N
OEt
OH
R2
O
R1
OH
OH N
OEt
OH
R2
O
R1
HO
E Z
R2 = Me, Et, iPr
R1 = Cl, Br, Me, NO2, H...
 
Figure 2-6. The isomer of oxime 
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Phenols with long alkyl chains i.e. a36 and a37 were also converted to their 
corresponding oximes under the optimized reaction conditions in good yields 
(Scheme 2-12).  
O
OH
CO2Et
OH
Me
HO
a36
NH3OHCl
Py/EtOH = 1/6
N
OH
CO2Et
OH
Me
HO
N
OH
CO2Et
OH
Me
HO
a74
HOOH
+
a73  
O
OH
CO2Et
OH
Me
HO
a37
NH3OHCl
Py/EtOH = 1/6
N
OH
CO2Et
OH
Me
HO
N
OH
CO2Et
OH
Me
HO
HOOH
+
a75 a76  
Scheme 2-12. The synthesis of oximes of phenols with longer alkyl chains. 
 
In a similar fashion, the pyridines obtained from the branching cascade strategy were 
transformed into their corresponding oximes which were purified by column 
chromatography into E- and Z-isomers in good yields (Scheme 2-13).  
OH O
N
OEt
O
NH3OHCl
Py/EtOH = 1/6
O2N
OH N
N
OEt
O
F
O2N
OH N
N
OEt
O
F
O2N
+
OH HO
F
a77 a78 a79  
Scheme 2-13. The synthesis of pyridine oxime. 
 
Pyridines with long alkyl chains were also successfully transformed into their oximes 
under the optimized reaction conditions (Scheme 2-14) in good yields. 
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Py/EtOH = 1/6
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N
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a39
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N
CO2Et
OH
OH
Me
a82
N
N
CO2Et
OH
OH
Me
OH HO
a81
a83 S
cheme 2-14. The synthesis of isomeric oximes with pyridine building blocks. 
 
2.4.1.2 The synthesis of oxazole 
 
As depicted in scheme 2-10, oximes can easily lead to isoxazoles. Therefore, both E- 
and Z-isomer of the oximes were separately exposed to Mitsunobu reaction conditions 
[108]. Thus, a mixture of oxime, DIAD (1.2eq) and PPh3 (1.3eq) was added to a 
degassed THF solution and was stirred at room temperature for 3-6 h under argon 
atmosphere (Table 2-4, Table 2-5). The reaction of E-oxime produced two 
products—isoxazole a90, and oxazoles a91. However, the Z-oxime afforded only one 
product oxazole a100. The LC-MS spectra showed that these three products had the 
same molecule weights. These results are however, in good agreement with literature 
[108]. 
OH N
OEt
OH
R3
O
OH
R2 = H, NO2
R1 = F, NO2, H...
DIAD(1.2eq), PPh3(1.3eq)
O N
OEt
OH
R3
O
+
N
O
OH
R3
O
OEt
THF
R1
R2
R1
R2
R1
R2
R3 = Me, H, Et  
COMPOUNDS R1 R2 R3 OXAZOLE(Y%) ISOXAZOLE(Y%) 
a90 F NO2 Me 43%  
a91 F NO2 Me  32% 
a92 NO2 H Me 45%  
a93 NO2 H Me  35% 
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a94 H H Me 52%  
a95 H H Me  38% 
a96 H H H 55%  
a97 H H H  39% 
a98 Me H H 50%  
a99 Me H H  33% 
Table 2-4 Reaction of E-oximes to yield isoxazoles and oxazoles. 
 
R2 = H, NO2
R1 = F,  H...
R3 = Me, H, Et
OH N
OEt
OH
R3
O
DIAD(1.2eq), PPh3(1.3eq)
O N
OEt
OH
R3
O
HO
THF
R1
R2
R1
R2
 
COMPOUNDS R1 R1 R1 isoxazole 
a91 F NO2 Me 37% 
a97 H H H 47% 
a99 NO2 H Me 39% 
Table 2-5 Reaction of Z-oximes to yield oxazoles 
 
Thus, differently substituted phenolic oximes were converted into the isoxazoles and 
oxazoles to provide a focused compound collection. 
 
C
NO
OH
O
O
H
HH
O
C
N
OH
O
OH
H
a b  
Figure 2-7. Identification of building blocks(a&b) by HMBC-NMR experiments. 
 
The generally accepted mechanism of the Backmann rearrangement follows 
protonation, etherification or esterification of the oximino hydroxyl group, then a 
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quasi three-member transition state is formed, in which the group anti to the hydroxyl 
migrates with synchronous lengthening of the N-O bond [109]. The departure of the 
leaving group is simultaneous accompanied with the [1,2]-shift of the anti group. The 
concept of a three-member transition state is involved in order to explain the observed 
retention of configuration of the migrating group and also the stereospecificity of the 
reaction [109]. If other nucleophiles (Nu¯) are present, they can intercept the reactive 
intermediates (both inter- or intra- molecularly) and several different 
imino-substituted derivatives can be formed. These facts demonstrate that, the 
transform of N-hydroxyl group of the oxime into a better leaving group is necessary 
[109].  
 
In our case, we assume that the phosphine does activate the oxime by formation of 
intermediate a107 supporting a leaving group that facilitates the migration of aryl 
moiety leading to a108 wherein the intermolecular addition of phenol to carbenium 
cation formed provides the isoxazole. However, when Z-oxime a104 had been 
activated by PPh3, the ethyl benzoate was transferred from the back of oxime to 
intermediate a105 wherein the addition of phenol to form a four-member ring is not 
facilitated. Therefore, the intermediate a106 may provide a nitrene type intermediate 
to which addition of phenol leads to formation of oxazoles a107 (Scheme 2-15).  
OH
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N
OH
O
O
OH
Beckmann rearrangement N
O
R1
OH
O
O
OH
R1
N
OH
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O
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N
O
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H
  oxime
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-POPh3
trans 
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a100 a103
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Scheme 2-15 The proposed mechanism of E-oxime 
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Scheme 2-16. The proposed mechanism of Z-oxime 
 
2.4.2 The hydrolysis of compounds 
 
2.4.2.1 The hydrolysis of isoxazole 
 
Free acid was good resolvable in body and the ester was hydrolyzed to get free acid 
by using the solution of sodium hydroxide (Scheme 2-17). The reaction was nearly 
quantitative and only less starting compound remained.  
NO
EtO2C OH
NaOH (aq, 2.0mol/l) NO
HO2C OH
a109 a110
98%
 
Scheme 2-17. Hydrolyzed the isoxazole 
 
2.4.2.2 The hydrolysis of oxime 
 
So as to develop the scaffold collection and to prove no effect with free acid under the 
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basic conditions, the free acid oximes with hydroxylamine were synthesized with 
good yields (Scheme2-18).  
OH O
N
COOH
R1
OH N
N
COOH
R1
NH2OH HCl(10 eq)
Py/EtOH = 1/6
OH
OH N
N
COOH
R1
HO
+
a110; R1 = H a113; R1 = H
a111; R1 = Br a114; R1 = Br
a112; R1 =Cl a115; R1 =Cl  
Compounds R1 Yield E (%) Yield Z (%) 
a110 H 47%  
a111 H  42% 
a112 Cl 45%  
a113 Cl  43% 
a114 Br 44%  
a115 Br  42% 
Scheme 2-18. The synthesis of free acid oxime 
 
2.4.3 Other modifications of the phenol moiety in pyridines. 
 
The regents controlled domino reaction offered molecules with various functionalities, 
which could be explored to add further diversity to the compound collections [102-104]. 
The phenol moiety in substituted pyridines was converted into intermediate esters by 
the treatment with bromoacetic acid esters under the basic conditions. Coumarin, as a 
‘‘privileged’’ scaffold, showed multiple biological properties, especially anti-HIV and 
antibiotic activities [111]. To combine our molecules with coumarin structure, the 
substituted pyridines were converted into the coumarin-substituted pyridine 
carboxylates by a one pot procedure with good yields (Scheme 2-18) [102]. Alkylation 
with diverse acetic acids, which was treated with Im2CO activation and base-mediated 
condensation, afforded the desired coumarin-substituted pyridine carboxylates [102] 
(Scheme 2-18). 
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N R2
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N R2
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O OR3
BrCH2CO2Et, K2CO3
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R4CH2CO2H, Im2CO, K2CO3
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R1
O
R4
R1= Me, iPr, Br, Cl,H...
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R4=
CF3
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a117
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1M NaOH, MeOH, 
THF(1:2), rt, 16h
a119
a120
1M NaOH, MeOH, 
THF(1:2), rt, 16h
 
Scheme 2-18. Diversification of substituted pyridine molecules. 
 
2.5 Summary 
 
The branching cascade strategy leading to skeletal diversity can follow two pathways 
(Figure 1-3):[42] One is reagent-based approach; another is substrate-based approach. 
The reagent-controlled branching cascade processes described in this chapter provide 
structurally-diverse functionalized molecules in a complementary manner. Diverse 
domino reaction sequences dictated by different cascade triggering reagents on the 
common chromonylidene precursors generated highly substituted and functionalized 
pyridines, phenols and benzoyprans which might be useful for chemical biology and 
medicinal chemistry research. The branching cascade products were further modified 
into oximes, oxazoles, isoxazoles and coumarins etc.   
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Scheme 2-19. Cascade reactions for skeletal diversity. 
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3. Substrate controlled branching cascades 
 
3.1 Introduction 
 
Small molecule libraries containing diverse and relatively complex molecules are 
required for drug discovery and chemical biology investigations. Compounds 
collection possessing skeletal or scaffold diversity can more effectively target 
bioactive regions of chemical space [4, 6, 14]. Natural products, for instance, represent 
the most diverse and complex compound library that exists in nature and have been a 
continuous source of interesting drug candidates and synthetic targets [4, 8]. Structural 
diversity, in particular, scaffold diversity and molecular complexity are thus two 
important criteria that enrich any compound collection in biological activity. 
Therefore, synthesis strategies targeting medium to large sized compound libraries 
based on diverse and relatively complex molecular architectures, including natural 
product-based molecular frameworks, offer great synthetic challenges to the art of 
organic syntheses [6, 14]. The previous chapter summarized exploring a reagent 
controlled branching cascade strategy wherein different reagents dictate and drive 
diverse reaction cascades to end up generating different scaffolds. However, after 
activation/modulation of a given functional moiety on the common substrate by a 
reagent, only intramolecular reactions of the common substrate would happen. 
Therefore, the scaffold diversity and the molecular complexity generated thereby 
would be very limited [112-115].  However, instead of reagents that only activate or 
induce a given cascade reaction sequence, if different substrates that can also trigger 
different cascade reaction sequences on a common substrate (just like different 
reagents could induce different cascade reactions depicted in previous chapter) are 
employed, it would not only generate the scaffold diversity in the ensuing products 
but also the resulting frameworks might be more complex owing to the addition of 
different sub-structures in intermolecular reactions. Thus, addition of molecules X, Y 
or Z to a common substrate might lead to more complex and diverse ring-systems or 
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scaffolds (Figure 3-1). This approach is termed as substrate controlled branching 
cascades and the following sections provide further details of this synthesis strategy 
[116-119].  
 
 
Figure 3-1. Substrate controlled branching cascades. 
 
3.2 Synthesis of a common multi-functionalized substrate 
 
In the reagent controlled branching cascade strategy, only limited access to scaffold 
diversity is possible because of mostly intramolecular cascade reactions happening 
after the activation by the reagents [120]. That is why these transformations do not add 
to the overall molecular complexity. In order to access more complex and diverse 
scaffolds with the branching cascade strategy, it might be useful to add additional 
substrates that can trigger the cascade reactions and also add up to the common 
substrates to provide more complex molecules (Figure 3-2). The cascade triggering 
substrates can be chosen with the desired structural features so that more privileged 
and/or desired compound classes can be accessed [121]. However, this again would 
require the common multifunctioanlized substrates which can accommodate a variety 
of cascade triggering substrates and end up with diverse scaffolds [122-124].  
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Figure 3-2 Scaffolds with the branching cascade strategy 
 
Recently, a novel phosphine catalyzed [4+2] annulation reaction between 
3-formylchromones (b1) and electron-deficient acetylene carboxylates (b2) was 
discovered. However, it was observed that tricyclic benzopyrones b3 were not stable 
under acidic conditions and efficiently reorganize themselves to yield the 
corresponding chromone substituted , -unsaturated ketoesters or aldehydes (b5, Eq. 
B, Scheme 3-1). For instance, an overnight treatment of the pure adduct b4 (R4 = 
CO2Me) with 1% trifluoroacetic acid (TFA) in dichloromethane at room temperature 
afforded dimethyl-2-oxo-3-[(4-oxo-4H- chromene-3-yl)methylene]succinate (b5, R4 = 
CO2Me)) in 55% isolated yield.
[125] Being multi-functionalized, electron-deficient and  
highly conjugated, the chromone substituted ketoesters and aldehydes (b5) could 
prove excellent common precursors for the substrate controlled branching cascade 
strategy. In particular, they might undergo different cascade reactions with diverse 
nucleophilic substrates. To explore the potential of these interesting chromon olefines, 
their synthesis was further optimized. 
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Scheme 3-1. The reactions of substrates. 
 
It was observed that increasing the concentration of TFA to 10% in dichloromethane 
led to completion of the reaction in half an hour yielding b5 quantitatively. Although, 
BF3.OEt2 could complete the reaction within ten minutes with slightly reduced yield 
of b5, the milder reaction conditions with TFA for this transformation were preferred 
to use. The reaction produced the conjugated ketoesters decorated with a substituted 
benzopyrone moiety in excellent yields (Table 3-1, entries 1-7). Interestingly, when a 
tricyclic benzopyrone with only one ester moiety was treated with TFA, the 
conjugated aldehyde b12 could be obtained in very good yield (entry 8, Table 3-1). 
Substrates b13-b18 afforded the corresponding chromonyl acrylates b13-b18 in 
acceptable yields (entries 9-14, Table 3-1). Moreover, employing the adduct b19 
supporting a phenyl group generated the corresponding phenyl ketone b19 in good 
yield (entry 15, Table 3-1) [125g].  
O
O
R1
R2
O
R4
CO2R
3
10% TFA
DCM
O
O
R1
CO2R
3
O
R4
R2
 
Entry compounds R1 R2 R3 R4 Yield 
(%) 
1 b5 H H Me CO2Me 99 
2 b6 Cl H Me CO2Me 94 
3 b7 iPr H Me CO2Me 98 
4 b8 iPr H Et CO2Et 98 
5 b9 Me H Et CO2Et 91 
6 b10 H H Et CO2Et 97 
7 b11 Cl H Et CO2Et 91 
8 b12 H H Me H 87 
9 b13 Cl Me Me H 94 
10 b14 Me H Me H 92 
11 b15 H H tBu H 98 
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12 b16 iPr H Me H 88 
13 b17 Cl H Me H 82 
14 b18 Br H Me H 83 
15 b19 H H Et Ph 89 
Table 3-1. Rearrangement of the substrates:  a, Reaction conditions; 10% TFA in 
dichloromethane, 30 minutes, room temp.; b, isolated yields after flash column chromatography.    
 
The NMR spectra and LC-MS analysis clearly indicated the formation of a single 
isomer b5-b19. The configuration of the molecules b5-b19 was identified with nOe 
NMR experiments. Selective irradiation of the aldehyde proton in b17 led to 
enhancement of the signal for C1´-H and on irradiating the latter, a clear enhancement 
for the C2-H (and vice versa) was observed. Therefore, the Z-configuration of the 
molecule was established (Figure 3-3, A). Similar nOe effects were observed in the 
case of ketoester b10. While irradiation of C2-H in b10 resulted in signal 
enhancement for C1´-H; the latter on irradiation led to the signal enhancement for 
C2-H besides a weak signal enhancement for the methylene(-OCH2Me) proton of the 
conjugated ester (established by HMBC and HSQC NMR experiments) (Figure 3-3, 
B). [125g]  Thus, E-configuration was assigned to the ketoesters b5-b11 (Figure 3-3, 
B).  
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Figure 3-3. 1D nOe NMR of substrates. 
 
Single crystal x-ray analysis of the keotester-b5 unambiguously proved the structure 
and assigned configuration (Figure 3-4). 
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Figure 3-4. X-ray structrue for b5  
 
Mechanistically, the [4+2] adducts b3 acted as push-pull system under acidic 
conditions. Facilitated by the formation of aromatic pyrilium cation, the chromone 
ring would open up to generate b20 which underwent intermolecular addition of the 
phenol leading to cyclic alkyl vinyl ether b21 formation. The vinyl-ether b21 could 
undergo protonation and ring-opening of the dihydropyran ring forming an extended 
enol b22 which tautomerized to the product b5 after a single bond rotation to avoid 
the steric proximity of the ester functionality to the benzopyrone ring. Alternatively, 
the Claisen ring opening of b21 would yield the isomer of product b23 which could 
isomerize via acid-catalyzed automatism to b22 before transforming to b5 [125g] 
(Scheme 3-2).  
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Scheme 3-2. The mechanism of reactions. 
 
In order to synthesize the products b5-b19 directly from the commercially available 
chromone-3-aldehydes, a one pot—two step procedure was developed. In this process, 
3-formylchromone was treated with dimethylacetylene-dicarboxylate (DMAD) and 
triphenylphosphine (PPh3) to generate the [4+2] adduct b5. It was quenched by slow 
addition of a solution of 10% TFA in DCM at low temperature (0−4°C) and stirring 
the solution at room temperature for three to four hours by using TLC to monitor the 
reaction (Table 3-2). 
10% TFA in DCM, r t, 30 minO
O
O
CO2R1R1O2C
PPh3 (40 mol%), rt, 8 h
1)
2)
R
O
O
O
R1O2C CO2R1
R
 
compounds R R1 yiELD % 
b5 H Me 55% 
b7 i-Pr Me 57% 
b9 Me Et 59% 
Table 3-2. One pot synthesis of b5, b7, b9 from commercially available 3-formylchromones.  
 
By using this method, the separate purification of adducts b3 could be avoid, however, 
the yields of the rearrangement products (b5, b7, b9) were obviously reduced (Table 
3-2). 
The significance of this methodology could be realized from the fact that other 
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possible routes to these molecules should be multistep and tedious considering the 
reactivity of 3-formylchromones [6, 14]. The reactive aldehyde and ketoester 
functionalities in the molecules (b5, b7, b9) would always compete with substrates in 
alternative routes [15]. Moreover, as compared to a possible Wittig olefination or an 
aldol condensation reaction of the chromone-3-aldehydes to yield b5, this protocol 
provides a completely atom economic, easy and efficient procedures to the interesting 
class of chromone substituted acrylates and succinates.  
 
3.3 Substrate Controlled Branching Cascades  
 
The dispersed electrophilicity of the common substrates b5-16 provides ample 
opportunities to employ diverse and desired nucleophiles as cascades triggering 
substrates. To identify the cascade triggering nulceophiles that can provide interesting 
new scaffold structures in acceptable yields, a simple reaction screening of a set of 
twenty three diverse nucleophiles was planned (Figure 3-5). This set of nucleophiles 
contains mono- and bisnulceophlic substrates. In particular, it was of great interest to 
find whether and how bisnucleophiles could trap more than one electrophilic sites of 
the common precursor and provide complex ring-systems. The reaction screening 
batch, a set of 23 diverse nucleophiles that included 12 bisnucleophiles (N-N, N-O, 
N-C and O-C bis-nucleophiles), 7 mono-nucleophiles and 4 zwitterionic species 
(Figure 3-6) was used to observe the substrate conversions, product profile and 
reaction conditions etc. Screening was performed by using a Radley’s Carousel 
Reaction Station with 12 reaction tubes under an argon atmosphere at room 
temperature. Mononucleophiles were screened as such in different concentrations (for 
HCl salts of hydroxylamines, an equimolar triethylamine was used), while most of the 
bisnucleophiles were screened for their reactions in the presence and absence of 
external base. After a quick aqueous work up, a LC-MS analysis of the crude reaction 
mixture was performed. Reactions with high conversions and relatively cleaner 
product profiles were then separately optimized (when required) for better results.  
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Figure 3-5. Cascade substrates and nucleophiles 
 
A clear reactivity pattern of the nucleophiles towards common substrates was 
observed. Whereas many bis-nucleophiles reacted cleanly with 1-ketoesters, their 
corresponding reactions with aldehydes often yielded mixtures of products and with 
varying conversions. Among the attempted mono-nucleophiles and zwitterions, only a 
few performed well in the branching cascades, albeit displaying unbiased reactivity 
towards 1-ketoesters and 1-aldehydes. The unsuccessful cases included 
diaminoalkane b25 and t-butylmalonate b36 which yielded a complex mixture of 
products; amino alcohols b29 and b30 which displayed sluggish reactivity and their 
products too were showing decomposition during column chromatographic 
purifications; and o-aminophenol b32 that did not yield any specific product 
consistently. 
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3.3.1 Scaffold diversity emerging from the branching cascades with 
bisnucleophiles 
 
The electrophilicity of the common precursor could be transformed into diverse 
molecular frameworks with different bisnucleophiles. Interestingly, the screening 
results displayed that many of the bis-nucleophiles yielded the addition products with 
the common substrates. In most of the cases, there was no further optimization 
required and therefore products could be purified and analyzed for their structure 
elucidation. In cases yielding interesting scaffolds, further derivatives/analogues were 
prepared.  
 
3.3.1.1 Branching cascades with N, N-Bisnuleophilies 
 
The diaminoalkane b25 provided a complex mixture of products, however, the amino 
alcohols b29 and b30 slowly reacted (conversions up to 50%) and their products 
decomposed during chromatographic purifications. In all three of these cases the 
formation of some amount of 3-formylchromones was observed, which were 
apparently the cleavage product of the precursor.  
 
2-(2-Aminophenyl）indole b27 proved to be an interesting cascade bisnucleophile and 
yielded a major and a minor products with different architecture (Scheme 3-3). 
Stirring a mixture of 1-ketoesters and b27 in dichloromethane at room temperature led 
to the formation of novel chromone substituted benzo[2,3]azocino[4,5-b]indoles b54 
according to NMR spectrums.  The azocine ring was easily characterized by the 
characteristic two doublets at δ 5.41 and δ 4.85 (J = 12.0) for the vicinal protons on 
the alpha carbon to the ester and the benzoyprone ring on the 8-member scaffold. This 
cascade reaction sequence, however, yielded a minor product with a different 
molecular architecture i.e. dihydroindolo-[3,2-c]- pyrido-[1,2-a]quinoline b55, b57 in 
varying yields (Scheme 3-3). The structure of the minor product could easily be 
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assigned due the open chromone ring characterized by a H-bonded phenolic OH peak 
appearing at δ11.20 in 1H NMR spectrum and corresponding cabonyl peak at 196.2 in 
13C NMR spectrum. Other ketoester precursors also yielded the azocines molecules in 
acceptable yields (Table 3-3) along with minor products.  
 
Mechanistically, b27 attacked the ketone first to form imine b50 followed by a 
conjugated addition of C3-indole to yield the azocine b54, b56, b58, b59. In other 
case, the intermediate imine b51 could also cyclize to yield tricylic aminal b53. 
Addition of C3-indole to the tricyclic amine followed by chromone ring openeing 
would then yield the minor product b55, b57 (Scheme 3-3).  
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Scheme 3-3. Proposed mechanism of the reaction of common precursor-ketone ester with 
2-(1H-indol-2-yl)-benzenamine b27. 
 
Compounds R1 R2 major (%)/ ratio minor (%) 
b54 H Me 62% / 5:1  
b55 H Me  31% 
b56 Me Me 65% / 2:1  
b57 Me Me  30% 
b58 iPr Me 59%  
b59 Cl Me 64%  
Table 3-3. The results of the reaction of common precursor with b27. 
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Interestingly, when a keto-ester substrate with ethyl esters (still bulkier) was 
employed in the reaction, the azocine molecule was formed as minor adduct while 
b61 was formed as major product (Scheme 3-4). 
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59%
b61b27b10 b60
O
O
O
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Scheme 3-4. The reaction of ketone ester b10 with 2-(1H-indol-2-yl)benzenamine b27. 
 
The eight membered imines are rare scaffolds and it was intriguing to examine and 
verify the structure of these cascade products. To this end, the imine moiety present in 
the azocine was reduced under Pd-catalyzed condition (Scheme 3-5). The reaction 
clearly confirmed that it was indeed an imine that was reduced to yield two 
diasteromeric amine molecules (ratio 1:1) whose structures were further corroborated 
by detailed spectroscopic analysis including NMR-gCOSY, NOESY, gHSQC and 
gHMBC (Figure 3-6). 
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Scheme 3-5. Reductionof the azocinimine 
 
The spectrum of b63 can clearly show the configuration of the reduce product. 
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Figure 3-6 The NOESY spectrum of the product b63 
 
One of the highlight of branching cascade methodology is that subtle changes in the 
reaction conditions could change the course of the reaction cascades and lead to 
different scaffold structure. The bis-nucleophile b27 represents this example nicely. 
On the one hand, under neutral reaction conditions, it yielded two scaffolds 
i.e.azocines (b54, b56, b58, b59) and indolopyridoquinolines (b55, b57); on the other 
hand, under basic reaction conditions using excess of triethylamine, a completely 
different scaffold was formed as the only product in a clean reaction and in excellent 
yields (Scheme 3-6). Thus treating ketone esters with 2-(1H-indol-2-yl)benzenamine 
b27 and three equivalents of triethylamine at room temperature in DCM led to the 
formation of b68-71 as red solids which were purified by silica gel column 
chromatography in excellent yield (Table 3-4).  
 
Mechanistically, under basic condition, the aniline undergoes a 1,2-addition fashion to 
yield aminal b64. The later forms the amide under basic condition which adds to 
chromone ring followed by removal of water to form b65 intermediate. The pyridinim 
ring b66 could easily be formed form b65 that also yields an indole amide in b66 that 
would prefer to add to the sterically less hindered pyridine site on b66 to yield the 
cascade product b67 (Scheme 3-6).  
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Scheme 3-6. The raction of the common precursor-ketone ester with b27 in base-TEA. 
 
compounds R1 R1 yield(%) 
b68 H Me 91% 
b69 Cl Me 86% 
b70 iPr Me 87% 
b71 H Et 88% 
Table 3-4. The result of the common presursor with b27 in basic conditions. 
 
Encouraged by above results, this reaction was performed with ketone aldehyde b14 
under basic conditions. Pleasingly, the common aldehyde precursor also yielded the 
desired ring-system b72 in good yield (71%). However, another product formed in the 
reaction could not be purified. 
N
NOHO
CO2Me
H+
NH2HN 3.0 eq TEA
DCM
O
O
MeO2C H
O
b27 b72  
Scheme 3-7. The reaction of ketone aldehyde with 2-(1H-indol-2-yl)benzenamine b27. 
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2-(1H-benzo[d]imidazol-2-yl)ethanamine b28, another N,N-bisnucleophile, pleasingly 
transformed 1-ketoesters into novel internal pyridinium salts b77-80 following yet 
another cascade reaction sequence. Complete spectroscopic analysis supported by 
palladium catalyzed hydrogenation of pyridinium internal salts to corresponding 
1,2-dihydropyridines corroborated the structural assignments of these novel internal 
salts. Thus, treating a mixture of ketoester and triethylamine with the bis-nucleophile 
b28 at room temperature till the consumption of ketoester (TLC) led to the formation 
of internal salts b77-80 which was purified as white solids after silica gel column 
chromatography.  
 
This cascade reaction sequence plausibly involved the formation of hemi-aminal  
b74 wherein the attack of amine on to chromone ring leads to intermediate b75. 
Under basic conditions the benzimide group adds on to the keto-ester to form a seven 
member lactam ring. Dehydration facilitated by aromatization thus provides the 
internal salts (Scheme 3-8) in excellent yields (Table 3-5).  
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Scheme 3-8. The reaction of the common precursor-ketone ester with b28 in base—TEA. 
 
compound R1 R1 yield(%) 
b77 Me Me 91% 
b78 iPr Me 82% 
b79 H Me 93% 
b80 H Et 88% 
Table 3-5. The result of the reaction of common precursor with b28 in basic conditions. 
 
In order to verify the structure of these unprecedented novel internal salts, palladium 
catalyzed hydrogenation reaction was resorted to. The salt b77 was terated with 0.1 
equivalent of 20% Pd (OH)2 / C dissolved in MeOH under the hydrogen atmosphere, 
and was stirred for more than two days (Scheme 3-9). Although it took quite long to 
reduce the pyridinium salt, only one product was formed which was purified by silica 
gel column chromatography and its spectral analysis revelaed it to be 
1,2-dihydropyridine b81-82.  
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Scheme 3-9. Reduction reaction of the salt. 
 
NMR analysis of HMBC and NOESY spectrum of the dihydropyridine corroborated 
the assigned structure (Figure 3-7). 
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Figure 3-7. HMBC and NOESY of reduce product. 
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Another N,N-bisnucleophile,  i.e. 4-aminopiperidine b26, worked very well in a 
cascade reaction sequence, and led to the formation of complex 
tetrahydro-1,4-ethanopyrido[1,2-a]pyrimidine ring-system b86-89 in high yields 
(Scheme 3-10).  
+
N
H
NH2
N
R2O2C CO2R2
O OH
O N
CO2R2
O
CO2R2
N
H
O N
CO2R2
O
CO2R2
DCM
N H
N
b84
b85
R1
R1
R1
b86; R1 = Cl, R2 = Me
b87; R1 = Cl, R2 =Et
b88; R1 = iPr, R2 = Me
b89; R1 = H, R2 = Et
b26O
O
O
R2O2C CO2R2
R1
Tautomerization
O
O
NH
R2O2C CO2R2
R1
HN
HO
b83
 
Scheme 3-10 The reaction of the common precursor with piperidin-4-amine b26. 
 
comopounds R1 R2 yield(y) 
b86 Cl Me 87% 
b87 Cl Et 85% 
b88 iPr Me 86% 
b89 Et Et 91% 
Table 3-6. The result of the reaction of common precursor with piperidin-4-amine 
b26. 
 
3.3.1.2 Branching cascades with N, O-bisnuleophilies 
 
Unlike b30, bisnucleophilic o-aminobenzyl alcohol b31 afforded a clean reaction 
profile (TLC) leading to the formation of tricyclic oxazine b92 in high yield (Table 
3-7). The structure of the oxazines b92 could be easily confirmed via spectroscopic 
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analysis. In particular, characteristic peaks in 13C NMR for quaternary aminal carbon 
(108 ppm) and ketone moiety of the ring- opened chromone (193.7 ppm), and the 
appearance of an H-bond -OH signal in the 1H-NMR spectrum at 11.5 ppm clearly 
supported the formation of oxazine b92. Apparently, two electrophilic sites C1 and C3 
were attacked by the bis-nucleophile in the cascade reaction sequence.  
 
Mechanistically, it is proposed that the ketone ester condensed with amine to form 
iminoester b91, which is attacked by the benzylic alcohol to yield an amine. Addition 
of amine to benzopyrone opens up the ring to yield the desired benoxazines in good 
yield. 
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Scheme 3-11. The reaction of the common precursor-ketone ester with o-aminobenzyl alcohol 
b31. 
 
compounds R1 R1 yield(%) 
b92 Me Me 91% 
b93 Cl Et 90% 
b94 H Me 94% 
b95 H Et 89% 
Table 3-7. The results of the reaction of common precursor with o-aminobenzyl alcohol b31. 
 
In the same way, bisnucleophilic o-aminobenzyl alcohol b31 was treated with 
aldehyde precursors that resulted in two products in good yield (Table 3-8). In this 
reaction, presumably the tricyclic intermediate b96 leads to an internal pyridine salt 
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b97 that has two eletrophilic sites available for addition of alkoxide. Therefore, 
addition of benzyl alcohol to either α-carbon of pyridine ring generate two 
benzoxazine rings (Scheme 3-12), which were quite difficult to isolate by column 
chromatograph. 1H-NMR spectra of the mixture clearly revealed two sets of peaks in 
the ratio 3: 2. 
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Scheme 3-12. The reaction of the common precursor aldehyde with o-aminobenzyl alcohol 
b31. 
 
compounds R1 ratio total yield (%) 
b98 H 2/3 93% 
b99 H 2/3 93% 
b100 Cl 2/3 89% 
b101 Cl 2/3 89% 
Table 3-8. The results of the aldehyde with o-aminobenzyl alcohol b31. 
 
2-aminophenol b32 did not prove to be an interesting N, O-bisnucleophile because 
of different products formed in different attempts. Ketone ester b6 was mixed with 
2-aminophenol b32 under basic conditions which resulted in the formation of many 
products judging from TLC and LC-MS. However a tricyclic lactone internal salt 
was isolated in very low yield (Scheme 3-13). Mechanistically, the ketoester b6 
condensed with aminophenol b32 first to form aminal b103 that cyclizes to yield 
b104. The lactone ring is formed by addition of phenol followed by chromone ring 
opening to yield the internal salt b106 (Scheme 3-13).  
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Scheme 3-13. The reaction of the common precursor b6 with 2-aminophenol b32. 
 
2-aminoethanol b29 is a very simple bis-nucleophile and its reaction was attempted 
with the ketoester. However this led to the formation of many products which could 
not be purified. To avoid side reactions, Boc-protected 2-aminoethanol b30 was 
resorted to. Addition of b30 to ketoester changed the light yellow color of reaction 
mixture quickly to deep yellow; however, soon many products began to appear (TLC). 
Addition of 10% TFA to remove the protecting group Boc further messed up the 
reaction mixture and therefore, this transformation was not further pursued.  
 
In order to incorporate stereogenic centers to the cascade products, L-serine methyl 
ester b33 was used as N,O-bisnucleophile. However, under basic conditions— TEA, 
racemization was observed. So the TEA was replaced by the weak base collidine. In 
this cascade reaction two diastereomeric products were formed which could be 
purified carefully. However, the methods attempt to define their absolute 
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configuration by using different NMR technique failed. Crystallization attempts were 
also unsuccessful. It is assumed that dihydro-2H-oxazole[3.2.a]-pyridines are formed 
from the tricyclic intermediate b108 (as in many others cases). Formation of two 
diastereoment also suggested that a flat pyridium salt b110 might be involved 
(Scheme 3-14). 
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Scheme 3-18 The reaction of the common precursor-ketone ester with L-serine methyl ester 
b56 
 
Compounds R1 R2 Yield (%) 
b111a Me Me 43% 
b111b Me Me 46% 
b112a Cl Me 44% 
b112b Cl Me 45% 
b113a H Me 41% 
b113b H Me 41% 
b114a H Et 45% 
b114b H Et 43% 
b115a iPr Me 47% 
Table 3-9. The results of the reaction of common precursor-ketone ester with L-serine methyl 
ester b33. 
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3.3.1.3 Branching cascades with N, C; O, C; and C, C-bisnuleophilies 
 
Among the other bisnucleophiles employed, two more bisnucleophiles that proved 
interesting cascade-triggering molecules in the branching-cascade strategy were the 
N,C- and O,C-bisnucleophiles b57 and b35, respectively. Both of these nucleophiles 
displayed very sluggish reactivities in the initial screening and required further 
optimization of the reaction conditions. Interestingly, the use of 
di-tert-butyl-2-(2-aminophenyl)malonate (b57) led to the formation of 
benzoindolizine b119-122 (Scheme 3-15): a scaffold that is part of many biologically 
active natural products. The use of silver triflate as a catalyst in ethanol at 60°C led to 
very good yields (Table 3-10) for this cascade reaction sequence (Schemes 3-15). 
Mechanistically, this cascade reaction too seems to form the tricyclic intermediate 
b118 to which adds the di-tert-butyl-melonate nucleophile to yield the 
benzoindolizine scaffold (Scheme 3-15) [126]. 
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Scheme 3-15. The mechanism of the common precursor-ketone aldehyde with b34 
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Compounds R1 Yield (%) 
b119 Me 83% 
b120 Cl 79% 
b121 iPr 87% 
b122 H 89% 
Table 3-10 The results of the common precursor with silver catalyzed 
 
2-Hydroxynaphthalene-1,4-dione b35,[127-128] a O,C-bisnucleophile beholds the 
naphthoquinone scaffold that exists in many biologically interesting natural products 
[133].  Although b35 did not show any promising reactivity in the initial screening, on 
tapping its potential to provide natural product based polycyclic quinones, in 
particular medicinally important pyranonaphthoquinones. Gratifyingly, the treatment 
of ketoester substrates b11 with b35 in the presence of acetic anhydride/acetic acid 
(1:3) at 150°C for a few minutes yielded chromone-substituted 
pyranonaphthoquinones b125-129 in good yields with good diastereoselectivity 
(Scheme 3-16, Table 3-11). Although aldehyde substrates b12 reacted well with b35 
under these conditions, the corresponding products were not stable enough and could 
not be purified.  
 
A proposal for the plausible cascade reaction mechanism is depicted in Scheme 3-16. 
A conjugated addition of quinone enolate to the substrate ketoester would provide an 
intermediate b124 after isomerization. The enolic hydroxyl group then adds to the 
ketone moiety to provide an anomerically stabilized and therefore stereoselective 
formation of pyranonaphthoquinone products (Scheme 3-16).  
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Scheme 3-17. The mechanism of the common precursor-ketone ester with b35.  
 
Compounds R1 R2 R3 yield(%) Ratio 
b125 Cl H Et 84% 5:1 
b126 iPr H Me 85% 8:1 
b127 Me H Me 88% 9:1 
b128 H H Me 90% 9:1 
b129 Cl Me Me 86% 9:1 
Table 3-11. The results of the common precursor with 2-hydroxynaphthalene-1,4-dione b35. 
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Figure 3-8 The NOESY spectrum of b127 
 
The NOESY spectrum of b127 shows the nOe interaction between the Ha and Hb 
which were assigned on the basis of 1H-13C correlation spectrum. The diaxial 
coupling value (J = 10.8 Hz) for Ha with the vicinal benzylic proton further supports 
the predicted stereorelationship. The axial position of the hydroxyl group is due to the 
extra stabilization provided by the double anomeric effect in these acetals. [129] 
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Figure 3-9. Most widely accepted explanation for the anomeric effect. 
 
The anomeric stabilization is observed in this example, and a brief explanation is 
provided for this effect. The anomeric effect nomally relates to the interaction 
between the orientation of the lone pair orbital on the endocyclic oxygen (Figure 3-9) 
and the exocyclic C-O sigma bond. In the case where the exocyclic oxygen is axial 
then there is an axially directed lone pair on the endocyclic oxygen that is in an 
antiperiplanar relationship to the exocyclic C-O bond and consequently is able, 
through the principle of maximum orbital overlap, to donate some electron density 
into the low energy C-O antibonding orbital [129]. The stabilization from the orbital 
interaction in the axial conformer can often be greater than the destabilization from 
steric clash with the axial hydrogen and the axial conformation can often be more 
stable than the equatorial conformation in these cases [129]. 
 
A C,C-bisnucleophilic di-tert-butyl malonate b36 was also used in the reaction 
screening. Although, b36 was completely consumed in the reaction (monitored by 
TLC and LC-MS), too many products were found which could not be purified by 
silica gel column chromatography.  
 
3.3.2 Branching cascades with Mononucleophiles 
 
It was very disappointing to realize that mononucleophiles b37-40 yielded complex 
mixtures of inseparable products in the initial reaction screening. However, N-benzyl- 
and N-phenylhydroxylamines b41 and b42, respectively, were found to be useful 
cascade-triggering substrates. These nucleophiles provided natural product related 
highly substituted tricyclic benzopyrones b134-149 in excellent yields and with 
appreciable diastereoselectivity (Scheme 3-18). In this branching cascade, the 
hydroxylamines act as O-nucleophiles rather than N-nucleophiles and add to the keto 
or aldehyde group of the common substrate to give an intermediate b131, which 
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cyclizes to yield a cyclic acetal b132. Chromone ring opening leads to a dihydropyran 
b133, which undergoes intramolecular conjugated addition of the phenol to provide 
benzopyrones b134-149. The conjugate addition of the phenol in b133 might occur 
preferentially anti to the initially added hydroxylamine for steric reasons and thus lead 
to the observed stereoselectivity in the formation of anomerically stabilized 
benzopyrone acetals b134-149 (Scheme 3-18). The structure and relative 
configuration of products are corroborated by the results of comprehensive NMR 
spectroscopic studies.  
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Scheme 3-17 The mechanism of the common precursor-ketone ester and aldehyde with 
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N-hydroxybenzenamine b40 and N-hydroxy(phenyl)methanamine b41;  
 
Compounds R1 R2 R3 R4 R5 ratio yield 
b134 Me H CO2Me Me Ph 84/16 93% 
b135 Me H H Me Bn 91/9 87% 
b136 Cl H CO2Et Et Ph 84/16 90% 
b137 iPr H H Me Bn 88/12 86% 
b138 iPr H H Me Ph 85/15 88% 
b139 Cl Me H Me Ph 81/19 89% 
b140 H H CO2Me Me Bn 90/10 94% 
b141 H H H Me Ph 82/18 88% 
b142 H H CO2Et Et Bn 87/13 91% 
b143 H H CO2Et Et Ph 87/13 93% 
b144 H H CO2Me Me Ph 82/18 95% 
b145 Me H H Me Bn 81/19 88% 
b146 H H H Me Bn 88/12 89% 
b147 Me H CO2Me Me Bn 86/14 94% 
b148 Cl H CO2Me Me Ph 85/15 92% 
b149 Cl H CO2Et Et Ph 86/14 88% 
Table 3-12. The results of the common precursor-ketone ester and aldehyde with 
N-hydroxybenzenamine b40 and N-hydroxy(phenyl)methanamine b41. 
 
The relative stereochemistry of the tricyclic benzopyrones was confirmed by NOESY, 
gHSQC, gHMBC etc (Figure 3-10). The observed anomeric effects might be more 
pronounced in these systems due to the special structure of the spirocycle and might 
contribute to the unexpected stability of these systems [130]. 
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Figure 3-10 Double anomeric stability function 
 
An analogue of ketone ester b150 supporting methyl ketone instead of keto-ester, was 
treated with N-hydroxybenzylamine b40 and N-methylhydroxylamine b42 under the 
same rection conditions. Pleasingly, this led to the formation of corresponding 
tricyclic benzoyprones b154 and b158 respectively in good yield (Scheme 3-18, 
Scheme 3-19). 
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Scheme 3-18. The mechanism of the ketone b154 with N-hydroxybenzylamine b40.  
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Scheme 3-19. The mechanism of ketone b158 and N-hydroxymethylamine b42. 
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Other mono-nucleophilic reactants like sodium ethoxide, vinylmagnesium bromide, 
hydroxyamino, and butan-1-amine could not provide appreciable product profiles and 
resulted in formation of complex mixture of many products including trans-esterified 
and hydrolyzed products. Therefore these reactions were not further optimized. 
 
3.3.3 Branching cascades with Zwitterions 
 
In the reaction screening, some zwitterionic species were intentionally added that 
could act as both simple nulceophiles or as dipoles for plausible dipolar annulations. 
Among the zwitterions attempted in the branching cascades strategy, b45 did not react 
at all and the allene derived zwitterion b46 was too slow to yield traces of an 
unidentified product. Zwitterion b44 i.e. methyl isocyanoacetate though reacted nicely 
with both aldehydes and ketoester substrates and yielded another flavonoid based 
benzopyrone molecules supporting substituted furan ring (b162-165, Scheme 3-20). 
An initial conjugated addition of b44 on to the C1´of 1 leads to formation of oxanion 
b160 was assumed which adds on to the iminium cation in the proximity to provide 
b161. Isomerization/aromatization of b161 provides the final products b162-165 in 
this branching cascade (Scheme 3-20) in excellent yields (Table 3-13).  
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Scheme 3-21. The mechanism of the common precursor-ketone ester with b44. 
 
Compounds R1 yield(%) 
b162 Me 94% 
b163 Cl 91% 
b164 iPr 93% 
b165 H 95% 
Table 3-13. The results of the common precursor with methyl 2-isocyanoacetate b44. 
 
Interestingly, when the common precursor-ketone ester was traded with b44 in the 
presence of triethylamaine, the results were totally different yielding highly 
electron-deficient benzenes b170-173 (Scheme 3-22) in excellent yields (Table 3-14). 
It is proposed that under basic condition, the anion of the b44 adds to the keto group 
of the ketoester moiety to form b166 which might also exist in the form of b167. The 
later leads to the s-cis conformation (b168) followed by 6 cyclization leading to 
b169 where decyanation occurs providing highly substituted and electron-deficient 
benzophenones (Scheme 3-21 and Table 3-14) [131].  
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Scheme 3-21. The mechanism of the common precursor-ketone ester with methyl 
2-isocyanoacetate b44 under basic conditions.  
 
Compounds R1 yield(%) 
b170 Me 93% 
b171 Cl 89% 
b172 iPr 91% 
b173 H 94% 
Table 3-14. The results of the common precursor with methyl 2-isocyanoacetate b44 under basic 
conditions. 
 
Huisgen´s zwitterions (b47, Figure 3-5) had been well explored on various aldehydes 
and ketones including chalcones. Based on their reported reactivity pattern, it was 
intriguing to find how they behave with the highly conjugated common substrates of 
the branching cascades. Precisely, the effort was to see if the expected intermediate 
b176 that is formed by addition of b47 to ketones, would follow a 1,4-addition or a 
possible yet rare 1,6-addition. Thus, a mixture of ketoester, 
dimethyldiazodicarboxylate (DIAD) and triphenlyphosphine was stirred overnight at 
room temperature in dichloromethane when all of the ketoester was consumed. 
Column chromatographic purification of the crude reaction mixture provided the 
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expected chromone substituted pyrazole as the major product. Differently substituted 
common substrates yielded the pyrazoles b177-180 in very good yields (Scheme 3-22 
and Table 3-15, Figure 3-11). Nevertheless, a pyrazole substitution on to the 
privileged chromone moiety brings structural features of the flavonoid natural 
products and might enrich the collection in interesting and related biological 
activities.  
 
Mechanistically, the zwitterion b174 is formed after the addition of triphenylphophine 
to DIAD and it adds to the ketone moiety to form the cyclic structure b175. The later 
removes the triphenylphosphine oxide to form the critical intermediate b176 which 
follows the 1,4-addition to yield the pyrazoles (Scheme 3-22). 
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Scheme 3-22. The mechanism of the common precursor-ketone ester with DIAD  
 
Compounds R1 R2 yield(%) 
b177 Cl Me 86% 
b178 Cl Et 84% 
b179 H Me 91% 
b180 H Et 89% 
Table 3-15. The results of the common precursor-ketone ester with DIAD. 
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Figure 3-11 X-ray structure of b179 
 
In all these cases, therefore the major reaction pathway the intermediate b176 follow 
is the 1,4-addition. However, in cases of aldehydes, minor products could be isolated 
(b185-186) that appear to be the 1,6-addition products, along with the expected 
pyrazoles as major products b183-184 (Table 3-16). Different spatial arrangement of 
the functional groups in the case of ketoesters and aldehydes i.e. different 
configurations might be playing a role in providing small amount of 
chromonodiazepines. It is obvious that in case of aldehydes the intermediate b182 is 
more proximal to the chromone ring than in ketoesters (Scheme 3-23). 
Substrate Controlled Branching Cascades 
 86 
O
O
CO2Me
O
Ph3P N
N CO2iPr
CO2iPr
OPPh3
O N N
CO2Me
CO2iPrPriO2C
O
N N
CO2iPr
PriO2C
O
O
N
N
CO2iPr
CO2iPr
CO2Me
PPh3
+
O
O
CO2Me
N
N CO2iPr
CO2iPr
R1
R1
R1 R1
O
O
MeO2C H
O
R1
b47
b181 b182
b183; R1 = H;
b184; R1 = Me
b185; R1 = H;
b186; R1 = Me
1.4-addition 1.6-addition
a
a
b
b
 
Scheme 3-23. The mechanism of the common precursor aldehyde with DIAD b47  
 
Compounds R1 Yield (%) 
b183 H 86% 
b184 H 13% 
b185 Me 73% 
b186 Me 11% 
Table 3-16. The results of the common precursor aldehyde with DIAD b47. 
 
3.4 Summary 
 
In the substrate controlled branching cascades, diverse chosen cascade triggering 
substrates can push different cascade reactions and incorporate their molecular 
complexity to the overall architectures that result from these reactions. Therefore, not 
only diverse scaffolds result from these efforts but also relatively more complex 
scaffolds are generated. The methodology also provides access to new unprecedented 
structures and chemical transformations of broader use and applications in general 
organic synthesis. The examples provided above clearly demonstrate these 
observations, wherein fourteen different nucleophiles provided seventeen complex 
and functionned scaffolds following ten different cascade reaction sequences. A very 
important point in this branching cascade strategy is to have suitable 
multifucntionalized common precursors which can facilitate numerous reaction 
cascades and entertain diverse addition substrates to yield skeletally diverse focused 
compound collections. In the presented strategy diverse nucleophiles i.e. 
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bisnucleophiles, mono-nucleophiles and zwitterions were employed on a common 
substrate that has largely dispersed eletrophilicity. These contrasting features along 
with inherent hard and soft nucleophilicities of the additional substrates helped direct 
different cascade reactions and as a consequence result in different scaffold structures. 
The strategy is particularly suitable to address the synthesis of natural product 
inspired compound collections wherein diverse and complex natural product-based 
motifs are desired but in efficient and quick manner. Because branching cascade 
design employs easily accessible common substrates that are ring-transformed 
efficiently, this strategy is highly amenable to generate diverse focused compound 
collections.  
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Figure 3-10. Substrate control branching cascades. 
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4. Summary 
 
4.1 Summary(English) 
 
The dilemma of any organic chemist in this era of highly interdisciplinary research, in 
particular when comes to explore small molecules for chemical genetics and chemical 
biology research, is that what kind of small molecules should be made? Different 
strategies therefore have emerged in the last decade covering different areas of vast 
chemical space. While on the one hand, diversity oriented synthesis (DOS) has 
emerged as a powerful combinatorial tool to cover largely unbiased chemical space, 
biology oriented synthesis (BIOS) focuses on the biologically relevant scaffold 
structures and tends to generate natural product inspired libraries. However, most of 
the compound collection synthesis strategies follow multi-step syntheses wherein 
typically a scaffold is generated in few steps followed by the modification or 
incorporation of functional groups that can help generate a sufficient number of 
molecules in a collection. Synthesis strategies that can provide easy, concise and 
efficient access to diverse sets of scaffold structures are very demanding and 
challenging to develop. Cascade or domino reaction sequences, where multiple 
reactions occur consecutively in a one-pot protocol could provide efficient access to 
compound collection synthesis.  
 
In the work presented in this thesis, a cascade reaction based synthesis strategy termed 
“branching cascades” was developed. Based on the branching pathways of DOS, in 
this strategy, a common substrate enters diverse scale reaction sequences, which are 
triggered either by activating reagents or by additional substrates and each cascade or 
domino reaction sequence yields diverse and complex scaffold structures (Figure 4-1). 
The scaffolds emerging from this strategy are already suitably functionalized for 
further functional group manipulation that provides the desired number of complex 
Summary 
 89
small molecules. Therefore, the most important aspect of this strategy is to design the 
common, multi-functionalized precursor which can support and facilitate diverse 
cascade reaction sequences. 
 
 
Figure 4-1. Branching Cascades 
 
In the second chapter of this thesis, the common substrate was designed to have 
different reactive sites along with a TBS protected alkyl ether handle. A branching 
cascade strategy was developed wherein diverse cascade reactions were triggered by 
different desilylating reagents. Thus, different reagents, i.e. ammonium fluoride, 
cesium fluoride and PPTS triggered different cascade reaction sequences and yielded 
a compound collection of highly substituted pyridines, benzophenones and 
benzopyran scaffolds. The resulting diverse collections were already decorated with 
functional groups that can be easily modified to make further small libraries. Thus, 
this strategy provides an easy access to libraries from a library. In this regard, a 
collection of benzoximes and benzoxazoles and isoxazoles was efficiently generated 
(Figure 4-2).  
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Figure 4-2. Reagent controlled branching cascades. 
 
The third chapter of this thesis explains the substrate controlled branching cascade 
strategy, wherein instead of reagents, different additional substrates are employed as 
cascade reaction triggers. This approach is more interesting and useful, because one 
can choose the substrates with sub-structures that should be incorporated into the 
resulting scaffolds. Thus, the resulting collection would have both scaffold diversity 
and enriched molecular complexity. It was good evident from the results presented in 
this chapter. A common substrate with multiple electrophilic centers was used with a 
group of twenty three diverse nucleophiles, which include mono- and bis-nucleophiles 
and nucleophilic zwitterionic species. Fourteen nucleophiles provided sufficiently 
clean reaction profiles and afford seventeen diverse and complex ring-systems 
including some unprecedented molecular frameworks (Figure 4-3). There were ten 
different cascade reaction pathways that were followed by these substrates on the 
common substrates. While one can choose the cascade triggering substrates with the 
desired sub-structures, this strategy is particularly useful for generating natural 
product inspired compound collection as depicted in Figure 3. In addition, there were 
novel scaffold structures generated that could be of further interest from a medicinal 
chemistry point of view. Moreover, this strategy also revealed novel chemical 
transformations, for instance, hydroxylamines acted as O-nucleophiles rather than 
N-nucleophiles in delivering natural product based tricyclic benzopyrones. Further, 
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subtle changes in reaction conditions changed the course of the reaction completely to 
a different cascade sequence. For instance, methyl isocyanoacetate under neutral 
reaction conditions provided furan substituted benzopyrones. However, in the 
presence of triethylamine, a completely different reaction course was adopted leading 
to benzophenones (Figure 4-3).  
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Figure 4-3 Triggering substrates cascade. 
 
While the branching cascade design employs easily accessible common substrates that 
are ring-transformed efficiently, this strategy is highly amenable to generate diverse 
focused compound collections.  
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4.2. Zusammenfassung (German) 
 
Die interdisziplinären Gebiete der Chemischen Genetik und der Chemischen Biologie 
stellen einen organischen Chemiker stets vor die herausforderung ein geeignetes 
Grundgerüst für die Synthese von biologisch aktiven Molekülen zu finden und eine 
entsprechend effiziente Syntheseroute zu etablieren. Mehrere Strategien wurden 
diesbezüglish in den letzten jahren entwickelt. Während sich die diversitätsorientierte 
Synthese(DOS) als kombinatorische Prozedur, auf eine möglichst große Diversität 
bezüglich der zu synthetisierenden Verbindungen fokussiert, zielt die biologisch 
orientierte Synthese(BIOS) auf Verbindungen ab, die bereits biologisch validierte 
Grundgerüste enthalten und generiert somit naturstoffinspirierte substanzbibliotheken. 
Die synthese der meisten Substanzbibliotheken basiert häufig auf mehreren 
Syntheseschritten, wobei ein Grundgerüst synthetisiert und derivatisiert werden muss. 
Synthesestrategien, die möglichst schnell und in hohen Ausbeuten eine Vielzahl an 
neuen Verbindungen generieren können, sind hierbei von besonderem Interesse. In 
dieser Hinsicht bieten Kaskaden- und Dominoreaktionen, besonders als 
“Eintopfreaktionen“, einen effizienten und raschen Zugang zu Substanzbibliotheken. 
 
In dieser Arbeit wurde eine Kaskadenreaktion basierte Strategie entwickelt und 
angewendet. Basierend auf dem DOS-Prinzip, wird in dieser Strategie eine 
herkömmliche Substanz mit weiteren Edukten in Domino- oder Kaskadenreaktionen 
umgesetzt und dabei eine große Anzahl an komplexen Molekülen synthetisiert(Abb.1). 
Die hierbei entstandenen Grundgerüstet sind bereits mit funktionellen Gruppen für 
weitere chemische Modifikationen ausgerüstet, um eine komplexe Substanzbibliothek 
zu etablieren. Der wichtigste Aspekt hierbei ist das Design und die Synthese einer 
geeigneten Ausgangsverbindungen, die für die Kaskadenreakion effizient eingesetzt 
werden kann. 
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    Vorläufer
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    Vorläufer
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Kaskade III
+ X
+ Y
+ Z
Verzweigung Weg Verzweigung Kaskaden
= Kaskaden reaktionen  
Abbildung 1. Branching Cascades 
 
Im zweiten Teil dieser Arbeit wird eine Substratklasse mit verschiedenen 
Reaktionszentren und TBS-geschützten Alkylether-Seitenketten etabliert, die einen 
Ausgangspunkt für Kaskadenreaktionen darstellt. Die Kaskadenreaktionen werden 
hierbei mit verschiedenen Desilylierungsreagenzien gestartet. Der Einsatz von 
verschiedenen Reagenzien, wie zum Beispiel Ammoniumfluorid, Cäsiumfluorid oder 
PPTS, führten zu einer Substanzbibliothek von substituierten Pyridinen, 
Benzophenonen und Benzopyranen. Die resultierenden Grundgerüste waren bereits 
entsprechend mit funktionellen Gruppen ausgestattet, so dass weitere Bibliotheken 
aus dieser Ursprungsbibliothek generiert werden konnten. Hierdurch konnten 
Substanzkollektionen basierend auf Benzoxim-, Benzoxazol und 
Isoxazolgrundgerüsten dargestellt werden. (Abb.2) 
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Abbildung 2. Reagenz kontrolliert Verzweigung Kaskaden. 
 
Das dritte Kapitel erklärt eine Substrat kontrollierte verzweigte Kaskadenstrategie, in 
der anstatt eines Reagenzes, verschiedene zusätzliche Substrate als Auslöser fungieren. 
Dieser Ansatz ist interessanter und nützlicher, weil man Substrate mit speziellen 
Substrukturen in das Gerüst mit einbauen kann. So besitzt die resultierende 
Substanzkollektion sowohl eine strukturelle Vielfalt als auch eine gesteigerte 
molekulare Komplexität, was aus den Ergebnissen dieses Kapitels klar hervorgeht. Es 
wurde ein gemeinsames Substrat mit mehreren elektrophilen Zentren mit einer Charge 
von 23 verschiedenen Nukleophilen umgesetzt, welche Mono- und Bis-Nukleophile 
und nukleophile-zwitterionische Spezies umfassten. Vierzehn Nukleophile zeigten ein 
sauberes Reaktionsprofil und ermöglichten 17 vielfältige und komplexe Ringsysteme 
einschließlich einiger noch nie gezeigter molekularer Gerüste (abb3). 
 
Darüber hinaus konnten neue Molekül-Gerüste erzeugt werden, die von weiterem 
Interesse für die Medizinische Chemie sein könnten. Zusätzlich konnte durch diese 
Strategie neu chemische Umwandlungen aufgezeigt werden, zum Beispiel 
Hydroxylamine, welche bei der Bereitstellung von trizyklischen Benzopyronen eher 
als O- und nicht als N-Nukleophile fungieren. Darüber hinaus zeigte sich, dass kleine 
Änderungen der Reaktionsbedingungen zu komplett unterschiedlichen 
Kaskadensequenz führen können. Zum Beispiel führen Reaktionen der 
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Isocyanoacetate unter neutralen Bedingungen zu Furan substituierten Benzopyronen. 
Aber in Gegenwart von Triethylamin wurde eine komplett andere Reaktionsfolge 
beobachtet, bei der diese zu Benzophenonen umgewandelt wurden(Abb 3). 
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Abbildung 3 Triggering Substrate Kaskade. 
 
Während das verzweigte Kaskaden-Design leicht zugängliche Substrate einsetzt, 
welche leicht zum Ringschluss neigen, ist diese Strategie sehr gut geeignet um diverse 
Substanzkollektionen zu generieren. 
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5. Experimental section 
 
5.1 General methods 
 
Silica gel flash liquid chromatography: 
 
Purifications were performed using silica gel from J. T. Baker or Merck (particle size 
40-60μm) under approximately 0.5 bar pressure. 
 
Nuclear magnetic resonance spectroscopy (NMR): 
 
1H- and 13C-NMR spectra were recorded using a Varian Mercury 400 spectrometer 
(400MHz)1(H) and 100.6MHz (13C)). Chemical shifts are expressed in parts per 
million (ppm) from internal deuterated solvent standard (CDCl3: δ H = 7.26 ppm, δC 
= 77.0 ppm; CD3OD: δ H = 4.84 ppm, δC = 49.05 ppm; DMSO: δ H = 2.50 ppm, δC 
= 39.43 ppm; CD3CN: δ H =1.94 ppm, δ H = 1.24 ppm). Coupling constants (J) are 
given in Hertz (Hz) and the following notations indicate the multiplicity of the signals: 
s (singlet), d (doublet), t (triplet), dd (doublet of doublet), m (multiplet), br (broad 
signal). 
 
Mass spectrometry (ESI-MS and FAB-HR/LR): 
 
Electrospray mass spectrometric analyses (ESI-MS) were performed on a Finnigan 
LCQ spectrometer. Fast atom bombardment (FAB) mass spectra were recorded on a 
Finnigan MAT MS 70 spectrometer, using m-nitrobenzylalcohol as matrix. Calculated 
masses were obtained using the software ChemDraw Ultra (CambridgeSoft 
Corporation) or Xcalibur. 
 
Reversed-phase liquid chromatography – electronspray ionization mass 
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spectrometry (LC-MS): 
 
LC-MS measurements were carried out on a Hewlett Packard HPLC 1100/Finnigan 
LCQ mass spectrometer system using Nucleodur C18 Gravity, Nucleosyl 100-5 C18 
Nautilus (Macherey-Nagel) or Jupiter C4 (Phenomenex) columns and detection at 215 
and 254 nm.  
 
Method A: Positive linear gradients of solvent B (0.1% formic acid in acetonitrile) and 
solvent A (0.1% formic acid in water) were used at 1mL/min flow rate. 
Method B: Negative linear gradients of solvent B (10mM NH4OH in acetonitrile) and 
solvent A (10mM NH4OH in water) were used at 1mL/min flow rate. 
Method C: Positive linear gradients of solvent B (0.1% formic acid and 5% THF in 
methanol) and solvent A (0.1% formic acid in water) were used at 1mL/min flow rate. 
Method D: Negative linear gradients of solvent B (10mM NH4OH and 5% THF in 
methanol) and solvent A (10mM NH4OH in water) were used at 1mL/min flow rate. 
 
Analytical reversed-phase high performance liquid chromatography (an. 
HPLC): 
 
Analyses were performed on a Varian prostar system using CC 125/4 Nucleodur C18 
Gravity 3 mm and CC 125/4 Nucleodur C4 Gravity columns (Macherey-Nagel), 
autosampler prostar 410 and UV/Vis detector with Varian prostar 335. Linear 
gradients were used at 1mL/min flow rate (A: water, B: acetonitrile, C: 2% TFA in 
water).  
 
Preparative reverse-phase high performance liquid chromatography (prep 
HPLC): 
 
Purification of compounds was performed on an Varian Prostar system using VP 
250/21 Nucleodur C4 Gravity 5 mm column (Macherey-Nagel), fraction collector 
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prostar 701 and detection at 220 ~ 240 nm with UV/V is prostar 340. Linear gradients 
of solvent A (water) and solvent B (acetonitrile) were used at 20mL/min flow rate. 
 
Thin layer chromatography (TLC): 
 
TLC was carried out on Merck precoated silica gel plates (60F-254) using ultraviolet 
light irradiation at 254 nm and 360 nm or the following solutions as developing agents: 
Staining solution A: molybdatophosphoric acid (25g) and cerium (IV) sulfate (10g) in 
concentrated sulfuric acid (60mL) and water (to 1000mL); 
Staining solution B: (for detection of free amino groups): ninhydrin (300mg) in 
ethanol (100mL) and acetic acid (3mL). 
Staining solution C: KMnO4 (1g), K2CO3 (6.6g), 5% NaOH solution (1.7mL) in H2O 
(to 100mL). 
 
Gas chromatography – mass spectrometry (GC-MS): 
 
Spectra were obtained from a Hewlett Packard 6890 GC system coupled to a Hewlett 
Packard 5973 Mass Selective Detector. A HP 5TA capillary column (0.33μm x 25m x 
0.2mm) and helium flow rate of 2mL/min were used. 
Method A: temperature gradient: 0min (100°C) → 1min (100°C) → 6min (300°C) → 
12min (300°C). 
Method B: temperature gradient: 0min (50°C) → 2min (50°C) → 8min (300°C) → 
12min (300°C). 
 
Optical rotation: 
 
Optical rotations were measured in a Schmidt + Haensch Polartronic HH8 polarimeter 
at 589 nm. Concentrations are given in g/100mL solvent. 
 
FT-IR: 
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Fourier transform infrared spectroscopy (FT-IR) spectra were measured in Bruker 
vector 22 with a diffuse reflectance head A527 from Spectra Tech (KBr as matrix) 
and a Bruker tensor 27 spectrometer with transmission and attenuated total reflection 
(ATR) and coupled with infrared microscope from Spectra Tech (neat). The following 
notations indicate the intensity of the absorption bands: s = strong, m = middle, w = 
weak, b = broad. 
 
Melting Point: 
 
Melting points were measured in Büchi melting point B-540 with open capillary 
(uncorrected). 
 
 
5.2 Abbreviations 
 
Ac       acetyl (CH3CO) 
Aq      aqueous 
Ar      aromatic 
Bn      benzyl (PhCH2) 
Bu      butyl 
Cy      cyclohexyl 
DBU     1,8-diazabicyclo[5.4.0]undec-7-ene 
DCC     N,N-dicyclohexyl carbodiimide 
DIPEA     N,N-diisopropylethylamine 
DMAP     N,N-dimethylamino pyridine 
DMF     N,N-dimethyl formamide 
DMSO     N,N-dimethyl sulfoxide 
ee      enantiomeric excess 
EI      electron impact 
eq      stoichiometic equivalent 
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Et      ethyl (CH3CH2) 
FAB     fast atom bombardment 
GC-MS     gas chromatography-mass spectroscopy 
h      hour 
HPLC     high performance liquid chromatography 
HRMS     high resolution mass spectroscopy 
Hz      hertz 
i-Pr      iso-propyl 
LC-MS     liquid chromatography-mass spectroscopy 
Me      methyl (CH3) 
Min      minute 
mmol     milimole 
NBS     N-bromosuccinimide 
n-Bu     normal butyl (CH3CH2CH2CH2) 
NMR     nuclear magnetic resonance 
Ph      phenyl (C6H5) 
ppm     parts per million 
Py      pyridine 
Rf      retention factor 
r.t.       room temperature 
TBAF     tetrabutylammonium fluoride 
t-Bu     tert-butyl [(CH3)3C] 
TFA     trifluoroacetic acid 
THF     tetrahydrofuran 
TLC     thin layer chromatography 
tR      retention time 
TS      transition state 
20 D     specific optical rotation 
 
5.3 Solvents and Reagents 
 
The reagents were purchased from Acros Chimica, Aldrich, Fluka, Merck, 
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Novabiochem, Riedel de Haen, Roth. Deionized water was obtained using a Millipore 
Q-plus System. 
 
Solvents and reagents purification. 
 
Dichloromethane, acetonitrile, 2,6-lutidine, DIPEA and triethylamine were refluxed 
and distilled from CaH2 under argon and stored with KOH. Acetonitrile was stored 
with molecular sieves 4Å. Ethanol was refluxed with Mg and I2 under argon and 
distilled, then stored with molecular sieves 4Å. Other anhydrous solvents like 
diethylether, DMF, MeOH, toluene and pyridine were directly purchased from Fluka. 
Triphenylphosphine (PPh3) was recrystallized from ethanol. Acetic anhydride was 
redistilled. 
 
5.4 Experimental: chapter 2 (Reagent Controlled Branching 
Cascades) 
 
5.4.1 Synthesis of common substrates 
 
General procedure: A solution of 3-chroman (1mmol, 1.0eq) and 3-oxopentanoate 
(1.0mmol, 1.0eq) was stirred at a preheating oilbath to reflux for 5min in 10mL 
Ac2O/AcOH=1/4. 10ml of water was added to black reaction mixture at room 
temperature. Ac2O and AcOH were removed under vacuum and the crude reaction 
mixture was added 10ml water and extracted with EtOAc (15mlX4). The organic 
layer was combined and washed with brine (15mlX2). The organic layer was dried 
with anhydrous Na2SO4 and evaporated to dryness. The residue was purified by flash 
column chromatography (eluent: petroleum ether/ethyl acetate 10/1) to give white 
solid product. 
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O
CO2Et
O
O
Cl
Cl
Chemical Formula: C17H14Cl2O5
Exact Mass: 368,0218
Molecular Weight: 369,1961  
a4; 
White solid;  
M.P.: 151°C;  
TLC: Rf = 0.45 cyclohexane/ethyl acetate (4:1); 
1H NMR (400 MHz, CDCl3): δ 8.29 (s, 1H), 8.20 (s, 2H), 7.97 (s, 1H), 7.50 (s, 1H), 
4.27(q, J = 7.2 Hz, 2H), 2.71(q, J = 7.2 Hz, 2H), 1.31(t, J = 7.2 Hz, 3H), 1.10(t, J = 
7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 170.1，164.1, 156.73, 156.72，154.6, 151.5, 139.9, 
139.8, 130.4, 128.1, 125.5, 119.1, 112.9, 61.7, 36.3, 14.0, 7.9;  
HRMS (ESI): Calculated for C34H37O10N [M+H
+]: 620.2488, Found: 620.2487. 
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5.4.2 General proceduce for cascade synthesis of functional phenols 
(E:Z= 1:1) 
 
A solution of 3-chromanylidene-β-ketoesters (a4, 1mmol, 1.0eq) and cesium fluorin 
(2mmol, 2.0eq) was stirred at a preheating 80OC oilbath for 5-20min in 10mL DMF. 
10ml of water was added to black reaction mixture at room temperature. DMF was 
removed under vacuum and the crude reaction mixture was added 10ml water and 
extracted with EtOAc (15mlX4). The organic layer was combined and washed with 
brine (15mlX3). The organic layer was dried with anhydrous Na2SO4 and evaporated 
to dryness. The residue was purified by flash column chromatography (eluent: 
petroleum ether/ethyl acetate 20/1) to give white solid product. 
 
Ethyl 2-hydroxy-5-(2-hydroxy-5-isopropylbenzoyl)-3-methylbenzoate 
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OOH
CO2Et
OH
Chemical Formula: C20H22O5
Exact Mass: 342,1467
Molecular Weight: 342,3857  
a7; 
White solid;  
M.P.: 137°C;  
TLC: Rf = 0.35 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.66 (s, 1H), 11.59 (s, 1H), 8.15 (s, 1H), 7.78 (s, 
1H), 7.46 (s, 1H), 7.39(d, J = 8.8 Hz, 1H), 7.01(d, J = 8.8 Hz, 1H), 4.42(q, J = 7.2 Hz, 
2H), 2.85(m, J =6.8 Hz, 1H), 2.34 (s, 3H), 1.39 (t, J = 7.2 Hz, 3H), 1.21(d, J = 6.8 Hz, 
6H);  
13C NMR (100 MHz, CDCl3): δ 199.1, 170.1, 163.4, 161.0, 138.9, 137.0, 134.6, 
130.5, 130.3, 128.2, 127.5, 118.8, 118.1, 111.2, 61.9, 33.2, 24.0, 15.7, 14.1;  
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Ethyl 2-hydroxy-5-(2-hydroxy-5-methylbenzoyl)-3-methylbenzoate 
OOH
CO2Et
OH
Chemical Formula: C18H18O5
Exact Mass: 314,1154
Molecular Weight: 314,3325  
a8; 
White solid;  
M.P.: 141-142°C;  
TLC: Rf = 0.35 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.68 (s, 1H), 11.57 (s, 1H), 8.13 (s, 1H), 7.71 (s, 
1H), 7.37 (s, 1H), 7.32(d, J = 8.0 Hz, 1H), 6.98(d, J = 8.0 Hz, 1H), 4.43(q, J = 7.2 Hz, 
2H), 2.34(s, 3H), 2.28 (s, 3H), 1.40 (t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 199.4, 170.1, 163.3, 160.9, 137.0, 136.8, 132.8, 
130.1, 128.4, 127.8, 127.3, 118.9, 118.2, 61.9, 20.5, 15.8, 14.2;  
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Ethyl 2-hydroxy-5-(2-hydroxy-5-nitrobenzoyl)-3-methylbenzoate 
OOH
CO2Et
OH
NO2
Chemical Formula: C17H15NO7
Exact Mass: 345,0849
Molecular Weight: 345,3035  
a9; 
White solid;  
M.P.: 133-134°C;  
TLC: Rf = 0.35 cyclohexane/ethyl acetate (5:1); 
1H NMR (400 MHz, CDCl3): δ 12.56 (s, 1H), 11.72 (s, 1H), 8.61 (d, J = 2.4 Hz, 1H), 
8.38 (d, J = 8.8 Hz, 1H), 8.16(d, J = 2.4 Hz, 1H), 7.76 (s, 1H), 7.18(d, J = 8.8 Hz, 1H), 
4.45(q, J = 7.2 Hz, 2H), 2.35(s, 3H), 1.40 (t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 198.0, 169.8, 167.8, 164.3, 139.4, 136.6, 130.6, 
130.5, 130.4, 129.0, 128.3, 126.7, 119.5, 118.0, 111.8, 62.2, 15.8, 14.1;  
 
 
Ethyl 3-ethyl-5-(5-fluoro-2-hydroxy-3-nitrobenzoyl)-2-hydroxybenzoate 
OOH
CO2Et
OH
F
Chemical Formula: C18H16FNO7
Exact Mass: 377,0911
Molecular Weight: 377,3205
O2N
 
a10; 
White solid;  
M.P.: 142-143°C;  
TLC: Rf = 0.435 cyclohexane/ethyl acetate (10:1); 
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1H NMR (400 MHz, CDCl3): δ 8.37 (s, 1H), 8.13-8.08 (m, 2H), 7.43 (s, 1H), 4.26 (q, 
J = 7.2 Hz, 2H), 2.72 (q, J = 7.2 Hz, 2H), 1.27 (t, J = 7.2 Hz, 3H), 1.09(t, J = 7.2 Hz, 
3H);  
13C NMR (100 MHz, CDCl3): δ 197.1, 172.4, 166.3, 163.9, 158.9, 156.4, 144.6, 
136.9, 129.0, 126.5, 119.0, 117.4, 61.8, 32.5, 13.9, 7.7;  
 
 
Ethyl 5-(5-chloro-2-hydroxy-4-methylbenzoyl)-2-hydroxy-3-methylbenzoate 
OOH
CO2Et
OH
Cl
Chemical Formula: C18H17ClO5
Exact Mass: 348,0765
Molecular Weight: 348,7776  
a11; 
White solid;  
M.P.: 146-145°C;  
TLC: Rf = 0.35 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.78 (s, 1H), 11.60 (s, 1H), 8.11 (s, 1H), 7.70 (s, 
1H), 7.56(s, 1H), 6.97(s, 1H), 4.45(q, J = 7.2 Hz, 2H), 2.41 (s, 3H), 2.34 (s, 3H), 1.42 
(t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 170.0, 163.5，161.4，145.3，136.6，132.4，130.0，
127.8，127.6，126.0，120.5，62.0，20.8，15.8，14.2;  
 
 
Ethyl 5-(5-bromo-2-hydroxybenzoyl)-2-hydroxy-3-methylbenzoate 
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OOH
CO2Et
OH
Br
Chemical Formula: C17H15BrO5
Exact Mass: 378,0103
Molecular Weight: 379,2020  
a12; 
White solid;  
M.P.: 137-138°C;  
TLC: Rf = 0.35 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.76 (s, 1H), 11.63 (s, 1H), 8.12 (s, 1H), 7.72 (s, 
1H), 7.58(d, J = 8.8 Hz, 1H), 7.00(d, J = 8.8 Hz, 1H), 4.45(q, J = 7.2 Hz, 2H), 2.35 (s, 
3H), 1.42 (t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ198.2,170.0, 163.7, 161.9, 138.6, 136.6, 135.0, 130.3, 
127.8, 120.5, 111.7, 110.2, 109.8, 62.1, 15.8, 14.2;  
 
 
Ethyl 5-(3,5-dichloro-2-hydroxybenzoyl)-2-ethylnicotinate 
O
N
OH
CO2Et
Chemical Formula: C17H15Cl2NO4
Exact Mass: 367,0378
Molecular Weight: 368,2113
Cl
Cl
 
White solid;  
M.P.: 157-158°C;  
TLC: Rf = 0.35 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 12.21 (s, 1H), 8.86 (s, 1H), 8.40 (s, 1H), 7.88 (s, 1H), 
7.58 (s, 1H), 4.36 (q, J = 7.2 Hz, 2H), 3.23 (q, J = 7.2 Hz, 2H), 1.36 (t, J = 7.2 Hz, 
3H), 1.32 (t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 197.1, 168.7, 165.4, 158.7, 151.2, 142.1, 139.1, 133.9, 
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129.9, 125.8, 120.5, 113.7, 110.7, 62.0, 30.5, 14.2, 13.6;  
 
 
To a solution of chromonylidene-β-ketoester (45.9 mg, 0.097 mmol, 1.0eq) in DMF 
(8 ml) was added Cesium fluoride (29.5 mg, 0.194 mmol, 2.0 eq.) at 80oC and the 
reaction mixture was stirred for 2h (TLC-control) at 80°C. The DMF was removed in 
vacuo, water was added, and the mixture was extracted with EtOAc (3 × 20ml). The 
combined organic phases were dried over anhydrous NaSO4, filtered and evaporated 
to give the crude phenol. The residue was purified by column chromatography. 
 
(R)-Ethyl 2-hydroxy-3-(3-hydroxy-2-methylpropyl)-5-(2-hydroxybenzoyl)-benzoate  
O
OH
CO2Et
OH
Me
HO
C20H22O6
Exact Mass: 358.14
Mol. Wt.: 358.39  
a36; 
White solid;  
M.P.: 165-167°C;  
TLC: Rf = 0.40 ethyl acetate /methol (20:1); 
1H NMR (400 MHz, CDCl3): δ 11.86 (s, 1H), 11.78 (s, 1H), 8.17 (s, 1H), 7.69 (s, 
1H), 7.58 (d, J = 8.0 Hz, 1H), 7.52 (d, J = 8.0 Hz, 1H), 7.08 (d, J = 8.0 Hz, 1H), 6.90 
(d, J = 8.0 Hz, 1H), 4.44 (q, J = 7.2 Hz, 2H), 3.47 (t, J = 6.0 Hz, 2H), 2.87 (q, J = 7.2 
Hz, 1H), 2.61 (q, J = 7.2 Hz, 1H), 2.07-2.02 (m, 1H), 1.41 (t, J = 7.2 Hz, 3H), 0.97 (d, 
J = 6.8 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 170.2, 163.1, 137.6, 136.2, 133.0, 132.98, 132.93, 
130.4, 129.4, 128.6, 119.1, 118.7, 118.5, 112.0, 66.8, 62.2, 36.3, 32.8, 16.7, 14.2; 
HRMS (ESI): Calculated for C20H23O6 [M+H
+]: 359.1489, Found: 359.1490; 
Optical rotation: [α]D
25 = -4.4 °(C = 0.16, MeOH). 
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(S)-ethyl 2-hydroxy-3-(3-hydroxy-2-methylpropyl)-5-(2-hydroxybenzoyl)benzoate  
O
OH
CO2Et
OH
Me
HO
C20H22O6
Exact Mass: 358.14
Mol. Wt.: 358.39  
a37; 
White solid;  
M.P.: 154-157°C;  
TLC: Rf = 0.40 ethyl acetate /methol (20:1); 
1H NMR (400 MHz, CDCl3): δ 11.87 (s, 1H), 11.78 (s, 1H), 8.17 (s, 1H), 7.70 (s, 
1H), 7.58 (d, J = 8.0 Hz, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.08 (d, J = 8.0 Hz, 1H), 6.90 
(d, J = 8.0 Hz, 1H), 4.44 (q, J = 7.2 Hz, 2H), 3.52-3.44 (m, 2H), 2.88 (q, J = 7.2 Hz, 
1H), 2.61 (q, J = 7.2 Hz, 1H), 2.09-2.03 (m, 1H), 1.41 (t, J = 7.2 Hz, 3H), 0.98 (d, J = 
6.8 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ169.5, 163.1, 137.6, 136.2, 133.0, 130.4, 129.5, 
128.6, 118.7, 118.5, 114.17, 114.16, 112.0, 109.8, 66.8, 62.2, 36.3, 32.8, 16.7, 14.2;  
HRMS (ESI): Calculated for C20H23O6 [M+H
+]: 359.1489, Found: 359.1490; 
Optical rotation: [α]D
25 = 6.2 °(C = 1.51, CHCl3). 
 
To a solution of chromonylidene-β-ketoester (45.9 mg, 0.097 mmol) in MeOH (5 ml) 
was added ammonium fluoride (35.9 mg, 0.97 mmol, 10.0 eq.) at room temperature 
and the reaction mixture was stirred for 6h (TLC-control) at 60°C. The methanol was 
removed in vacuo, water was added, and the mixture was extracted with EtOAc (3 × 
20ml). The combined organic phases were dried over anhydrous NaSO4, filtered and 
evaporated to give the crude pyridine. The residue was purified by column 
chromatography. 
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(R)-ethyl 2-(4-hydroxy-3-methylbutyl)-5-(2-hydroxybenzoyl)nicotinate  
O
N
CO2Et
OH
OH
Me
C20H23NO5
Exact Mass: 357.16
Mol. Wt.: 357.4  
a38; 
White solid;  
M.P.: 181-183°C;  
TLC: Rf = 0.36 ethyl acetate /methol (20:1); 
1H NMR (400 MHz, CDCl3): δ 10.70 (s, 1H), 8.89 (s, 1H), 8.49 (s, 1H), 7.53 (d, J = 
8.0 Hz, 1H), 7.48 (d, J = 8.0 Hz, 1H), 7.08 (d, J = 8.0 Hz, 1H), 6.90 (d, J = 8.0 Hz, 
1H), 4.39 (q, J = 7.2 Hz, 2H), 3.52-3.39 (m, 2H), 3.35-3.22 (m, 2H), 1.89-1.84 (m, 
2H), 1.55-1.51 (m, 1H), 1.38 (t, J = 7.2 Hz, 3H), 0.97 (d, J = 6.8 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 166.514, 166.505, 163.3, 157.5, 140.0, 137.3, 132.8, 
126.2, 119.31, 119.28, 118.9, 68.2, 62.0, 36.2, 33.5, 26.0, 16.6, 14.2;  
HRMS (ESI): Calculated for C20H24O5N [M+H
+]: 358.1649., Found: 358.1650; 
Optical rotation: [α]D
25 = -6.7 °(C = 1.56, DMSO). 
 
 
(S)-Ethyl 2-(4-hydroxy-3-methylbutyl)-5-(2-hydroxybenzoyl)nicotinate  
O
N
CO2Et
OH
OH
Me
C20H23NO5
Exact Mass: 357.16
Mol. Wt.: 357.4  
a39; 
white solid;  
M.P.: 158-160°C;  
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TLC: Rf = 0.36 ethyl acetate /methol (20:1); 
1H NMR (400 MHz, CDCl3): δ 10.60 (s, 1H), 8.91 (s, 1H), 8.61 (s, 1H), 7.55 (d, J = 
7.2 Hz, 1H), 7.45 (d, J = 7.2 Hz, 1H), 7.08 (d, J = 7.2 Hz, 1H), 6.91 (d, J = 7.2 Hz, 
1H), 4.41 (q, J = 7.2 Hz, 2H), 3.52-3.41 (m, 2H), 3.38-3.32 (m, 2H), 1.90-1.74 (m, 
2H), 1.58-1.52 (m, 1H), 1.39 (t, J = 7.2 Hz, 3H), 0.97 (d, J = 6.8 Hz, 3H);  
HRMS (ESI): Calculated for C20H24O5N [M+H
+]: 358.1649., Found: 358.1649; 
Optical rotation: [α]D
25 = 4.5 °(C = 0.98, DMSO) 
 
5.4.3 Synthesis of diverse oxime from cascade 
 
5.4.3.1 General synthesis proceduce products 
 
Bisaryl ketone (1mmol) and hydroxylamine hydrochloride (10mmol, 10eq) were 
dissoluted in a solution of pyridine/enthanol= 1/6 (10ml) and the solution was heated 
to reflux for overnight. 10ml water was added to the reaction mixture at the room 
temperature.The soluent was evaporated under vacuum to yield a concentrated 
solution. 10ml water was added to this crude mixture and extracted with EtOAc 
(15mlX4), The organic layers were combined; washed with brine (15ml) and dried 
over anhydrous Na2SO4. After evaporating the solution in vacuum, the residue was 
purified by flash chromatography (eluent: petroleum ether/ethyl acetate 20/1) to give 
white solid oximes as E and Z-isomers 
 
The structures of E and Z-isomers were comfirmed by the followed mitsunobu 
reactions. The structure of E-oxime got two products―isoxazole and oxazole, and the 
structure of Z-oxime only got one product―isoxazole. 
 
(E)-ethyl-2-hydroxy-5-((2-hydroxy-5-methylphenyl)(hydroxyimino)methyl)-3-methyl
benzoate  
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NOH
CO2Et
OH
OH
Chemical Formula: C18H19NO5
Exact Mass: 329,1263
Molecular Weight: 329,3472  
a51; 
White solid;  
M.P.: 171-173°C;  
TLC: Rf = 0.36 cyclohexane/ethyl acetate (10 :1); 
1H NMR (400 MHz, CDCl3): δ 11.30 (s, 1H), 7.75 (s, 1H), 7.23 (s, 1H), 7.03 (d, J = 
8.0 Hz, 1H), 6.87(d, J = 8.0 Hz, 1H), 6.59 (s, 1H), 4.36(q, J = 7.2 Hz, 2H), 2.29 (s, 
3H), 2.11 (s, 3H), 1.35 (t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 170.3, 160.7, 155.7, 136.1, 131.9, 130.6, 128.2, 
127.7, 127.3, 118.2, 117.0, 112.0, 61.7, 20.5, 15.8, 14.2;  
HRMS (ESI): Calculated for C18H20O5N [M+H
+]: 330.1336, Found: 330.1337. 
 
 
(Z)-methyl-2-hydroxy-5-((2-hydroxy-5-methylphenyl)(hydroxyimino)methyl)-3-meth
ylbenzoate  
NOH
CO2Me
OH
HO
Chemical Formula: C17H17NO5
Exact Mass: 315,1107
Molecular Weight: 315,3206  
a52; 
White solid;  
M.P.: 1193-195°C;  
TLC: Rf = 0.37 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.24 (s, 1H), 7.69 (s, 1H), 7.29 (s, 1H), 7.08 (d, J = 
8.0 Hz, 1H), 6.93(d, J = 8.0 Hz, 1H), 6.63(s, 1H), 3.94(s, 3H), 2.33(s, 3H), 2.15(s, 
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3H);  
13C NMR (100 MHz, CDCl3): δ 170.6, 160.7, 155.8, 136.3, 132.1, 130.6, 128.2, 
127.9, 127.5, 118.2, 117.0, 111.7, 112.0, 52.5, 20.5, 15.8;  
HRMS (ESI): Calculated for C17H18O5N [M+H
+]: 316.1180, Found: 316.1181; 
 
 
(E)-ethyl-5-((5-bromo-2-hydroxyphenyl)(hydroxyimino)methyl)-2-hydroxy-3-methyl
benzoate  
NOH
CO2Et
OH
OH
Chemical Formula: C17H16BrNO5
Exact Mass: 393,0212
Molecular Weight: 394,2166
Br
 
a53; 
White solid;  
M.P.: 155-157°C;  
TLC: Rf = 0.38 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.30 (s, 1H), 7.59 (s, 1H), 7.26 (d, J = 8.8 Hz, 1H), 
6.89 (s, 1H), 6.84(d, J = 8.8 Hz, 1H), 4.35(q, J = 7.2 Hz, 2H), 2.26(s, 3H), 1.32 (t, J = 
7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 170.1, 161.0，157.2，135.9，133.9，132.7，132.6，
127.7，120.3，120.1，119.1，112.1，110.8，61.8，15.8，14.2;  
HRMS (ESI): Calculated for C17H17BrO5N [M+H
+]: 394.0285, 396.0264, Found: 
394.0280, 396.0258 
 
 
(Z)-ethyl-5-((5-bromo-2-hydroxyphenyl)(hydroxyimino)methyl)-2-hydroxy-3-methyl
benzoate  
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NOH
CO2Et
OH
HO
Br
Chemical Formula: C17H16BrNO5
Exact Mass: 393,0212
Molecular Weight: 394,2166  
a54; 
White solid;  
M.P.: 171-174°C;  
TLC: Rf = 0.37 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.37 (s, 1H), 7.66 (t, J = 2.4 Hz, 1H), 7.35 (dd, J = 
8.8, 2.4 Hz, 1H), 6.95 (d, J = 2.4 Hz, 1H), 6.91(d, J = 8.8 Hz, 1H), 4.41(q, J = 7.2 Hz, 
2H), 2.33 (s, 3H), 1.40 (t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 170.3, 162.2, 156.4, 136.1, 135.1, 134.1, 133.2, 
132.9, 128.3, 127.8, 121.1, 120.9, 119.3, 62.0, 15.9, 14.5;  
HRMS (ESI): Calculated for C17H17BrO5N [M+H
+]: 394.0285, 396.0264 Found: 
394.0279, 396.0254. 
 
 
(Z)-ethyl-2-hydroxy-5-((2-hydroxy-5-isopropylphenyl)(hydroxyimino)methyl)-3-met
hylbenzoate 
NOH
CO2Et
OH
HO
Chemical Formula: C20H23NO5
Exact Mass: 357,1576
Molecular Weight: 357,4003  
a55; 
White solid;  
M.P.: 143-144°C;  
TLC: Rf = 0.35 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.36 (s, 1H), 7.73 (s, 1H), 7.34 (s, 1H), 7.15 (d, J = 
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8.4 Hz, 1H), 6.96 (d, J = 8.4 Hz, 1H), 6.73 (s, 1H), 4.41(q, J = 7.2 Hz, 2H), 2.72(m, J 
= 7.2 Hz, 1H), 2.33(s, 3H), 1.38(t, J = 7.2 Hz, 3H), 1.10(d, J = 7.2 Hz, 6H);  
13C NMR (100 MHz, CDCl3): δ 170.3, 161.1, 160.7,155.9, 139.4, 136.5, 129.0, 
128.4, 128.1, 127.1, 120.9, 118.1, 117.0, 111.8, 61.7, 33.1, 24.0, 15.8, 14.1;  
HRMS (ESI): Calculated for C20H24O5N [M+H
+]: 358.1649, Found: 358.1652; 
 
 
(Z)-ethyl-5-((5-fluoro-2-hydroxy-3-nitrophenyl)(hydroxyimino)methyl)-2-hydroxy-3-
methylbenzoate 
NOH
CO2Et
OH
HO
Chemical Formula: C17H15FN2O7
Exact Mass: 378,0863
Molecular Weight: 378,3086
F
O2N
 
a56; 
Yellow solid;  
M.P.: 165-167°C;  
TLC: Rf = 0.33 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.26 (s, 1H), 10.48 (s, 1H), 7.89 (d, J = 7.2 Hz, 1H), 
7.71(s, 1H), 7.41 (s, 1H), 7.26 (d, J = 7.2 Hz, 1H), 4.32(q, J = 7.2 Hz, 2H), 2.19 (s, 
3H), 1.30 (t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 170.1, 161.7, 160.7, 155.9, 139.4, 134.0, 133.9, 
127.6, 126.2, 126.1, 126.0, 112.0, 111.8, 111.5, 61.7, 15.8, 14.1;  
HRMS (ESI): Calculated for C17H16FO7N2 [M+H
+]: 379.0936, Found: 379.0937. 
 
 
(E)-ethyl-2-hydroxy-5-((2-hydroxy-5-nitrophenyl)(hydroxyimino)methyl)-3-methylbe
nzoate 
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NOH
CO2Et
OH
OH
NO2
Chemical Formula: C17H16N2O7
Exact Mass: 360,0958
Molecular Weight: 360,3181  
a57; 
White solid;  
M.P.: 191-192°C;  
TLC: Rf = 0.39 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.42 (s, 1H), 8.17 (d, J = 9.2 Hz, 1H), 7.87 (s, 1H), 
7.69 (s, 1H), 7.28 (s, 1H), 7.10 (d, J = 9.2 Hz, 1H), 4.42(q, J = 7.2 Hz, 2H), 2.34(s, 
3H), 1.38(t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 170.8, 161.4, 156.5, 149.7, 135.83, 135.75, 128.1, 
127.8, 126.74, 126.71, 118.0, 117.9, 107.1, 61.9, 15.9, 14.1;  
HRMS (ESI): Calculated for C17H17O7N2 [M+H
+]: 361.1030, Found: 361.1031; 
 
 
(Z)-ethyl-2-hydroxy-5-((2-hydroxy-5-nitrophenyl)(hydroxyimino)methyl)-3-methylbe
nzoate 
NOH
CO2Et
OH
HO
NO2
Chemical Formula: C17H16N2O7
Exact Mass: 360,0958
Molecular Weight: 360,3181  
a58; 
White solid;  
M.P.: 177-179°C;  
TLC: Rf = 0.38 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, MD3OD): δ 8.17 (dd, J = 9.2, 2.8 Hz, 1H), 7.97 (d, J = 2.8 Hz, 
1H), 7.71 (d, J = 2.8 Hz, 1H), 7.55-7.54 (m, 1H), 7.01(d, J = 9.2 Hz, 1H), 4.33(q, J = 
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7.2 Hz, 2H), 2.19 (s, 3H), 1.30 (t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 171.6, 162.1, 153.4, 141.6, 135.2, 127.8, 127.6, 
127.1, 122.9, 117.0, 112.8, 62.7, 15.8, 14.4;  
HRMS (ESI): Calculated for C17H17O7N2 [M+H
+]: 361.1030, Found: 361.1031; 
 
 
(E)-ethyl-5-((5-chloro-2-hydroxy-4-methylphenyl)(hydroxyimino)methyl)-2-hydroxy-
3-methylbenzoate 
NOH
CO2Et
OH
OH
Chemical Formula: C18H18ClNO5
Exact Mass: 363,0874
Molecular Weight: 363,7922
Cl
 
a59; 
White solid;  
M.P.: 193-194°C;  
TLC: Rf = 0.33 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.36 (s, 1H), 7.67 (s, 1H), 7.19 (s, 1H), 6.90 (s, 1H), 
6.80(s, 1H), 4.41(q, J = 7.2 Hz, 2H), 2.33 (s, 6H), 1.40 (t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 170.2, 168.0, 156.4, 139.5, 135.9, 130.1, 127.7, 
127.6, 119.4, 117.7, 112.1, 109.8, 97.1, 61.8, 20.1, 15.8, 14.2;  
HRMS (ESI): Calculated for C18H19ClO5N [M+H
+]: 364.0946, 366.0917. Found: 
364.0948, 366.0917. 
 
 
(Z)-ethyl-5-((5-chloro-2-hydroxy-4-methylphenyl)(hydroxyimino)methyl)-2-hydroxy-
3-methylbenzoate 
  Experimental section  
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NOH
CO2Et
OH
HO
Cl
Chemical Formula: C18H18ClNO5
Exact Mass: 363,0874
Molecular Weight: 363,7922  
a60; 
White solid;  
M.P.: 181-183°C;  
TLC: Rf = 0.32 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.36 (s, 1H), 7.67 (s, 1H), 7.26 (s, 1H), 6.90 (s, 1H), 
6.80(s, 1H), 4.42(q, J = 7.2 Hz, 2H), 2.33(s, 6H), 1.40 (t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 170.2, 160.9, 160.5, 156.4, 139.5, 135.9, 130.1, 
127.6, 124.3, 120.4, 119.4, 112.1, 61.8, 20.1, 15.8, 14.2;  
HRMS (ESI): Calculated for C18H19ClO5N [M+H
+]: 364.0948, 366.0919, Found: 
364.0946, 366.0917; 
 
 
(E)-ethyl 2-hydroxy-5-((hydroxyimino)(2-hydroxyphenyl)methyl)-3-methylbenzoate  
NOH
CO2Et
OH
OH
Chemical Formula: C17H17NO5
Exact Mass: 315,1107
Molecular Weight: 315,3206  
a61; 
White solid;  
M.P.: 171-174°C;  
TLC: Rf = 0.37 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.35 (s, 1H), 7.71 (s, 1H), 7.30 (s, 1H), 7.27 (d, J = 
8.4 Hz, 1H), 7.02(d, J = 8.4 Hz, 1H), 6.90 (dd, J = 8.0, 1.6 Hz, 1H), 6.79 (dt, J = 8.0, 
1.2 Hz, 1H), 4.40(q, J = 7.2 Hz, 2H), 2.33 (s, 3H), 1.39 (t, J = 7.2 Hz, 3H);  
  Experimental section  
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13C NMR (100 MHz, CDCl3): δ 170.3, 160.7, 157.8, 136.2, 131.1, 130.6, 127.7, 
127.3, 121.0, 119.1, 118.7, 117.1, 111.9, 61.7, 15.8, 14.1;  
HRMS (ESI): Calculated for C17H18O5N [M+H
+]: 316.1180, Found: 316.1180. 
 
 
(E)-ethyl 2-hydroxy-5-((2-hydroxy-5-methylphenyl)(hydroxyimino)methyl)benzoate  
NOH
CO2Et
OH
OH
Chemical Formula: C17H17NO5
Exact Mass: 315,1107
Molecular Weight: 315,3206  
a62; 
White solid;  
M.P.: 168-170°C;  
TLC: Rf = 0.37 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.08 (s, 1H), 7.85 (d, J = 2.0 Hz, 1H), 7.43 (dd, J = 
8.4, 2.0 Hz, 1H), 7.36 (s, 1H), 7.30-7.26 (m, 1H), 7.12 (d, J = 8.4 Hz, 1H), 7.02 (dd, J 
= 8.4, 1.2 Hz, 1H), 6.87 (dd, J = 8.0, 2.0 Hz, 1H), 6.78 (dt, J = 8.0, 1.2 Hz, 1H), 
4.41(q, J = 7.2 Hz, 2H), 2.17(s, 3H), 1.39(t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 169.8, 162.2, 161.0, 158.1, 135.9, 131.2, 130.6, 
121.7, 119.0, 118.4, 117.9, 117.3, 112.7, 108.8, 61.8, 30.9, 14.1;  
HRMS (ESI): Calculated for C17H18O5N [M+H
+]: 316.1338, Found: 316.1336; 
 
 
(E)-ethyl 2-hydroxy-5-((hydroxyimino)(2-hydroxyphenyl)methyl)benzoate  
NOH
CO2Et
OH
OH
Chemical Formula: C16H15NO5
Exact Mass: 301,0950
Molecular Weight: 301,2940  
a63; 
  Experimental section  
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White solid;  
M.P.: 177-178°C;  
TLC: Rf = 0.38 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.02 (s, 1H), 7.78 (d, J = 2.4 Hz, 1H), 7.36 (d, J = 
8.4 Hz, 1H), 7.19 (t, J = 8.4 Hz, 1H), 7.04 (d, J = 8.4 Hz, 1H), 6.94 (d, J = 8.4 Hz, 
1H), 6.80 (d, J = 7.6 Hz, 1H), 6.71 (t, J = 7.6 Hz, 1H), 4.33(q, J = 7.2 Hz, 2H), 1.31(t, 
J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 169.8, 162.2, 160.8, 157.8, 135.9, 131.1, 130.5, 
130.4, 121.7, 119.2, 118.5, 117.9, 117.2, 112.7, 61.8, 14.1;  
HRMS (ESI): Calculated for C16H16O5N [M+H
+]: 302.1023, Found: 302.1024; 
a63 H spectrum; 
 
a63 C spectrum; 
  Experimental section  
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a63 gcosy spectrum; 
 
a63 noesy spectrum; 
  Experimental section  
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a63 ghsqc spectrum; 
 
a63 ghmbc spectrum; 
  Experimental section  
 124 
 
 
 
(Z)-ethyl 2-hydroxy-5-((hydroxyimino)(2-hydroxyphenyl)methyl)benzoate  
NOH
CO2Et
OH
HO
Chemical Formula: C16H15NO5
Exact Mass: 301,0950
Molecular Weight: 301,2940  
a64; 
White solid;  
M.P.: 164-165°C;  
TLC: Rf = 0.37 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.06 (s, 1H), 7.98 (d, J = 2.4 Hz, 1H), 7.47 (dd, J = 
8.4, 2.4 Hz, 1H), 7.42 (dt, J = 8.4, 2.4 Hz, 1H), 7.26 (s, 1H), 7.11 (d, J = 8.4 Hz, 1H), 
6.97 (s, 1H), 6.95 (d, J = 8.4 Hz, 1H), 4.39(q, J = 7.2 Hz, 2H), 1.36(t, J = 7.2 Hz, 3H); 
13C NMR (100 MHz, CDCl3): δ 170.4，163.1, 155.3, 135.7, 132.1, 130.9, 130.8, 
130.3, 126.8, 120.5, 120.1, 118.9, 117.9, 112.6, 61.8, 14.1;  
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HRMS (ESI): Calculated for C16H16O5N [M+H
+]: 302.1023, Found: 302.1025; 
 
a64 1H spectrum; 
 
a64 13C spectrum; 
 
a64 gcosy spectrum 
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a64 noesy spectrum 
 
a64 ghsqc spectrum 
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a64 ghnbc spectrum 
 
 
 
(E)-ethyl-3-ethyl-2-hydroxy-5-((2-hydroxy-5-methylphenyl)(hydroxyimino)methyl)b
  Experimental section  
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enzoate  
NOH
CO2Et
OH
OH
Chemical Formula: C19H21NO5
Exact Mass: 343,1420
Molecular Weight: 343,3737  
a65; 
White solid;  
M.P.: 164-166°C;  
TLC: Rf = 0.37 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.37 (s, 1H), 7.72 (d, J = 2.0 Hz, 1H), 7.29 (d, J = 
2.0 Hz, 1H), 7.26 (s, 1H), 7.08 (dd, J = 8.0, 2.0 Hz, 1H), 6.92 (d, J = 8.0 Hz, 1H), 
6.65 (d, J = 2.0 Hz, 1H), 4.42 (q, J = 7.2 Hz, 2H), 2.76 (q, J = 7.2 Hz, 2H), 2.16 (s, 
3H), 1.39(t, J = 7.2 Hz, 3H), 1.26(t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 170.4, 161.3, 160.4, 155.7, 134.6, 133.0, 131.8, 
130.6, 128.1, 127.7, 121.1, 118.2, 117.0, 112.0, 61.7, 22.8, 20.5, 13.5;  
HRMS (ESI): Calculated for C19H22O5N [M+H
+]: 344.1495, Found: 344.1496; 
 
 
(E)-ethyl-5-((5-bromo-2-hydroxyphenyl)(hydroxyimino)methyl)-3-ethyl-2-hydroxybe
nzoate  
NOH
CO2Et
OH
OH
Br
Chemical Formula: C18H18BrNO5
Exact Mass: 407,0368
Molecular Weight: 408,2432  
a66; 
Yellow solid;  
M.P.: 181-182°C;  
TLC: Rf = 0.39 cyclohexane/ethyl acetate (10:1); 
  Experimental section  
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1H NMR (400 MHz, CDCl3): δ 11.39 (s, 1H), 7.69 (d, J = 2.4 Hz, 1H), 7.35 (dd, J = 
8.8, 2.4 Hz, 1H), 7.27 (s, 1H), 6.97 (d, J = 2.4 Hz, 1H), 6.91 (d, J = 8.8 Hz, 1H), 4.42 
(q, J = 7.2 Hz, 2H), 2.75 (q, J = 7.2 Hz, 2H), 1.40 (t, J = 7.2 Hz, 3H), 1.26(t, J = 7.2 
Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 170.2, 160.7, 160.5, 157.2, 134.4, 133.8, 133.4, 
132.7, 127.7, 120.4, 120.2, 119.1, 112.2, 110.8, 61.8, 22.8, 14.2, 13.5;  
HRMS (ESI): Calculated for C18H19BrO5N [M+H
+]: 408.0441, 410.0421; Found: 
408.0440, 410.0419; 
 
 
(Z)-ethyl-5-((5-bromo-2-hydroxyphenyl)(hydroxyimino)methyl)-3-ethyl-2-hydroxybe
nzoate  
NOH
CO2Et
OH
HO
Chemical Formula: C18H18BrNO5
Exact Mass: 407,0368
Molecular Weight: 408,2432
Br
 
a67; 
Yellow solid;  
M.P.: 177-179°C;  
TLC: Rf = 0.38 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.40 (s, 1H), 7.69 (d, J = 2.4 Hz, 1H), 7.35 (dd, J = 
8.8, 2.4 Hz, 1H), 6.96 (d, J = 2.4 Hz, 1H), 6.91 (d, J = 8.8 Hz, 1H), 4.41 (q, J = 7.2 Hz, 
2H), 2.74 (q, J = 7.2 Hz, 2H), 1.40 (t, J = 7.2 Hz, 3H), 1.26(t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 170.2, 160.7, 157.2, 137.3, 134.4, 133.9, 133.4, 
132.7, 129.1, 127.9, 127.7, 120.7, 120.3, 120.1, 119.1, 112.2, 110.8, 61.8, 22.8, 14.2, 
13.5;  
HRMS (ESI): Calculated for C18H19BrO5N [M+H
+]: 408.0441, 410.0421;Found: 
408.0438, 410.0417; 
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(E)-ethyl 3-ethyl-2-hydroxy-5-((hydroxyimino)(2-hydroxyphenyl)methyl)benzoate 
(a68) 
NOH
CO2Et
OH
OH
Chemical Formula: C18H19NO5
Exact Mass: 329,1263
Molecular Weight: 329,3472  
a68; 
White solid;  
M.P.: 178-180°C;  
TLC: Rf = 0.0,37 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.39 (s, 1H), 8.33 (bs, 1H), 7.75 (d, J = 2.0 Hz, 1H), 
7.33 (d, J = 2.0 Hz, 1H), 7.28 (dt, J = 8.0, 1.6 Hz, 1H), 7.04 (d, J = 8.0 Hz, 1H), 6.93 
(dd, J = 8.0, 1.6 Hz, 1H), 6.81 (t, J = 8.0 Hz, 1H), 4.43 (q, J = 7.2 Hz, 2H), 2.76 (q, J 
= 7.2 Hz, 2H), 1.40 (t, J = 7.2 Hz, 3H), 1.27(t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 170.3, 161.0, 160.4, 157.7, 134.6, 133.0, 131.0, 
130.5, 127.7, 121.1, 119.2, 118.7, 117.1, 111.9, 61.7, 22.7, 14.1, 13.5;  
HRMS (ESI): Calculated for C18H20O5N [M+H
+]: 330.1336, Found: 330.1338; 
 
 
(Z)-ethyl 3-ethyl-2-hydroxy-5-((hydroxyimino)(2-hydroxyphenyl)methyl)benzoate 
(a69) 
NOH
CO2Et
OH
HO
Chemical Formula: C18H19NO5
Exact Mass: 329,1263
Molecular Weight: 329,3472  
a69; 
White solid;  
  Experimental section  
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M.P.: 161-163°C;  
TLC: Rf = 0.36 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.34 (s, 1H), 7.77 (d, J = 2.0 Hz, 1H), 7.42 (dt, J = 
8.0, 2.4 Hz, 1H), 7.36 (d, J = 8.0 Hz, 1H), 7.26 (s, 1H), 6.99-6.96 (m, 1H), 6.94 (t, J = 
8.0 Hz, 1H), 4.35 (q, J = 7.2 Hz, 2H), 2.62 (q, J = 7.2 Hz, 2H), 1.34 (t, J = 7.2 Hz, 
3H), 1.15(t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 170.2, 161.4, 155.7, 134.6, 133.1, 132.2, 131.1, 
128.1, 125.9, 120.4, 120.2, 119.0, 111.9, 61.7, 22.8, 14.1, 13.6;  
HRMS (ESI): Calculated for C18H20O5N [M+H
+]: 6330.1336, Found: 330.1339; 
 
 
(Z)-ethyl-5-((5-chloro-2-hydroxyphenyl)(hydroxyimino)methyl)-2-hydroxy-3-methyl
benzoate  
NOH
CO2Et
OH
HO
Chemical Formula: C17H16ClNO5
Exact Mass: 349,0717
Molecular Weight: 349,7656
Cl
 
a70; 
Yellow solid;  
M.P.: 170-172°C;  
TLC: Rf = 0.36 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.24 (s, 1H), 7.29 (s, 1H), 7.07 (d, J = 8.4 Hz, 1H), 
6.91 (d, J = 8.4 Hz, 1H), 6.63(s, 1H), 3.94 (s, 3H), 2.33 (s, 3H), 2.16 (s, 3H);  
13C NMR (100 MHz, CDCl3): δ 170.7, 161.1, 160.6, 155.7, 136.3, 131.9, 130.5, 
128.2, 127.8, 127.3, 121.2, 118.2, 116.9, 111.7, 52.4, 20.5, 15.8;  
HRMS (ESI): Calculated for C17H17O5ClN [M+H
+]: 350.0797, Found: 350.0793. 
 
 
(E)-methyl 2-hydroxy-5-((hydroxyimino)(2-hydroxyphenyl)methyl)-3-methylben- 
  Experimental section  
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zoate 
NOH
OH
O
O
OH
C16H15NO5
Exact Mass: 301.1
Mol. Wt.: 301.29  
a71; 
White solid;  
M.P.: 172-173°C;  
TLC: Rf = 0.30 ethyl acetate/MeOH (5:1); 
1H NMR (400 MHz, DMSO): δ 7.45 (s, 1H), 7.24 (s, 1H), 7.04 (t, J = 8.0 Hz, 1H), 
6.75-6.70 (m, 2H), 6.58 (t, J = 8.0 Hz, 1H), 3.70(s, 3H), 2.04 (s, 3H);  
13C NMR (100 MHz, DMSO): δ 169.9, 159.1, 157.2, 136.7, 130.3, 129.9, 127.7, 
126.1, 122.6, 120.0, 118.8, 116.5, 111.3, 53.7, 15.4; 
HRMS (ESI): Calculated for C16H15O5N [M+H
+]: 302.1023, Found: 302.1023; 
 
 
(Z)-methyl 2-hydroxy-5-((hydroxyimino)(2-hydroxyphenyl)methyl)-3-methylben- 
zoate 
NOH
OH
O
O
C16H15NO5
Exact Mass: 301.1
Mol. Wt.: 301.29
HO
 
a72; 
White solid;  
M.P.: 177-178°C;  
TLC: Rf = 0.31 ethyl acetate/MeOH (5:1); 
1H NMR (400 MHz, DMSO): δ 7.47-7.46 (m, 2H), 7.13 (t, J = 8.0 Hz, 1H), 6.88 (d, 
J = 8.0 Hz, 1H), 6.81-6.74 (m, 2H), 3.73(s, 3H), 2.07 (s, 3H);  
  Experimental section  
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13C NMR (100 MHz, DMSO): δ 169.9, 159.2, 154.2, 152.6, 133.7, 129.8, 129.6, 
127.5, 126.0, 125.3, 120.7, 118.8, 115.8, 111.2, 52.7, 15.6; 
HRMS (ESI): Calculated for C15H15O4N2 [M+H
+]: 302.1023, Found: 302.1023; 
 
 
(S,E)-ethyl-2-(4-hydroxy-3-methylbutyl)-5-((hydroxyimino)(2-hydroxyphenyl)methyl
)nicotinate  
N
N
CO2Et
OH
OH
Me
OH
C20H24N2O5
Exact Mass: 372.17
Mol. Wt.: 372.41  
a73; 
White solid;  
M.P.: 188-190°C;  
TLC: Rf = 0.40 ethyl acetate /methol (20:1); 
1H NMR (400 MHz, CDCl3): δ 10.82 (bs, 1H), 9.21 (bs, 1H), 8.63 (s, 1H), 8.23 (s, 
1H), 7.30-7.28 (m, 1H), 6.02 (d, J = 8.0 Hz, 1H), 6.80-6.74 (m, 2H), 4.39 (q, J = 7.2 
Hz, 2H), 3.66-3.55 (m, 2H), 3.33-3.29 (m, 2H), 1.93-1.83 (m, 2H), 1.77-1.71 (m, 1H), 
1.38 (t, J = 7.2 Hz, 3H), 1.02 (d, J = 6.8 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 163.9, 158.0, 157.3, 150.6, 139.9, 131.4, 129.8, 
125.6, 125.2, 119.3, 117.8, 117.5, 109.8, 67.2, 62.0, 35.7, 33.5, 32.9, 16.8, 14.2;  
HRMS (ESI): Calculated for C20H25O5N2 [M+H
+]: 373.1758, Found: 373.1759; 
Optical rotation: [α]D
25 = 5.1 °(C = 0.23, MeOH). 
 
 
(S,E)-ethyl-2-hydroxy-3-(3-hydroxy-2-methylpropyl)-5-((hydroxyimino)(2-hydroxyp
henyl)methyl)benzoate  
  Experimental section  
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N
OH
CO2Et
OH
Me
HO
HO
C20H23NO6
Exact Mass: 373.15
Mol. Wt.: 373.4  
a74; 
White solid;  
M.P.: 177-179°C;  
TLC: Rf = 0.35 ethyl acetate /methol (20:1); 
1H NMR (400 MHz, CDCl3): δ 11.49 (s, 1H), 7.67 (d, J = 2.0 Hz, 1H), 7.23-7.20 (m, 
2H), 6.95 (d, J = 8.0 Hz, 1H), 6.80 (d, J = 8.0 Hz, 1H), 6.70 (t, J = 8.0 Hz, 1H), 4.33 
(q, J = 7.2 Hz, 2H), 3.45-3.36 (m, 2H), 2.77 (q, J = 2.8 Hz, 1H), 2.56 (q, J = 2.8 Hz, 
1H), 2.00-1.93 (m, 1H), 1.31 (t, J = 7.2 Hz, 3H), 0.99 (d, J = 6.8 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ170.3, 161.0, 160.3, 158.1, 146.5, 137.1, 131.1, 
130.5, 129.3, 128.3, 121.3, 119.0, 117.3, 112.3, 66.8, 61.9, 36.3, 32.6, 16.7, 14.1;  
HRMS (ESI): Calculated for C20H24NO6 [M+H
+]: 374.1598, Found: 374.1602; 
Optical rotation: [α]D
25 = -4.0 °(C = 0.31, MeOH). 
 
 
(R,Z)-ethyl-2-hydroxy-3-(3-hydroxy-2-methylpropyl)-5-((hydroxyimino)(2-hydroxyp
henyl)methyl)benzoate  
N
OH
CO2Et
OH
Me
HO
OH
C20H23NO6
Exact Mass: 373.15
Mol. Wt.: 373.4  
a75; 
White solid;  
  Experimental section  
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M.P.: 166-168°C;  
TLC: Rf = 0.35 ethyl acetate /methol (20:1); 
1H NMR (400 MHz, CDCl3): δ 10.66 (bs, 1H), 8.57 (s, 1H), 8.14 (s, 1H), 7.26-7.22 
(m, 1H), 6.98 (dd, J = 8.0,2.0 Hz, 1H), 6.76-6.71 (m, 2H), 4.33 (q, J = 7.2 Hz, 2H), 
3.58-3.50 (m, 2H), 3.26-3.21 (m, 2H), 1.85-1.77 (m, 2H), 1.70-1.66 (m, 1H), 1.32 (t, J 
= 7.2 Hz, 3H), 0.95 (d, J = 6.8 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 163.39, 163.38, 157.2, 150.1, 150.0, 133.8, 132.3, 
130.7, 129.2, 129.1, 128.0, 127.9, 118.4, 116.7, 66.4, 61.0, 34.8, 32.0, 16.0, 13.4; 
HRMS (ESI): Calculated for C20H23O6 [M+H
+]: 374.1598, Found: 374.1600; 
Optical rotation: [α]D
25 = 4.0 °(C = 0.17, MeOH). 
 
 
(R,E)-ethyl-2-(4-hydroxy-3-methylbutyl)-5-((hydroxyimino)(2-hydroxyphenyl)methy
l)nicotinate  
N
OH
CO2Et
OH
Me
HO
HO
C20H23NO6
Exact Mass: 373.15
Mol. Wt.: 373.4  
a76; 
White solid;  
M.P.: 155-156°C;  
TLC: Rf = 0.40 ethyl acetate /methol (20:1); 
1H NMR (400 MHz, CDCl3): δ 10.86 (bs, 1H), 9.70 (bs, 1H), 8.57 (s, 1H), 8.15 (s, 
1H), 7.22-7.20 (m, 1H), 6.94 (d, J = 8.4 Hz, 1H), 6.73-6.70 (m, 2H), 4.31 (q, J = 7.2 
Hz, 2H), 3.58-3.48 (m, 2H), 3.25-3.20 (m, 2H), 1.86-1.74 (m, 2H), 1.68-1.63 (m, 1H), 
1.31 (t, J = 7.2 Hz, 3H), 0.94 (d, J = 6.8 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 165.7, 164.0, 158.0, 157.2, 151.8, 139.7, 131.3, 
129.8, 125.5, 125.2, 119.3, 117.9, 117.4, 62.2, 61.9, 35.6, 33.6, 32.9, 16.8,14.2;  
  Experimental section  
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HRMS (ESI): Calculated for C20H25O5N2 [M+H
+]: 373.1758, Found: 373.1762; 
Optical rotation: [α]D
25 = -4.6 °(C = 0.21, MeOH). 
 
 
(E)-ethyl-2-ethyl-5-((5-fluoro-2-hydroxy-3-nitrophenyl)(hydroxyimino)methyl)nicoti
nate  
N
N
OH
CO2Et
OH
Chemical Formula: C17H16FN3O6
Exact Mass: 377,1023
Molecular Weight: 377,3238
F
O2N
 
a78; 
White solid;  
M.P.: 181-183°C;  
TLC: Rf = 0.12 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.29 (bs, 1H), 8.77 (s, 1H), 8.26 (s, 1H), 7.81-7.79 
(m, 1H), 7.29-7.26 (m, 1H), 4.40 (q, J = 7.2 Hz, 2H), 3.25 (q, J = 7.2 Hz, 2H), 
1.41-1.33 (m, 6H);  
13C NMR (100 MHz, CDCl3): δ 165.8, 165.1, 151.8, 151.0, 149.8, 139.2, 135.4, 
125.8, 125.0, 124.4, 124.2, 113.1, 112.8, 61.9, 30.1, 14.2, 14.0;  
HRMS (ESI): Calculated for C17H17FO6N3 [M+H
+]: 378.1096, Found: 378.1097; 
 
 
(Z)-ethyl-2-ethyl-5-((5-fluoro-2-hydroxy-3-nitrophenyl)(hydroxyimino)methyl)nicoti
nate  
N
N
OH
CO2Et
Chemical Formula: C17H16FN3O6
Exact Mass: 377,1023
Molecular Weight: 377,3238
F
O2N
HO
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a79; 
White solid;  
M.P.: 167-169°C;  
TLC: Rf = 0.11 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 10.53 (bs, 1H), 8.77 (s, 1H), 8.25 (s, 1H), 7.99-7.97 
(m, 1H), 7.39-7.37 (m, 1H), 4.39 (q, J = 7.2 Hz, 2H), 3.20-3.18 (m, 2H), 1.39 (t, J = 
7.2 Hz, 3H), 1.31 (q, J = 7.2 Hz, 3H);  
HRMS (ESI): Calculated for C17H17FO6N3 [M+H
+]: 378.1096, Found: 378.1103; 
 
5.4.3.2 The hydrolysis of ester 
 
To a solution of ester in THF/MeOH 2:1 (v/v) was added 2N NaOH solution (5.0 eq.) 
at 0°C and the reaction mixture was stirred for 16h (TLC control). The reaction 
mixture was acidified with 25% HCl to pH 3-4. After water was added, the mixture 
was extracted with EtOAc (2 × 20ml). The combined organic phases were dried over 
anhydrous MgSO4, filtered and evaporated to give the crude acid. The residue was 
purified by column chromatography. 
 
5-(2-hydroxybenzoyl)-2-methylnicotinic acid 
OH O
N
OH
O
C14H11NO4
Exact Mass: 257.07
Mol. Wt.: 257.24  
White solid, 
M.P.: 164-166°C;  
TLC: Rf = 0.34 EtOAc/MeOH (5:3); 
1H NMR (400 MHz, DMSO-d6): δ(ppm) = 10.52 (br s, 1H), 8.83 (d, J = 2.2 Hz, 1H), 
8.36 (d, J = 2.2 Hz, 1H), 7.52-7.38 (m, 2H), 6.98 (m, 2H), 2.80 (s, 3H);  
13C NMR (100 MHz, DMSO-d6): δ(ppm) = 194.7, 167.0, 162.4, 156.8, 151.3, 138.4, 
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133.9, 130.7, 130.5, 125.6, 124.0, 119.4, 116.8, 24.6;  
HRMS (ESI): Calculated for C14H12NO4[M+H
+]:258.07608;Found 258.07605  
 
(E)-2-ethyl-5-((hydroxyimino)(2-hydroxyphenyl)methyl)nicotinic acid 
NOH
N
OH
O
OH
C15H14N2O4
Exact Mass: 286.1
Mol. Wt.: 286.28  
White solid;  
M.P.: 181-182°C;  
TLC: Rf = 0.29 ethyl acetate/MeOH (5:1); 
1H NMR (400 MHz, MeOD): δ 8.56 (d, J = 3.6 Hz, 1H), 8.22 (d, J = 3.6 Hz, 1H), 
7.25 (dt, J = 8.0, 2.0 Hz, 1H), 6.94 (d, J = 8.0 Hz, 1H), 6.84-6.78 (m, 2H), 3.24(q, J = 
7.2 Hz, 2H), 1.34 (t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, MeOD): δ; 169.0, 165.6, .159.1,. 157.0, 152.0, 141.0, 131.9, 
130.8, 127.43,. 127.41, 120.3, 120.2, 118.6, 30.8, 14.6; 
HRMS (ESI): Calculated for C15H15O4N2 [M+H
+]: 287.1027, Found: 287.1026; 
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5.4.4 Synthesis of oxazoles and isoxazoles from oximes 
 
General Proceduce: To the solution of anhydrous THF (15ml) E-oxime (1.0mmol, 
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1.0eq) was added DIAD (1.2mmol, 1.2eq) and PPh3 (1.5mmol, 1.5eq) at room 
temperature under argon atmosphere. The colour of solution turned from straw yellow 
to yellow. The reaction mixture was stired for 2-4 hours when oxime was consumed 
(TLC using cyclohexane/ethyl acetate (10:1) as eluent).The reaction mixture was 
added 10ml water to quench the reaction. THF was evaporated and 10ml water was 
added to residue that was extracted with EtOAc (15mlX4). Organic layers were 
combined and washed with brine (15ml) and dried over anhydrous Na2SO4. The 
residue was purified by flash chromatography (eluent: petroleum ether/ethyl acetate 
20/1) to give two yellow solid products. 
 
General Proceduce: To the solution of anhydrous THF (15ml) Z-oxime (1.0mmol, 
1.0eq) was added DIAD (1.2mmol, 1.2eq) and PPh3 (1.5mmol, 1.5eq) at room 
temperature under argon atmosphere. The colour of solution turned from straw yellow 
to yellow. The reaction mixture was stired for 2-4 hours when oxime was consumed 
(TLC using cyclohexane/ethyl acetate (10:1) as eluent).The reaction mixture was 
added 10ml water to quench the reaction. THF was evaporated and 10ml water was 
added to residue that was extracted with EtOAc (15mlX4). Organic layers were 
combined and washed with brine (15ml) and dried over anhydrous Na2SO4. The 
residue was purified by flash chromatography (eluent: petroleum ether/ethyl acetate 
20/1) to give one yellow solid product. 
 
Ethyl 5-(5-fluoro-7-nitrobenzo[d]isoxazol-3-yl)-2-hydroxy-3-methylbenzoate  
NO
OH
O
OEt
F
O2N
Chemical Formula: C17H13FN2O6
Exact Mass: 360,0758
Molecular Weight: 360,2933  
a91; 
Yellow solid;  
  Experimental section  
 141 
M.P.: 137.2°C;  
TLC: Rf = 0.46 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.65 (s, 1H), 8.62 (d, J = 2.4 Hz, 1H), 8.19 (d, J = 
2.4 Hz, 1H), 7.81 (dd, J = 9.2, 2.4 Hz, 1H), 7.67(dd, J = 7.6, 2.4 Hz, 1H), 4.44(q, J = 
7.2 Hz, 2H), 2.32(s, 3H), 1.41 (t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 169.9, 164.0, 159.8, 157.1, 135.2, 128.6, 128.5, 
115.8, 113.1, 112.9, 112.6, 108.3, 108.0, 62.2, 15.7, 14.2;  
HRMS (ESI): Calculated for C17H14O6FN2 [M+H
+]: 361.0830, Found: 361.0832; 
 
 
Ethyl 2-hydroxy-3-methyl-5-(5-nitrobenzo[d]oxazol-2-yl)benzoate  
N
O
OH
O
O
Chemical Formula: C17H14N2O6
Exact Mass: 342,0852
Molecular Weight: 342,3029
O2N
 
a92; 
White solid;  
M.P.: 157-159°C;  
TLC: Rf = 0.43 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.63 (s, 1H), 8.59 (t, J = 2.4 Hz, 2H), 8.28 (dd, J = 
8.8, 2.4 Hz, 1H), 8.19 (s, 1H), 7.64(d, J = 8.8 Hz, 1H), 4.49(q, J = 7.2 Hz, 2H), 2.36 (s, 
3H), 1.49 (t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 169.9, 165.5, 163.6, 154.2, 145.4, 142.7, 135.0, 
128.3, 128.1, 120.8, 116.3, 115.8, 112.4, 110.5, 62.1, 15.7, 14.3;  
HRMS (ESI): Calculated for C17H15O6N2 [M+H
+]: 343.0926, Found: 343.0927. 
 
 
Ethyl 2-hydroxy-3-methyl-5-(5-nitrobenzo[d]isoxazol-3-yl)benzoate  
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NO
OH
O
O
NO2
Chemical Formula: C17H14N2O6
Exact Mass: 342,0852
Molecular Weight: 342,3029  
a93; 
White solid;  
M.P.: 174-176°C;  
TLC: Rf = 0.42 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.64 (s, 1H), 8.60 (t, J = 2.8 Hz, 2H), 8.29 (dd, J = 
8.8, 2.4 Hz, 1H), 8.21-8.20 (m, 1H), 7.65(d, J = 8.8 Hz, 1H), 4.49(d, J = 7.2 Hz, 1H), 
2.37(s, 3H), 1.49(t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 169.9, 165.5, 163.6, 154.2, 142.7, 135.0, 128.3, 
128.1, 120.8, 116.3, 115.8, 112.5, 110.5, 62.1, 15.7, 14.3;  
HRMS (ESI): Calculated for C34H37O10N [M+H
+]: 343.0925, Found: 343.0924; 
 
 
Ethyl 5-(benzo[d]oxazol-2-yl)-2-hydroxy-3-methylbenzoate  
N
O
OH
O
O
Chemical Formula: C17H15NO4
Exact Mass: 297,1001
Molecular Weight: 297,3053  
a94; 
White solid;  
M.P.: 147-149°C;  
TLC: Rf = 0.41 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.04 (s, 1H), 8.60 (d, J = 2.4 Hz, 1H), 8.22-8.21 (m, 
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1H), 7.58-7.55 (m, 1H), 7.35-7.32 (m, 1H), 4.07(q, J = 7.2 Hz, 2H), 2.36(s, 3H), 
1.48(t, J = 7.2 Hz, 3H); . 
13C NMR (100 MHz, CDCl3): δ 170.2, 162.8, 150.7, 42.1, 134.8, 127.9, 127.4, 124.8, 
124.5, 119.7, 117.6, 112.3, 110.4, 61.9, 15.7, 14.3;  
HRMS (ESI): Calculated for C17H16O4N [M+H
+]: 298.1075, Found: 298.1074; 
 
 
Ethyl 5-(benzo[d]isoxazol-3-yl)-2-hydroxy-3-methylbenzoate  
NO
OH
O
OEt
Chemical Formula: C17H15NO4
Exact Mass: 297,1001
Molecular Weight: 297,3053  
a95; 
White solid;  
M.P.: 138-139°C;  
TLC: Rf = 0.40 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.32 (s, 1H), 8.27 (d, J = 1.6 Hz, 1H), 7.88 (s, 1H), 
7.84 (d, J = 8,0 Hz, 1H), 7.57 (t, J = 8,0 Hz, 1H), 7.54 (t, J = 8,0 Hz, 1H), 7.33 (t, J = 
8,0 Hz, 1H), 4.40(q, J = 7.2 Hz, 2H), 2.31(s, 3H), 1.38(t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 161.7, 135.4, 129.8, 128.0, 127.3, 123.8, 122.1, 
120.4, 119.3, 112.4, 110.2, 61.8, 15.8, 14.2;  
HRMS (ESI): Calculated for C17H16O4N [M+H
+]: 298.1074, Found: 298.1074; 
 
 
Ethyl 5-(benzo[d]oxazol-2-yl)-2-hydroxybenzoate  
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N
O
OH
O
O
Chemical Formula: C16H13NO4
Exact Mass: 283,0845
Molecular Weight: 283,2787  
a96; 
White solid;  
M.P.: 157-159°C;  
TLC: Rf = 0.44 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.13 (s, 1H), 8.50 (d, J = 2.4 Hz, 1H), 8.07 (dd, J = 
8.4, 2.4 Hz, 1H), 7.90 (d, J = 8.0 Hz, 1H), 7.65 (t, J = 8.4 Hz, 1H), 7.61 (t, J = 8.4 Hz, 
1H), 7.40 (t, J = 8.0 Hz, 1H), 7.17 (t, J = 8.4 Hz, 1H), 4.48(q, J = 7.2 Hz, 2H), 1.46(t, 
J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 169.8, 163.9, 163.1, 156.2, 134.9, 129.8, 123.9, 
121.9, 120.3, 120.1, 118.6, 113.2, 110.3, 61.9, 14.2;  
HRMS (ESI): Calculated for C16H14O4N [M+H
+]: 284.0917, Found: 284.0917; 
 
 
Ethyl 5-(benzo[d]isoxazol-3-yl)-2-hydroxybenzoate  
NO
OH
O
OEt
Chemical Formula: C16H13NO4
Exact Mass: 283,0845
Molecular Weight: 283,2787  
a97; 
White solid;  
M.P.: 183-184°C;  
TLC: Rf = 0.43 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.24 (s, 1H), 8.67-8.64 (m, 1H), 8.25 (d, J = 8.8 Hz, 
1H), 7.70 (d, J = 8.8 Hz, 1H), 7.52-7.48 (m, 1H), 7.31-7.28 (m, 2H), 7.06 (t, J = 8.8 
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Hz, 1H), 4.43(q, J = 7.2 Hz, 2H), 1.45(t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 169.6, 164.0, 162.0, 150.5, 142.0, 134.3, 129.7, 
124.8, 124.5, 119.6, 118.3, 112.9, 110.3, 61.9, 14.2;  
HRMS (ESI): Calculated for C16H14O4N [M+H
+]: 284.0917, Found: 284.0918; 
 
 
Ethyl 3-ethyl-2-hydroxy-5-(5-methylbenzo[d]oxazol-2-yl)benzoate  
N
O
OH
O
O
Chemical Formula: C19H19NO4
Exact Mass: 325,1314
Molecular Weight: 325,3585  
a98; 
White solid;  
M.P.: 169-170°C;  
TLC: Rf = 0.40 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.39 (s, 1H), 8.33 (d, J = 2.4 Hz, 1H), 7.93-7.92 (m, 
1H), 7.64-7.63 (m, 1H), 7.52 (d, J = 8.4 Hz, 1H), 7.40 (dd, J = 8.4, 1.6 Hz, 1H), 4.46 
(q, J = 7.2 Hz, 2H), 2.80 (q, J = 7.2 Hz, 2H), 2.52 (s, 3H), 1.45 (t, J = 7.2 Hz, 3H), 
1.31(t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 170.3, 162.5, 161.3, 125.1, 133.8, 133.7, 133.5, 
131.3, 127.2, 121.2, 120.6, 119.6, 112.4, 109.7, 61.8, 22.9, 21.3, 14.2, 13.7;  
HRMS (ESI): Calculated for C19H20O4N [M+H
+]: 326.1387, Found: 326.1388; 
 
a98 1H spectrum; 
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a98 13C spectrum; 
 
 
a98 gcosy spectrum; 
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a98 noesy spectrum; 
 
 
a98 ghsqc spectrum; 
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a98 ghmbc spectrum; 
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Ethyl 3-ethyl-2-hydroxy-5-(5-methylbenzo[d]isoxazol-3-yl)benzoate  
NO
OH
O
OEt
Chemical Formula: C19H19NO4
Exact Mass: 325,1314
Molecular Weight: 325,3585  
a99; 
White solid;  
M.P.: 159-161°C;  
TLC: Rf = 0.41 cyclohexane/ethyl acetate (10:1); 
1H NMR (400 MHz, CDCl3): δ 11.53 (s, 1H), 8.56 (dd, J = 5.6, 2.0 Hz, 1H), 
8.19-8.18 (m, 1H), 7.50 (s, 1H), 7.41 (dd, J = 8.4, 4.0 Hz, 1H), 7.11 (dd, J = 8.4, 2.0 
Hz, 1H), 4.46 (q, J = 7.2 Hz, 2H), 2.75 (q, J = 7.2 Hz, 2H), 2.46 (s, 3H), 1.46 (t, J = 
7.2 Hz, 3H), 1.29(t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 170.2, 162.4, 148.9, 142.3, 134.3, 133.6, 133.3, 
127.3, 125.8, 119.6, 117.9, 112.3, 109.7, 61.9, 22.8, 21.5, 14.3, 13.6;  
HRMS (ESI): Calculated for C19H20O4N [M+H
+]: 326.1387, Found: 326.1387; 
 
a99 1H spectrum; 
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a99 13C spectrum; 
 
 
a99 gcosy spectrum; 
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a99 noesy spectrum; 
 
 
a99 ghsqc spectrum; 
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a99 ghmbc spectrum; 
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5.4.5 Preparation of free acid 
 
General Proceduce: The compound of isoxazole (1.0mmol, 1.0eq) was added to the 
solution of sodium hydroxygen (2mol/l) 10ml. The reaction was stired for overnight 
in the room temperature. The reaction was monitored by TLC using ethyl 
acetate/MeOH (5:1) as eluent. The reaction was very clear showing nearly 
quantitative conversion. The solution was added 10ml water and extracted with 
EtOAc (25mlX5), the organic layer were combined and washed with brine (10ml); 
dried over anhydrous Na2SO4 and concentrated. The residue was purified by flash 
chromatography with short column (eluent: ethyl acetate/MeOH (10:1)) to give white 
solid product. 
 
5-(benzo[d]isoxazol-3-yl)-2-hydroxy-3-methylbenzoic acid 
N
O
CO2H
OH
C15H11NO4
Exact Mass: 269.07
Mol. Wt.: 269.25  
a110; 
White solid;  
M.P.: 167-168°C;  
TLC: Rf = 0.16 ethyl acetate/MeOH (5:1); 
1H NMR (400 MHz, CD3OD): δ 8.62 (s, 1H), 8.03 (s, 1H), 7.65 (q, J = 3.2 Hz, 1H), 
7.61 (q, J = 3.2 Hz, 1H), 7.35 (q, J = 3.2 Hz, 2H), 2.30 (s, 3H);  
13C NMR (100 MHz, CD3OD): δ 172.1, 166.0, 163.4, 150.0, 142.0, 131.2, 127.8, 
126.1, 124.5, 124.4, 119.0, 113.1, 110.4, 15.7; 
HRMS (ESI): Calculated for C15H13O4N [M+H
+]: 270.0761, Found: 270.0761; 
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5.4.6 Preparation of Nicotinie acid 
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Free acid (1mmol) and hydroxylamine hydrochloride (10mmol, 10eq) was mixed in 
solution of pyridine/enthanol= 1/6 (10ml), and the solution was heated to reflux for 
overnight. The solution was cooled down to room temperature and diluted with 10ml 
water. Pyridine and enthanol were removed under vacuum. To the solution 
concentrated 10ml water was added and extracted with EtOAc (25mlX4). Combined 
the organic layers were washed with brine (10ml) and dried with anhydrous Na2SO4 
and evaporated to dryness. The residue was purified by flash chromatography (eluent: 
ethyl acetate/MeOH (10:1)) to give two white solid product E-oxime and Z-oxime, in 
approx 1:1 ratio. E and Z were very difficult to isolate and in some case all of the 
isomer could be purified. 
 
(E)-5-((5-chloro-2-hydroxyphenyl)(hydroxyimino)methyl)-2-methylnicotinic acid 
NOH
N
OH
O
Cl
C14H11ClN2O4
Exact Mass: 306.04
Mol. Wt.: 306.7
OH
 
One isomer E or Z 
a110; 
White solid;  
M.P.: 172-173°C;  
TLC: Rf = 0.26 ethyl acetate/MeOH (5:1); 
1H NMR (400 MHz, DMSO): δ 12.0 (bs, 1H), 10.48 (bs, 1H), 8.56 (s, 1H), 8.16 (s, 
1H), 7.30-7.27 (m, 1H), 7.06 (d, J = 2.4 Hz, 1H), 6.88 (d, J = 8.4 Hz, 1H), 2.72(s, 
3H);  
13C NMR (100 MHz, DMSO): δ; 172.6, 167.9, 158.4, 155.2, 150.5, 137.9, 130.1, 
129.3, 125.9, 123.2, 122.5, 118.1, 117.5, 24.3; 
HRMS (ESI): Calculated for C14H12ClO4N2 [M+H
+]: 307.0480, 309.0451; Found: 
307.0480, 309.0449; 
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(Z)-2-ethyl-5-((hydroxyimino)(2-hydroxyphenyl)methyl)nicotinic acid 
NOH
N
OH
O
Cl
C14H11ClN2O4
Exact Mass: 306.04
Mol. Wt.: 306.7
OH
 
One isomer  E or Z 
a111; 
White solid;  
M.P. : 162-163°C;  
TLC : Rf = 0.30 ethyl acetate/MeOH (5:1); 
1H NMR (400 MHz, DMSO): δ 7.70 (d, J = 2.4 Hz, 1H), 7.60 (d, J = 2.4 Hz, 1H), 
7.29-7.7 (m, 1H), 6.95-6.92 (m, 2H), 3.32(q, J = 7.2 Hz, 2H), 2.22 (t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, DMSO): δ; 172.2,161.8, 156.0, 155.9, 135.9, 131.3, 131.2, 
128.9, 127.8, 127.6, 122.4, 120.6, 117.5, 112.4, 30.8, 15.8; 
HRMS (ESI): Calculated for C15H15O4N2 [M+H
+]: 287.1026, Found: 287.1026; 
 
 
(E)-5-((5-bromo-2-hydroxyphenyl)(hydroxyimino)methyl)-2-methylnicotinic acid 
NOH
N
OH
O
Br
C14H11BrN2O4
Exact Mass: 349.99
Mol. Wt.: 351.15
OH
 
a112; 
White solid;  
M.P.: 171-173°C;  
TLC: Rf = 0.17 ethyl acetate/MeOH (5:1); 
1H NMR (400 MHz, DMSO): δ 11.96 (bs, 1H), 10.49 (bs, 1H), 8.57 (d, J = 2.0 Hz, 
1H), 8.11 (d, J = 2.0 Hz, 1H), 7.40 (dd, J = 8.8, 2.4 Hz, 1H), 7.19 (d, J = 2.4 Hz, 1H), 
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6.84 (d, J = 8.8 Hz, 1H), 2.72 (s, 3H);  
13C NMR (100 MHz, DMSO): δ 167.9, 158.4, 155.6, 151.7, 150.6, 141.1, 138.0, 
133.0, 132.1, 125.9, 123.8, 118.6, 109.9, 24.3; 
HRMS (ESI): Calculated for C14H12BrO4N2 [M+H
+]: 350.9975, 352.9955; Found: 
350.9977, 352.9954; 
 
 
(Z)-5-((5-chloro-2-hydroxyphenyl)(hydroxyimino)methyl)-2-methylnicotinic acid 
NOH
N
OH
O
Cl
C14H11ClN2O4
Exact Mass: 306.04
Mol. Wt.: 306.7
OH
 
a113; 
White solid;  
M.P.: 159-160°C;  
TLC: Rf = 0.27 ethyl acetate/MeOH (5:1); 
1H NMR (400 MHz, CD3OD): δ 8.70 (d, J = 1.6 Hz, 1H), 8.63 (d, J = 1.6 Hz, 1H), 
7.29 (dd, J = 8.8, 2.8 Hz, 1H), 7.21 (d, J = 2.4 Hz, 1H), 6.99 (d, J = 8.8 Hz, 1H), 
2.95(s, 3H);  
13C NMR (100 MHz, CD3OD): δ 172.6, 167.9, 158.4, 154.5, 149.7, 144.0, 142.4, 
134.0, 131.8, 131.1, 125.2, 120.6, 118.7, 21.5; 
HRMS (ESI): Calculated for C14H12ClO4N2 [M+H
+]: 307.0480, 309.0451; Found: 
307.0481, 309.0450; 
 
 
(Z)-5-((5-bromo-2-hydroxyphenyl)(hydroxyimino)methyl)-2-methylnicotinic acid 
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NOH
N
OH
O
Br
C14H11BrN2O4
Exact Mass: 349.99
Mol. Wt.: 351.15
OH
 
a115; 
White solid;  
M.P.: 171-173°C;  
TLC: Rf = 0.16 ethyl acetate/MeOH (5:1); 
1H NMR (400 MHz, CD3OD): δ 8.54 (s, 1H), 8.30 (s, 1H), 7.40 (d, J = 8.8 Hz, 1H), 
7.27 (s, 1H), 6.86 (d, J = 8.8 Hz, 1H), 2.78 (s, 3H);  
13C NMR (100 MHz, CD3OD): δ 168.5, 165.9, 159.8, 151.2, 149.1, 143.8, 141.3, 
137.8, 134.3, 133.9, 119.1, 112.1, 23.9; 
HRMS (ESI): Calculated for C14H12BrO4N2 [M+H
+]: 350.9975, 352.9955; Found: 
350.9977, 352.9954; 
 
5.4.7 Other modifications of the phenol moiety in pyridines 
 
5.4.7.1 General procedure for the conversion of ethyl bromoacetic ester 
with pyridine derivates 
 
Pyridine derivate (1.0eq.), K2CO3 (1.0 eq.) and ethyl 2-bromoacetate (1.0 eq.) were 
dissolved in acetone (5 ml) and heated under an argon atmosphere for 10h at 50 °C. 
The acetone was removed in vacuo, water was added, and the mixture was extracted 
with EtOAc (3 × 20ml). The combined organic phases were dried over anhydrous 
NaSO4, filtered and evaporated to give crude pyridine. The residue was purified by 
column chromatography. 
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Ethyl 5-(2-(2-ethoxy-2-oxoethoxy)-5-methylbenzoyl)-2-methylnicotinate 
O O
N
OEt
O
O OEt
C21H23NO6
Exact Mass: 385.15
Mol. Wt.: 385.41  
 
a117; 
White solid;  
M.P.: 155-157°C;  
TLC: Rf = 0.37 PE/TtOAc (2:1); 
1H NMR (400 MHz, MeOD): δ (ppm) = 8.85 (d, J = 2.2 Hz, 1H), 8.55 (d, J = 2.2 Hz, 
1H), 7.29-7.11 (m, 2H), 6.68 (d, J = 8.4 Hz, 1H), 4.41 (s, 2H), 4.31 (q, J = 7.1 Hz, 
2H), 4.06 (q, J = 7.1 Hz, 2H), 2.81 (s, 3H), 2.27 (s, 3H), 1.32 (t, J = 7.1 Hz, 3H), 1.17 
(t, J = 7.1 Hz, 3H);  
13C NMR (100 MHz, MeOD): δ (ppm) = 193.6, 167.9, 166.0, 163.3, 153.6, 152.7, 
138.8, 133.4, 131.6, 131.0, 130.8, 127.6, 125.4, 112.3, 65.6, 61.4, 61.2, 24.9, 20.2, 
14.1, 13.9;  
GC-MS(EI): tR = 10.08 min; m / z (rel. Int. [%]): 385 (20) [M+], 340 (29), 312 (79), 
284 (76), 251 (70), 179 (100), 135 (96). 
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5.4.7.2 General procedure for hydrolysis to diacids 
 
To a solution of ester 20 in THF/MeOH 2:1 (v/v) was added 1N NaOH solution (5.0 
eq.) at 0°C and the reaction mixture was stirred for 16h (TLC control). The reaction 
mixture was acidified with 25% HCl to pH 3-4. After water was added, the mixture 
was extracted with EtOAc (3 × 20ml). The combined organic phases were dried over 
anhydrous MgSO4, filtered and evaporated to give crude acid. The residue was 
purified by column chromatography. 
 
5-(2-(carboxymethoxy)-5-methylbenzoyl)-2-methylnicotinic acid 
 
O O
N
OH
O
O OH
C17H15NO6
Exact Mass: 329.09
Mol. Wt.: 329.3  
a118; 
White solid;  
M.P.: 175-176°C;  
TLC: Rf = 0.43 ethyl acetate/MeOH (5:2); 
1H NMR (400 MHz, DMSO-d6): δ 8.85 (d, J = 2.2 Hz, 1H), 8.38 (d, J = 2.2 Hz, 1H), 
7.35 (ddd, J = 8.6 Hz, J = 2.3 Hz, J = 0.6 Hz, 1H), 7.26-7.23 (m, 1H), 6.97 (d, J = 
8.6 Hz, 1H), 4.58 (s, 2H), 2.78 (s, 3H), 2.29 (s, 3H);  
13C NMR (100 MHz, DMSO-d6): δ (ppm) = 193.6, 169.5, 167.0, 162.7, 153.3, 151.7, 
138.3, 133.3, 130.4, 130.4, 129.7, 127.0, 125.8, 112.8, 64.8, 24.7, 19.8;  
HRMS (ESI): Calculated for C17H17NO6 [M+H]
+ 330.0972, found 330.0972. 
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5.4.7.3 General procedure for the synthesis of coumarin-derivates 
 
Pyridine derivate (1.0 eq.), carbonyl diimidazole (2.0 eq.), K2CO3 (1.0 eq.), DMAP 
(0.1 eq.), and 2-substituted-acetic acid (2.0 eq.) were dissolved in DMF (5 ml) and 
heated under an argon atmosphere for 6h at 80 °C. After addition of EtOAc and brine, 
the biphasic mixture was several times extracted with brine. The combined organic 
phases were dried over anhydrous NaSO4, filtered and evaporated to give crude 
phenol. The residue was purified by column chromatography. 
 
Ethyl 2-methyl-5-(2-oxo-3-phenyl-2H-chromen-4-yl)nicotinate 
O
N
OEt
O
O
Ph
C24H19NO4
Exact Mass: 385.13
Mol. Wt.: 385.41  
a119; 
White solid;  
M.P.: 175-176°C;  
TLC: Rf = 0.42 PE/EtOAc (2:1); 
1H NMR (400 MHz, CDCl3): δ (ppm) = 8.37 (d, J = 2.3 Hz, 1H), 8.05-7.95 (d, J = 
2.3 Hz，1H), 7.59-7.55 (m, 1H), 7.46-7.44 (m, 1H), 7.26-7.21 (m, 4H), 7.15–7.10 (m, 
3H), 4.41-4.22 (q, J = 7.2 Hz, 2H), 2.38 (s, 3H), 1.34 (t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ (ppm) = 165.7, 160.6, 159.9, 153.2, 151.4, 146.9, 
139.2, 133.0, 131.9, 130.4, 128.5, 128.2, 127.9, 126.9, 125.0, 124.5, 119.8, 117.1, 
61.5, 24.7, 14.2;  
HRMS (ESI): Calculated for C24H20NO4 [M+H]
+ : 386.1387, found 386.1390. 
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5.4.7.4 General procedure for hydrolysis of coumarins 
 
To a solution of ester in THF/MeOH 2:1 (v/v) was added 1N NaOH solution (5.0 eq.) 
at 0°C and the reaction mixture was stirred for 16h (TLC control). The reaction 
mixture was acidified with 25% HCl to pH 3-4. After water was added, the mixture 
was extracted with EtOAc (3 × 20ml). The combined organic phases were dried over 
anhydrous NaSO4, filtered and evaporated to give crude acid. The residue was 
purified by column chromatography. 
 
2-methyl-5-(2-oxo-3-phenyl-2H-chromen-4-yl)nicotinic acid 
O
N
OH
O
O
Ph
C22H15NO4
Exact Mass: 357.1
Mol. Wt.: 357.36  
a120; 
White solid;  
M.P.: 175-176°C;  
TLC: Rf = 0.37 ethyl acetate/MeOH (7:2); 
1H NMR (400 MHz, MeOD-d4): δ 8.22 (d, J = 2.2 Hz, 1H), 8.10 (d, J = 2.2 Hz, 1H), 
7.56 (ddd, J = 8.4 Hz, J = 7.3 Hz, J = 1.6 Hz, 1H), 7.40 (dd, J = 8.3 Hz, 0.8 Hz, 1H), 
7.25-7.19 (m, 1H), 7.18-7.11 (m, 3H), 7.08 (ddd, J = 7.3 Hz, J = 4.7 Hz, J = 1.6 Hz, 
3H), 2.67 (s, 3H); 
13C NMR (400 MHz, MeOD-d4): δ (ppm) = 167.2, 159.8, 158.1, 152.4, 150.7, 146.8, 
138.6, 133.6, 131.8, 130.3, 127.7, 127.7, 127.5, 126.9, 124.6, 119.8, 116.4, 24.1; 
HRMS (ESI): Calculated for C22H16NO4 [M+H]
+ :358.10738, found 358.10736. 
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5.5 Experimental section: Chapter 3 (Substrate Controlled 
Branching Cascades 
 
5.5.1 Synthesis of common substrates 
 
General procedure: The chromene (1.0mmol, 1.0eq), acetylene carboxylates, and 
PPh3(0.4mmol, 0.4eq) were mixed in 10ml toluene on the room temperature. The 
reaction mixture was stirred at room temperature for 8 hour under argon. The reaction 
was monitored by TLC using cyclohexane/ethyl acetate (5:1) as eluent. After 
evaporation of the solvent, the crude product was purified by column chromatography 
on silica gel with cyclohexane/ethyl acetate as the eluent 
 
General procedure for the rearrangement of the adducts: TFA (1mL in 5 mL 
dichloromethane) was added slowly dropwise to the dichloromethane (5 mL) solution 
of the tricyclic benzopyrones (1 mmol). The reaction mixture was stirred at room 
temperature for 30 min under argon. The reaction was monitored by TLC using 
cyclohexane/ethyl acetate (7:3) as eluent. After evaporation of the solvent, the crude 
product was purified by column chromatography on silica gel with cyclohexane/ethyl 
acetate as the eluent 
 
O
O
O
MeO2C CO2Me
C16H12O7
Exact Mass: 316.06
Mol. Wt.: 316.26  
Yellow solid;  
M.P.: 177°-178°C;  
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TLC:Rf = 0.33 (cyclohexane/ethyl acetate 6:4);  
1H NMR (400 MHz, CDCl3): δ 8.32 (d, J = 0.7 Hz, 1H), 8.21-8.19 (dd, J = 1.6 Hz, J 
= 8.0 Hz, 1H), 7.63 (td, J = 1.6, 7.8 Hz, 1H), 7.50 (d, J = 0.7 Hz, 1H), 7.49-7.47 (dd, J 
= 1.0,7.4 Hz, 1H), 7.43 (td, J = 1.0, 7.4 Hz,1H), 3.98 (s, 3H), 3.82 (s, 3H).;  
13C NMR (100 MHz, CDCl3): δ 180.8, 174.0, 164.8, 161.1, 159.6, 155.7, 134.6, 
132.9, 131.6, 126.7, 126.2, 123.3, 118.3, 118.0, 53.1, 52.6.;  
HRMS (ESI): Calculated for C16H13O7 [M+H
+]: 317.0656, Found: 317.0657. 
 
O
O
O
H CO2Me
C14H10O5
Exact Mass: 258.05
Mol. Wt.: 258.23  
Yellow solid;  
M.P. 120°-122°C;  
TLC: Rf = 0.39 (cyclohexane/ethyl acetate 6:4);  
1H NMR (400 MHz, CDCl3): δ 9.71 (s, 1H, CHO), 8.66 (d, J = 0.8 Hz, 1H), 
8.28-8.24 (m, 2H), 7.73 (d, J = 0.8 Hz, 1H), 7.52-7.44 (m, 2H), 3.89 (s, 3H).;  
13C NMR (100 MHz, CDCl3): δ 189.3, 174.8, 165.6, 158.4, 155.8, 140.8, 134.5, 
133.8, 126.4, 126.3, 123.6, 118.4, 118.3, 52.6.;  
HRMS (ESI): Calculated for C14H11O5 [M+H
+]: 259.0601, Found: 259.0602. 
 
O
O
O
Ph CO2Et
C21H16O5
Exact Mass: 348.1
Mol. Wt.: 348.35  
Yellow solid;  
M.P. 171°-173°C;  
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TLC: Rf = 0.45 (cyclohexane/ethyl acetate 6:4);  
1H NMR (400 MHz, CDCl3): δ 8.18-8.16 (dd, J = 1.3 Hz, J = 8.4 Hz, 1H), 8.15 (d, J 
= 1.0 Hz, 1H), 8.05 (d, J = 1.0, 1H), 7.93-7.91 (dd, J = 1.3, 8.4 Hz, 1H), 7.63 (td, Hz, 
J = 7.8 Hz, 1H), 7.48-7.55-7.35 (m, 5H), 7.28-7.25 (m, 1H), 4.25-4.19 (q, J = 7.1 Hz, 
2H), 1.17 (t, J = 7.1 Hz, 3H).;  
13C NMR (100 MHz, CDCl3): δ 194.5, 175.2, 164.3, 156.2, 155.8, 140.6, 136.1, 
134.1, 133.8, 132.9, 129.8, 129.0, 128.7, 128.5, 126.1, 125,7, 123.5, 119.0, 118.1, 
61.5, 13.9.;  
HRMS (ESI): Calculated for C21H17O5 [M+H
+]: 349.1071, Found: 349.1072.  
 
5.5.2. Bisnuleophilies 
 
5.5.2.1 N, N-Bisnuleophilies 
 
General procedure for synthesis of 8,13-dihydro-7H-benzo[2,3]azocino[4,5-b] 
indole-6-carboxylates and 10,14c-dihydroindolo[3,2-c]-pyrido[1,2-a] quinoline 
(b75-b81) from common precursor and bis-nucleophile b51.  
 
2-(2-aminophenyl ） indole (b27, 1,1 equiv.) was added to a anhydrous 
dichloromethane (25 mL) solution of ketoester (b5, 50 mg scale, 1 equiv.) under 
argon atmosphere. The color of solution turned straw yellow to red slowly. After 
completion of the reaction (monitored by TLC), then water (20 mL) was added to the 
reaction mixture to quench the reaction and the mixture extracted with ethyl acetate(2 
*10 mL). The combined organic layers were dried over anhydrous Na2SO4 and then 
evaporated in vacuo. The crude residue was purified by column chromatography over 
silica gel using cyclohexane/ethyl acetate (4:1) as eluent to afford pure yellow 
solid-8,13-dihydro-7H-benzo[2,3]azocino[4,5-b] indole-6-carboxylates b52 62% and 
red solid-10,14c-dihydroindolo[3,2-c]-pyrido[1,2-a] quinoline b53 31% 
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NN
H
CO2Me
CO2Me
O O
C30H22N2O6
Exact Mass: 506.15
Mol. Wt.: 506.51  
b54 (mixture of two diastereoisomers ~ 5:1),  
Yield 62%;  
Yellow solid;  
M.P.: 192°C;  
TLC: Rf = 0.64 cyclohexane/ethyl acetate (2:1);  
1H NMR (400 MHz, CDCl3): δ 8.24 (s, 1H), 8.05 (d, J = 8.0 Hz, 1H), 7.95 (s, 1H), 
7.70 (d, J = 7.6 Hz, 1H), 7.58 (d, J = 8.0 Hz, 1H), 7.52-7.48 (m, 2H), 7.34 (s, 1H), 7.32 
(s, 1H), 7.27 (d, J = 8.4 Hz, 1H), 7.25 (s, 1H), 7.23 (s, 1H), 7.16-7.10 (m, 2H), 5.41 (d, 
J = 12.0 Hz, 1H), 4.85 (d, J =12.0 Hz, 1H), 3.84 (s, 3H), 3.57 (s, 3H);  
13C NMR (100MHz, CDCl3): δ 176.2, 169.5, 163.4, 158.7, 155.8, 153.9, 146.2, 135.8, 
133.1, 131.2, 130.3, 129.2,127.3, 126.1, 125.9, 125.5, 124.7, 124.1, 123.6, 122.7, 
122.1, 119.9, 119.1, 117.7, 114.2, 110.8, 53.1, 52.1, 48.6, 34.3;  
HRMS (ESI): Calculated for C30H23O6N2 [M+H
+]: 507.1551, Found: 507.1546. 
 
 
 
b55;  
Yield 31%;  
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red solid;  
M.P.: 150°C;  
TLC: Rf = 0.40 cyclohexane/ethyl acetate (2:1);  
1H NMR (400 MHz, CDCl3): δ 11.12 (s, 1H), 8.58 (s, 1H), 7.88 (d, J = 8.0 Hz, 1H), 
7.66 (s, 1H), 7.48 (d, J = 7.6 Hz, 1H), 7.33 (d, J = 7.6 Hz, 1H), 7.25 (d, J = 7.2 Hz, 1H), 
7.22 (d, J = 8.0 Hz, 1H),, 7.18-7.15 (m, 2H), 7.06 (t, J = 8.4 Hz, 1H), 7.00 (q, J = 7.6 Hz, 
2H), 6.84 (d, J = 7.6 Hz, 1H), 6.45 (s, 1H), 3.60 (s, 3H), 3.52 (s, 3H);  
13C NMR (100 MHz, CDCl3): δ 196.1, 164.6, 163.4, 161.7, 138.6, 136.8, 136.5, 
135.2, 131.30, 131.25, 130.7, 128.8, 127.1, 126.9, 124.6, 123.1, 122.7, 121.9, 120.8, 
120.7, 119.61, 119.57, 119.0, 118.7, 113.5, 111.8, 99.3, 52.8, 51.8;  
HRMS (ESI): Calculated for C30H23O6N2 [M+H
+]: 507.1551, Found: 507.1542.; 
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NN
H
CO2Me
CO2Me
O O
Me
C31H24N2O6
Exact Mass: 520.16
Mol. Wt.: 520.53  
b56;  
Yield 65%;  
Yellow solid;  
M.P.: 278°C;  
TLC: Rf = 0.58 cyclohexane/ethyl acetate (2:1);  
1H NMR (400 MHz, CDCl3): δ 8.06 (s, 1H), 7.84 (s, 1H), 7.78 (s, 1H), 7.63 (d, J = 
8.0 Hz, 1H), 7.52 (d, J = 7.6 Hz, 1H), 7.42 (t, J = 7.6 Hz, 1H), 7.30-7.22 (m, 3H), 
7.18-7.16 (m, 1H), 7.11-7.01 (m, 3H), 5.32 (d, J = 12.0 Hz, 1H), 4.77 (d, J =12.0 Hz, 
1H), 3.76 (s, 3H), 3.49 (s, 3H), 2.24 (s, 3H);  
13C NMR (100 MHz,CDCl3): δ 176.3, 169.5, 163.4, 158.8, 154.1, 153.8, 146.3, 135.8, 
134.6, 134.3, 131.19, 131.16, 130.3, 129.2, 127.3, 126.2, 125.3, 123.8, 123.7, 122.8, 
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122.1, 120.0, 119.1, 117.5, 114.4, 110.7, 60.4, 53.1, 52.1, 48.7, 34.2;  
HRMS (ESI): Calculated for C31H25O6N2 [M+H
+]: 521.1707, Found: 521.1701. 
 
 
NN
H
CO2Me
CO2Me
O O
C33H28N2O6
Exact Mass: 548.19
Mol. Wt.: 548.59  
b58 
Yield 64%;  
Yellow solid;  
M.P.: 157°C;  
TLC: Rf = 0.45 cyclohexane/ethyl acetate (2:1);  
1H NMR (400 MHz, CDCl3): δ 7.98 (s, 1H), 7.93 (s, 1H), 7.92 (d, J = 2.0 Hz, 1H), 
7.71 (d, J = 8.0 Hz, 1H), 7.64 (d, J = 7.6 Hz, 1H), 7.54 (t, J = 7.6 Hz, 1H), 7.43-7.35 (m, 
3H), 7.25-7.21 (m, 1H), 7.16 (t, J = 7.2 Hz, 1H), 7.11 (t, J = 7.2 Hz, 1H), 5.40 (d, J = 
12.0 Hz, 1H), 4.85 (d, J =12.0 Hz, 1H), 3.86 (s, 3H), 3.57 (s, 3H), 2.92 (m, 1H), 1.20 (d, 
J = 6.8 Hz, 6H);  
13C NMR (100 MHz, CDCl3): δ 176.4, 169.5, 163.4, 158.8 ,154.3, 153.8, 146.3, 
145.6, 135.8, 132.1 ,131.2, 130.4, 129.3, 127.4, 126.2, 125.2, 123.9, 123.7, 122.9, 
122.7, 122.2, 120.0, 119.2, 117.4, 114.5, 110.7, 53.2, 52.2, 48.7, 34.3, 33.7, 23.9, 23.8; 
HRMS (ESI): Calculated for C33H28O6N2 [M+H
+]: 549.2020, Found: 549.2014. 
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NN
H
CO2Me
CO2Me
O O
Cl
C30H21ClN2O6
Exact Mass: 540.11
Mol. Wt.: 540.95  
b59; 
Yield 59%;  
Yellow solid;  
M.P.: 185°C;  
TLC: Rf = 0.43 cyclohexane/ethyl acetate (2:1);  
1H NMR (400 MHz, CDCl3): δ 8.04 (d, J = 2.8 Hz, 1H), 7.98 (s, 1H), 7.67 (d, J = 8.0 
Hz, 1H), 7.63 (d, J = 7.6 Hz, 1H), 7.56 (t, J = 7.6 Hz, 1H), 7.47-7.41 (m, 2H), 7.36 (d, J 
= 7.6 Hz, 1H), 7.29-7.24 (m, 2H), 7.19-7.10 (m, 2H), 5.33 (d, J = 12.0 Hz, 1H), 4.85 (d, 
J =12.0 Hz, 1H), 3.86 (s, 3H), 3.58 (s, 3H);  
13C NMR (100 MHz, CDCl3): δ 175.0,  169.5, 163.4, 158.6, 154.1, 154.0, 146.3, 
135.8, 133.3, 131.4, 130.7, 130.3, 129.4, 127.3, 126.3, 125.4, 125.1, 123.6, 122.9, 
122.2, 120.1, 119.5, 119.0, 113.8, 110.8, 53.2, 52.2, 48.3, 34.6;  
HRMS (ESI): Calculated for C30H22ClO6N2 [M+H
+]: 541.1161, Found: 541.1154. 
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OHO
N
N
H
EtO2C
EtO2C
C32H26N2O6
Exact Mass: 534.18
Mol. Wt.: 534.56  
b61: 
Yield 29%;  
Red solid;  
M.P.: 141°C;  
TLC: Rf = 0.37 cyclohexane/ethyl acetate (2:1);  
1H NMR (400 MHz, CDCl3): δ 11.22 (s, 1H), 8.52 (s, 1H), 7.96 (d, J = 8.0 Hz, 1H), 
7.77 (s, 1H), 7.55 (t, J = 8.4 Hz, 1H), 7.44 (d, J = 6.8 Hz, 1H), 7.40-7.35 ( m, 3H), 7.27 
(t, J = 8.4 Hz, 1H), 7.14 (s, 1H), 7.12 (s, 1H), 7.04 (t, J = 7.2 Hz, 1H), 6.95 (t, J = 7.2 Hz, 
1H), 6.51 (s, 1H), 4.13 (q, J = 6.8 Hz, 2H), 4.01 (q, J =6.8 Hz, 2H), 1.21 (t, J = 6.8 Hz, 
6H);  
13C NMR (100 MHz, CDCl3): δ 196.1, 164.0, 162.7, 161.7, 139.2, 136.8, 136.7, 135.2, 
131.3, 130.8, 128.7, 127.1, 127.0, 124.8, 123.8, 122.9, 121.5, 120.9, 120.5, 119.8, 
119.6, 118.9, 118.7, 113.9, 111.7, 99.6, 62.2, 54.1, 14.1, 13.6;  
HRMS (ESI): Calculated for C32H26O6N2 [M+H
+]: 535.1864, Found: 535.1857; 
 
 
A mixture of b54 and 20%Pd(OH)2/C(0.1eq) degassed methol under hydrogen 
balloon at the room temperature for overnight. The reaction was monitored by TLC. 
Filtered Pd(OH)2/C with diatomite carefully, and concentrated to remove most of 
methol( not very dry), added water, the solution was extracted with EtOAc, the 
organic layer was washed with brine, dried over Na2SO4, and concentrated. The 
product was purifed by chromatography on silica gel eluted with a gradient of ethyl 
cyclohexane/ethyl acetate 10/1 to 4/1 to two products each 46% yield as yellow solids. 
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NHN
H
CO2Me
CO2Me
O
O
Chemical Formula: C30H24N2O6
Exact Mass: 508,1634
Molecular Weight: 508,5214  
b62: 
Yield 46%;  
Yellow solid;  
M.P.: 153-155°C;  
TLC: Rf = 0.39; cyclohexane/ethyl acetate (2:1);  
1H NMR (400 MHz, CDCl3): 　 8.06 (d, J =8.0 Hz, 1H), 7.81 (s, 1H), 7.60 (d, J =7.6 
Hz, 1H), 7.41 (d, J =8.0 Hz, 1H), 7.32 (t, J = 7.2 Hz, 1H), 7.19 (s, 1H), 7.14 (t, J = 7.6 
Hz, 1H), 7.02 (t, J =7.2 Hz, 1H), 6.96 (d, J = 7.6 Hz, 1H), 6.71-6.68 (m, 3H), 6.62 (t, J 
=7.2 Hz, 1H), 6.52 (d, J =7.2 Hz, 1H), 4.36 (d, J = 10.4 Hz, 1H), 4.29 (d, J= 12.0 Hz, 
1H), 3.62 (s, 3H), 3.52 (s, 3H), 3.32 (dt, J = 12.0, 1.6 Hz, 1H);  
13C NMR (100MHz, CDCl3): 177.5, 172.1, 156.2, 154.9, 149.0, 147.6, 133.5, 131.2, 
130.2, 130.0, 128.3, 125.7, 125.1, 124.4, 123.8, 123.2, 121.2, 120.4, 119.1, 118.1, 111.4, 
109.1, 86.1, 82.1, 57.4, 57.0, 52.4, 51.7, 50.3;  
HRMS (ESI): Calculated for C30H25 O6N2 [M+H
+]:509.1707, Found: 509.1698; 
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NHN
H
CO2Me
CO2Me
O O
Chemical Formula: C30H24N2O6
Exact Mass: 508,1634
Molecular Weight: 508,5214  
b63; 
Yield 46%;  
Yellow solid;  
M.P. : 148.1°C;  
TLC : Rf = 0.36 cyclohexane/ethyl acetate (2:1);  
1H NMR (400 MHz, CDCl3):  8.29 (s, 2H), 7.61 (t, J = 7.6 Hz, 2H), 7.53 (t, J = 7.6 
Hz, 1H), 7.40 (q, J = 7.6 Hz, 3H), 7.31 (d, J = 8.0 Hz, 1H), 7.22-7.17 (m, 2H), 7.06 (s, 
2H), 6.75 (d, J =8.0 Hz, 1H), 5.43 (s, 1H), 4.54 (d, J = 7.6 Hz, 1H), 4.23 (d, J = 7.6 Hz, 
1H), 3.46 (s, 6H);  
13CNMR (100MHz, CDCl3): 177.4, 173.0, 156.1, 154.9, 144.1, 133.3, 129.5, 129.0, 
128.9, 125.9, 124.9, 123.8, 123.3, 122.74, 122.69, 122.66, 122.35, 122.32, 122.1, 
122.0, 119.97, 119.88, 119.0, 118.1, 110.6, 59.1, 52.4, 51.9, 44.4, 34.1;  
HRMS (ESI): Calculated for C30H24 O6N2 [M+H
+]:509.1707, Found: 509.1700; 
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General procedure for synthesis of 9aH-indolo[1,2-c]pyrido[1,2-a]quinazolines (b5) 
from common precursor and bis-nucleophile b27.  
 
Triethylamine (3,0 equiv.) was added to a degassed dichloromethane (20 mL) solution 
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of ketoester (1 mmol.) and 2-(2-aminophenyl)indole (1.2 mmol.). The reaction mixture 
was stirred at room temperature for 3-5 h under argon. The color of solution turned 
straw yellow into red slowly. The reaction was monitored by TLC using 
cyclohexane/ethyl acetate (2:1) as eluent. Water (20 mL) was then added to the 
reaction mixture and the mixture extracted with ethyl acetate (2*10 mL). The 
combined organic layers were dried over anhydrous Na2SO4 and then evaporated in 
vacuo. The crude residue was purified by column chromatography over silica gel 
using cyclohexane/ethyl acetate (4:1) as eluent to afford red solid. Following is the 
spectroscopic data for the representative compounds. 
 
N
NOHO
COOMe
COOMe
C30H22N2O6
Exact Mass: 506.15
Mol. Wt.: 506.51  
b68; 
Yield 91%;  
Red solid;  
M.P.: 191°C;  
TLC: Rf = 0.39 cyclohexane/ethyl acetate (2:1);  
1H NMR (400 MHz, CDCl3): δ 11.04 (s, 1H), 8.15(s, 1H), 7.97 (d, J = 7.6 Hz, 1H), 
7.86 (d, J = 7.6 Hz, 1H), 7.63-7.56 (m, 2H), 7.49-7.45 (m, 1H), 7.33-7.31 (m, 2H), 7.13 
(d, J = 8.0 Hz, 1H), 7.10 (d, J = 7.2 Hz, 1H) 7.07 (s, 1H), 7.05-7.03 (m, 2H), 7.01 (s, 
1H), 3.94 (s, 1H), 3.74 (s, 3H) , 3.63 (s, 3H);  
13C NMR (100 MHz, CDCl3): δ 195.1, 163.9, 162.6, 161.9, 149.3, 140.1, 136.9, 135.6, 
134.4, 134.3, 131.1, 129.1, 128.8, 127.5, 127.3, 125.3, 123.1, 122.5, 121.4, 120.1, 
119.3, 119.2, 118.9, 115.7, 111.3, 101.7, 100.3, 66.7, 53.1, 52.1;  
HRMS (ESI): Calculated for C30H23O6N2 [M+H
+]:507.1551, Found: 507.1544; 
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N
NOHO
COOMe
COOMe
Cl
C30H21ClN2O6
Exact Mass: 540.11
Mol. Wt.: 540.95  
b69; 
Yield 86%;  
Red solid;  
M.P.: 169°C;  
TLC: Rf = 0.41 cyclohexane/ethyl acetate (2:1);  
1H NMR (400 MHz, CDCl3): δ 10.71 (s, 1H), 8.40(s, 1H), 8.07 (s, 1H), 7.81-7.78 (m, 
1H), 7.54 (dd, J = 6.0, 3.2 Hz, 1H), 7.44 (dd, J = 9.2, 2.4 Hz, 1H), 7.41-7.38 (m, 1H), 
7.25-7.24 (m, 1H), 7.13 (dd, J = 6.0, 3.2 Hz, 1H), 7.04 (s, 1H) 7.00-6.97 (m, 2H), 6.94 
(s, 1H), 6.92 (s, 1H), 3.97 (s, 1H), 3.69 (s, 3H), 3.56(s, 3H);   
13C NMR (100 MHz, CDCl3): δ 194.0, 163.8, 162.5, 160.2, 140.6, 149.7, 137.2, 135.6, 
135.4, 134.1, 131.7, 130.2, 129.3, 128.8, 127.6, 125.4, 124.0, 123.2, 122.5, 121.5, 
120.5, 120.4, 120.2, 115.1, 111.2, 102.0, 100.5, 66.9, 53.2, 52.2;  
HRMS (ESI): Calculated for C30H21ClO6N2 [M+H
+]: 541.1088, Found: 541.1153; 
 
 
N
NOHO
COOMe
COOMe
Me
Me
C33H28N2O6
Exact Mass: 548.19
Mol. Wt.: 548.59  
B70; 
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Yield 87%;  
Red solid;  
M.P.: 177°C;  
TLC: Rf = 0.37 cyclohexane/ethyl acetate (2:1);  
1H NMR (400 MHz, CDCl3): δ 10.86 (s, 1H), 8.19(s, 1H), 7.87-7.85 (m, 2H), 7.62 (d, 
J = 7.6 Hz, 1H), 7.46 (d, J = 7.2 Hz, 2H), 7.37-7.30 (m, 3H), 7.16 (s, 1H), 7.09-7.01 (m, 
3H), 3.95 (s, 1H), 3.74 (s, 3H), 3.64 (s, 3H), 3.00 (m, 1H), 1.35 (d, J = 7.2 Hz, 6H);  
13C NMR (100 MHz, CDCl3): δ 195.1, 163.9, 162.6, 159.9, 149.0, 140.2, 139.4, 
136.7, 135.6, 134.7, 134.4, 134.3, 129.1, 128.4, 127.5, 127.4, 125.3, 123.0, 122.5, 
121.4, 120.1, 118.8, 118.5, 115.9, 111.2, 101.5, 100.3, 66.5, 53.1, 51.9, 33.3, 24.1, 24.0; 
HRMS (ESI): Calculated for C33H29O6N2 [M+H
+]: 549.2020, Found: 549.2012; 
 
 
N
NOHO
COOEt
COOEt
C32H26N2O6
Exact Mass: 534.18
Mol. Wt.: 534.56  
B71; 
Yield 88%;  
Red solid;  
M.P.: 179°C;  
TLC: Rf = 0.48 cyclohexane/ethyl acetate (2:1);  
1H NMR (400 MHz, CDCl3): δ 10.99 (s, 1H), 8.09(s, 1H), 7.90 (d, J = 8.0 Hz, 1H), 
7.78 (d, J = 8.0 Hz, 1H), 7.55-7.48 (m, 2H), 7.39 (t, J = 7.6 Hz, 1H), 7.25-7.22 (m, 2H), 
7.18 (d, J = 2.0 Hz, 1H), 7.06 (d, J = 8.8 Hz, 1H) 7.02-6.95 (m, 3H), 6.93 (s, 1H), 4.11 
(q, J = 7.2 Hz, 2H), 4.06-3.95 (m, 3H), 1.17 (t, J = 7.2 Hz, 3H), 0.89 (t, J = 7.2 Hz, 3H); 
13C NMR (100 MHz, CDCl3): δ 195.2, 163.5, 162.03, 161.96, 149.3, 140.5, 140.0, 
135.8, 135.6, 134.5, 131.1, 129.1, 128.8, 127.6, 127.4, 125.1, 123.1, 123.0, 121.4, 
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120.1, 119.3, 119.1, 118.9, 115.6, 111.4, 102.0, 100.2, 66.7, 62.5, 61.0, 14.2, 13.5; 
HRMS (ESI): Calculated for C32H27O6N2 [M+H
+]:535.1864, Found: 535.1857; 
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N
NOHO
COOMe
C29H22N2O4
Exact Mass: 462.16
Mol. Wt.: 462.5  
b72; 
Yield 71%;  
Yellow solid;  
M.P.: 151°C;  
TLC: Rf = 0.43 hexane/EA (2:1);  
1H NMR (400 MHz, CDCl3): δ 11.16 (s, 1H), 8.25 (d, J = 2.4 Hz, 1H), 7.87 (dd, J = 
8.0, 1.6 Hz, 1H), 7.60 (s, 1H), 7.62 (d, J = 8.0 Hz, 1H), 7.45-7.36 (m, 3H), 7.29 (d, J 
= 8.0 Hz, 1H), 7.26-7.25 (m, 1H), 7.16 (dt, J = 8.0,1.6 Hz, 1H), 7.18-7.08 (m, 2H), 
6.96 (s, 1H), 6.92 (d, J = 8.0 Hz, 1H), 3.83 (s, 3H), 2.23 (s, 3H);  
13C NMR (100 MHz, CDCl3): δ 193.5, 166.1, 159.5, 146.5, 137.5, 137.4, 136.3, 
136.0, 134.0, 130.7, 128.9, 128.6, 128.3, 127.8, 125.4, 124.9, 123.4, 121.3, 120.3, 
119.6, 119.2, 118.1, 110.9, 110.4, 109.2, 99.9, 67.0, 52.4, 20.6;  
HRMS (ESI): Calculated for C29H23O4N2 [M+H
+]: 463.1652, Found: 463.1638; 
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General procedure for synthesis of benzimidazo[1,2-d]pyrido[1,2-a] 
-[1,4]diazepinium-3-carbonyl)phenolate internal salts (b78-b81) from common 
precursor 1 and bis-nucleophile b28.  
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Triethylamine (3.0 mmol.) was added to a anhydrous dichloromethane (10 mL) 
solution of ketoester (1 mmol, 1 equiv.) and 2-(1H-benzo[d]imidazol-2-yl) ethanamine 
2xHCl salt (1 mmol.). The reaction mixture was stirred at room temperature for 2-4 h 
under argon. The color of solution turned colorless into yellow slowly. The reaction 
was monitored by TLC using dichloromethane/methanol (5:1) as eluent. After 
evaporation of the solvent, the crude product was purified by column chromatography 
on silica gel with cyclohexane/ethyl acetate as the eluent.  
 
 
N
N
N
O O
O
MeOOC
Me
C25H19N3O5
Exact Mass: 441.13
Mol. Wt.: 441.44  
b77; 
Yield 91%;  
Yellow solid;  
M.P.: 154°C;  
TLC: Rf = 0.61 DCM/methol (5:1);  
1H NMR (400 MHz, CDCl3): δ 8.55 (s, 1H), 8.39 (d, J = 2.0 Hz, 1H), 7.48 (t, J = 4.0 
Hz, 2H), 7.28 (d, J = 8.0 Hz, 1H), 7.17-7.15 (m, 2H), 7.12 (s, 1H), 6.92 (d, J = 8.4 Hz, 
1H), 4.64 (t, J = 6.4 Hz, 2H), 3.89 (s, 3H), 3.54-3.52 (m, 2H), 2.18 (s, 3H) ;  
13C NMR (100 MHz, DMSO): δ 193.5, 184.2, 164.9, 160.6, 160.1, 149.7, 149.6, 
144.6, 137.7, 131.0, 128.7,123.21, 123.13, 123.12, 123.10, 121.6, 121.58, 118.5, 118.2, 
117.7, 109.8, 52.9, 49.4, 27.9, 20.4;  
HRMS (ESI): Calculated for C25H21O6N3 [M+H
+]: 460.1503, Found: 460.1495; 
 
1H, 13C and HMBC Spectra measured in DMSO-d6 solvent 
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N
N
N
O O
O
MeOOC
Me
b77
C2
C3-H
C5-H
C6-H2
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N
N
N
O O
O
MeOOC
Me Me
C27H23N3O5
Exact Mass: 469.16
Mol. Wt.: 469.49  
b78; 
Yield 82%;  
Yellow solid;  
M.P.: 149°C;  
TLC: Rf = 0.32 DCM/methol (5:1);  
1H NMR (400 MHz, CDCl3): δ 8.61 (s, 1H), 8.40 (s, 1H), 7.48 (d, J =4.0 Hz, 2H), 
7.36 (dd, J = 8.0, 2.0 Hz, 1H), 7.20 (d, J =2.4 Hz, 1H), 7.16-7.13 (m, 2H), 6.95 (d, J 
=8.8 Hz, 1H), 4.64 (t, J = 6.4 Hz, 2H), 3.85 (s, 3H), 3.54 (m, 2H), 2.87-2.68 (m, 1H), 
1.16 (d, J =6.8 Hz, 6H) ;  
13C NMR (100 MHz, DMSO): δ 193.4, 184.1, 164.9, 160.5, 160.0, 149.9, 144.7, 
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139.7, 135.1, 128.7, 123.16, 123.13, 123.12, 123.08, 123.07, 123.04, 123.01, 121.2, 
118.5, 118.2, 52.9, 49.4, 33.0, 28.0, 23.9;  
HRMS (ESI): Calculated for C27H25O6N3 [M+H
+]: 488.1816, Found: 488.1807; 
 
 
N
N
N
O O
O
MeOOC
C24H17N3O5
Exact Mass: 427.12
Mol. Wt.: 427.41  
B79; 
Yield 93%;  
Yellow solid;  
M.P.: 147°C;  
TLC: Rf = 0.40 DCM/methol (5:1);  
1H NMR (400 MHz, CDCl3): δ 8.34 (dd, J = 12.8, 2.4 Hz, 2H), 7.49 (dd, J = 5.6, 0.8 
Hz, 2H), 7.40 (t, J = 6.2 Hz, 1H), 7.17 (dd, J = 6.0, 3.2 Hz, 2H), 7.09 (dd, J = 8.0, 1.6 Hz, 
1H), 6.98 (dd, J = 8.4, 0.8 Hz, 1H), 6.48 (dt, J = 7.6, 1.2 Hz, 1H), 4.55 (t, J = 6.0 Hz, 
2H), 3.86 (s, 3H), 3.47 (t, J = 6.2 Hz, 2H);  
13C NMR (100 MHz, DMSO): δ 190.7, 185.1, 166.7, 164.8, 160.1, 155.9, 152.1, 
151.2, 151.1, 143.9, 138.3, 138.2, 133.3, 130.0, 124.0, 121.5, 119.8, 119.3, 116.76, 
116.72, 114.55, 114.50, 52.4, 48.5, 27.3;  
HRMS (ESI): Calculated for C24H19O6N3 [M+H
+]: 446.1347, Found: 446.1338; 
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N
N
N
O O
O
EtOOC
C25H19N3O5
Exact Mass: 441.13
Mol. Wt.: 441.44  
b80; 
Yield 88%;  
Yellow solid;  
M.P.: 152°C;  
TLC: Rf = 0.34 DCM/methol (5:1);  
1H NMR (400 MHz, DMSO): δ 10.33(s, 1H), 8.78 (d, J = 2.8 Hz, 1H), 8.35 (d, J = 2.8 
Hz, 1H), 7.45 (dd, J = 6.0, 3.2 Hz, 2H), 7.40 (dt, J = 7.6, 1.6 Hz, 1H), 7.24 (dd, J = 7.6, 
1.6 Hz, 1H), 7.13 (dd, J = 6.0, 3.2 Hz, 2H), 6.97 (d, J = 8.4 Hz, 1H), 6.81 (t, J = 7.2 Hz, 
1H), 4.56 (t, J = 6.8 Hz, 2H), 4.30 (q, J = 7.2 Hz, 2H), 3.29 (t, J = 6.8 Hz, 2H), 1,27 (t, 
J = 7.2 Hz, 3H);  
13C NMR (100 MHz, DMSO): δ190.7, 185.3, 164.3, 160.0, 155.9, 152.0, 151.2, 143.9, 
133.2, 130.0, 124.0, 121.4, 120.0, 119.3, 116.71, 116.68, 61.6, 48.4, 27.3, 13.7;  
HRMS (ESI): Calculated for C25H21O6N3 [M+H
+]: 460.1503, Found: 460.1491; 
 
 
A mixture of b78 and 20%Pd(OH)2/C(0.1eq) degassed methol under hydrogen 
balloon at the room temperature for overnight. The reaction was monitored by TLC, 
Filtered Pd(OH)2/C with diatomite carefully and concentrated to remove most of 
methol( not very dry), added water, the solution was extracted with EtOAc, the 
organic layer was washed with brine, dried over Na2SO4, and concentrated. The 
product was purifed by chromatography on silica gel eluted with a gradient of ethyl 
acetate /methanol 40/1 to 20/1 to 72% yield as yellow solids. 
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N
N
N
O OH
O
MeOOC
.H2O Me
C25H23N3O6
Exact Mass: 461.16
Mol. Wt.: 461.47  
b81; 
Yield 41%;  
White solid;  
M.P.: 159°C;  
TLC: Rf = 0.43 DCM/methol (10:1);  
1H NMR (400 MHz, CDCl3): δ 8.12 (s, 1H), 7.90 (s, 1H), 7.68-7.65 (m, 2H), 
7.34-7.32 (m, 2H), 7.28-7.26 (m, 2H), 6.91 (d, J = 8.0 Hz, 1H), 5.23 (s, 1H), 4.75 (s, 
1H), 4.43 (s, 1H), 3.77 (s, 2H), 3.67 (s, 3H), 2.20 (s, 3H) ;  
13C NMR (100 MHz, DMSO): δ 194.0, 172.7, 162.7, 162.5, 159.4, 156.9, 149.6, 
143.3, 137.3, 131.2, 131.1, 128.7, 128.6, 126.12, 126.09, 118.9, 118.6, 118.3, 114.2, 
70.9, 52.9, 48.6, 26.2, 20.3;  
HRMS (ESI): Calculated for C25H24O6N3 [M+H
+]: 462.1660, Found: 462.1648; 
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N
N
N
O OH
O
EtOOC
.H2O N
N
N
O OH
O
EtOOC
Ha
Hb
Hc
HMBC interactions
NOESY interactions
151.40
139.35
Ha; 5.14; 
HMBC: 129.39 (quat.)
               139.40
               161.62
               172.53
C25H23N3O6
Exact Mass: 461.16
Mol. Wt.: 461.47  
b82; 
Yield 72%;  
Yellow solid;  
M.P.: 134.1°C;  
TLC: Rf = 0.38 ethyl acetate /methanol (10:1);  
1H NMR (400 MHz, CDCl3):  11.22 (bs, 1H), 7.95 (s, 1H), 7.86 (s, 1H), 7.53 (s, 2H), 
7.42 (t, J = 8.0 Hz, 1H), 7.21-7.19 (m, 2H), 7.07 (d, J = 8.0 Hz, 1H), 6.99 (d, J =8.0 Hz, 
1H), 6.55 (d, J = 7.6 Hz, 1H), 5.15 (s, 1H), 4.56-4.42 (m, 2H), 4.27-4.17 (m, 2H), 3.44 
(t, J = 6.0 Hz, 2H), 2.91 (dd, J= 30.4, 1.6Hz, 1H), 1.25 (t, J = 7.2 Hz, 3H);  
13CNMR (100MHz, CDCl3): 194.4, 172.2, 162.1, 161.4, 150.6, 143.8, 138.7, 136.2, 
131.3, 129.1, 122.7, 119.2, 118.6, 117.2, 70.8, 62.3, 50.1, 27.9, 14.1;  
HRMS (ESI): Calculated for C25H23 O6N3 [M+H
+]:462.1660, Found: 462.1651;  
 
 
General procedure for synthesis of tetrahydro-1,4-ethanopyrido[1,2-a] -pyrimidens 
(b86) from common precurosor 1 and bis-nucleophile b26.  
 
4-aminopiperidine (1.2 equiv.) was added to a degassed dichloromethane (15 mL) 
solution of b5 (1.0 equiv., 30-40 mg scale). The reaction mixture was stirred at room 
temperature for 3-6 h under argon. The reaction was monitored by TLC using ethyl 
acetate /methol (5:1) as eluent. After evaporation of the solvent, the product was 
purified by column chromatography over silica gel with cyclohexane/ethyl acetate as 
the eluent to yield b86.  
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N
N
O
COOMe
COOMe
OH
Cl  
b86,  
Yield 87%;  
Yellow solid;  
M.P.: 173°C;  
TLC: Rf = 0.20 ethyl acetate /methol (5:1);  
1H NMR (400 MHz, CD3OD): δ 7.87-7.81 (m, 1H), 7.38-7.30 (m, 2H), 7.19 (s, 1H), 
6.93-6.81 (m, 1H), 3.82 (s, 3H), 3.74 (s, 3H), 3.53-3.44 (m, 3H), 3.18 (t, J = 12.0 Hz, 
2H), 2.26-2.18 (m, 2H), 1.93-1.86 (m, 2H);  
13C NMR (100 MHz, CDCl3): δ 193.8, 171.0, 164.0, 159.8, 146.3, 134.4, 132.9, 
130.0, 120.2, 120.0, 119.8, 114.7, 106.1, 85.2, 56.7, 54.2, 53.5, 52.0, 45.7, 35.4, 32.9;  
HRMS (ESI): Calculated for C21H21ClO6N2 [M+H
+]: 433.1161, Found: 433.1158. 
 
 
N
N
O
CO2EtEtO2C
OH
Cl  
b87; 
Yield 85%;  
Yellow solid;  
M.P.: 159°C;  
TLC: Rf = 0.18 ethyl acetate /methol (5:1);  
1H NMR (400 MHz, C DCl3): δ 7.89-7.82 (m, 1H), 7.39-7.30 (m, 2H), 7.19 (s, 1H), 
6.93-6.79 (m, 1H), 4.42-4.14 (m, 4H), 3.15 (t, J = 12.0 Hz, 2H), 2.67 (dt, J = 12.0, 1.2 
Hz, 1H), 2.55-2.53 (m, 2H), 1.73-1.65 (m, 2H), 1.34 (t, J = 7.2 Hz, 2H), 1.23 (t, J = 7.2 
Hz, 6H);  
13C NMR (100 MHz, CDCl3): δ 193.1, 167.5, 164.6, 161.3, 147.1, 136.2, 134.6, 
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130.4, 119.6, 118.6, 118.3, 111.1, 106.7, 90.5, 62.6, 60.7, 56.4, 50.4, 45.6, 33.2, 29.6, 
14.1, 13.9;  
HRMS (ESI): Calculated for C23H25ClO6N2 [M+H
+]: 461.1474, Found: 461.1465. 
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N
N
O
CO2MeMeO2C
OH
 
b88; 
Yield 86%;  
Yellow solid;  
M.P.: 178°C;  
TLC: Rf = 0.25 ethyl acetate /methol (5:1);  
1H NMR (400 MHz, CD3OD): δ 8.09 (d, J = 1.6 Hz, 1H), 7.88 (d, J = 1.6 Hz, 1H), 
7.31 (d, J = 8.4 Hz, 1H), 7.22 (d, J = 1.6 Hz, 1H), 6.87 (d, J = 8.4 Hz, 1H), 3.84(s, 3H), 
3,74 (s, 3H), 3.53-3.44 (m, 2H), 3.22-3.15 (m, 2H), 3.09-3.04 (m, 1H), 2.88 (m, J = 7.2 
Hz, 1H), 2.26-2.19 (m, 2H), 1.94-1.88 (m, 2H), 1.24 (d, J = 6.8 Hz, 6H);  
13C NMR (100 MHz, CDCl3): δ 193.3, 170.9, 166.1, 159.2, 145.3, 138.8, 133.9, 
133.3, 128.2, 119.4, 117.9, 113.7, 106.9, 85.5, 54.9, 54.2, 51.8, 45.8, 44.5, 33.2, 30.8, 
23.9, 14.8;  
HRMS (ESI): Calculated for C24H28O6N2 [M+H
+]: 441.2020, Found: 441.2015; 
 
 
N
N
O
CO2EtEtO2C
OH
 
b89; 
Yield 91%;  
Yellow solid;  
M.P.: 160°C;  
TLC: Rf = 0.21 ethyl acetate /methol (5:1);  
1H NMR (400 MHz, CDCl3): δ 8.15 (s, 1H), 7.91 (s, 1H), 7.48-7.39 (m, 2H), 7.00 (d, 
J = 8.8 Hz, 1H), 6.88 (t, J = 7.2 Hz, 1H), 4.46-4.24 (m, 2H), 4.18 (q, J = 7.2 Hz, 2H), 
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3.70-3.62 (m, 1H), 3.21-3.15 (m, 2H), 2.78-2.58 (m, 2H), 1.98-1.81 (m, 2H), 1.80-1.64 
(m, 2H), 1.27 (t, J = 7.2 Hz, 6H);  
13C NMR (100 MHz, CDCl3): δ 193.1, 167.6, 164.6, 161.3, 147.1, 136.2, 134.6, 
130.4, 119.6, 118.6, 118.4, 111.1, 106.7, 90.5, 62.6, 60.7, 56.4, 50.4, 45.6, 33.6, 29.6, 
14.1, 14.0;  
HRMS (ESI): Calculated for C23H26O6N2 [M+H
+]: 427.1864, Found: 427.1863; 
 
5.5.2.2 N, O-bisnuleophilies 
 
General procedure for synthesis of benzopyrido-oxazine b91 from common precurosor 
and bis-nucleophile b31. 
 
To a solution of keton ester (2 mmol) in anhydrous dichloromethane (15 mL/mmol) 
was added 2-aminobenzyl alcohol (2.4 mmol), and the solution was stirred at room 
temperature for 3-6 h at argon atmosphere. The color of reaction turned straw yellow 
into deep yellow after about 30 minutes. The reaction was monitored by TLC using 
cyclohexane/ethyl acetate (2:1) as eluent. Water was added to quench the reaction. The 
solution was extracted with DCM, and then washed with brine. The organic layer was 
separated, dried over Na2SO4, evaporated, and purified by column chromatography on 
silica gel using cyclohexane/ethyl acetate (4:1) as eluant to afford yellow solid. 
Following is the spectroscopic data for the representative compounds. 
 
O
N O
OH
CO2Me
CO2Me
C24H21NO7
Exact Mass: 435.13
Mol. Wt.: 435.43  
b92; 
Yield 91%;  
  Experimental section  
 197 
Yellow solid;  
M.P.: 132°C;  
TLC: Rf = 0.37 cyclohexane/ethyl acetate (2:1);  
1H NMR (400 MHz, CDCl3): δ 8.04 (d, J = 1.6 Hz, 1H), 7.97 (d, J = 1.6 Hz, 1H), 7.39 
(d, J = 2.0 Hz, 1H), 7.35-7.26 (m, 3H), 7.23 (dd, J = 7.6, 1.2 Hz, 1H), 7.13 (d, J = 7.2 Hz, 
1H), 6.95 (d, J = 8.4 Hz, 1H), 5.72 (d, J = 14.8 Hz, 1H), 5.09 (d, J = 14.8 Hz, 1H), 3.80 
(s, 3H), 3.60 (s, 3H), 2.32 (s, 3H);  
13C NMR (100 MHz, CDCl3): δ 193.6, 167.8, 165.2, 159.4, 144.3, 136.3, 135.9, 
133.9, 130.6, 129.6, 128.2, 127.8, 127.4, 125.5, 119.25, 119.15, 118.2, 114.4, 108.2, 
66.0, 53.3, 52.0, 20.6;  
HRMS (ESI): Calculated for C24H22O7N [M+H
+]: 436.1391, Found: 436.1387; 
 
 
O
N O
OH
COOEt
COOEt
Cl
C25H22ClNO7
Exact Mass: 483.11
Mol. Wt.: 483.9  
b93; 
Yield 90%;  
Yellow solid;  
M.P. : 165°C;  
TLC : Rf = 0 34 cyclohexane/ethyl acetate (2:1);  
1H NMR (400 MHz, CDCl3): δ 11.10 (s, 1H), 7.95(d, J = 1.6 Hz, 1H), 7.89 (d, J = 1.6 
Hz, 1H), 7.52 (d, J = 2.4 Hz, 1H), 7.34 (dd, J = 8.8, 2.8 Hz, 1H), 7.27 (dd, J = 7.6, 1.6 
Hz, 1H), 7.24 (td, J = 7.2, 1.6 Hz, 1H), 7.19-7.16 (m, 1H), 7.06 (d, J = 7.6 Hz, 1H), 6.93 
(d, J = 8.8 Hz, 1H), 5.63 (d, J = 14.8 Hz, 1H), 5.03 (d, J = 14.8 Hz, 1H), 4.22 (t, J = 7.2 
Hz, 2H), 4.01 (q, J = 7.2 Hz, 2H), 1.25 (t, J = 7.2 Hz, 3H), 0.92 (t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 192.2, 167.0, 164.5, 156.0, 144.5, 136.2, 134.6, 133.0, 
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129.8, 129.8, 128.2, 127.6, 125.4, 123.4, 120.4, 112.0, 119.3, 115.3, 107.7, 66.1, 62.4, 
61.0, 14.2, 13.7;  
HRMS (ESI): Calculated for C25H23O7N [M+H
+]: 484.1158, Found: 484.1150. 
 
 
O
N O
OH
COOMe
COOMe
C23H19NO7
Exact Mass: 421.12
Mol. Wt.: 421.4  
b94; 
Yield 94%;  
Yellow solid;  
M.P.: 139°C;  
TLC: Rf = 0.37 cyclohexane/ethyl acetate (2:1);  
1H NMR (400 MHz, CDCl3): δ 11.33 (s, 1H), 8.04(d, J = 1.6 Hz, 1H), 7.96 (d, J = 1.2 
Hz, 1H), 7.62 (dd, J = 8.0, 1.2 Hz, 1H), 7.47 (td, J = 7.2, 1.6 Hz, 1H), 7.36-7.28 (m, 2H), 
7.24 (d, J = 8.0 Hz, 1H), 7.12 (d, J = 7.2 Hz, 1H), 7.05 (d, J = 8.0 Hz, 1H), 6.93 (t, J = 
7.6 Hz, 1H), 5.70 (d, J = 14.8 Hz, 1H), 5.07 (d, J = 14.8 Hz, 1H), 3.80 (s, 3H), 3.59 (s, 
3H);  
13C NMR (100 MHz, CDCl3): δ 193.6, 167.7, 165.2, 161.6, 144.4, 136.2, 135.0, 
133.7, 130.7, 129.6, 128.2, 127.4, 125.4, 119.5, 119.2, 118.7, 118.5, 114.6, 108.2, 66.0, 
53.3, 52.0;  
HRMS (ESI): Calculated for C23H20O7N [M+H
+]: 422.1234, Found: 422.1232. 
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O
N O
OH
COOEt
COOEt
C25H23NO7
Exact Mass: 449.15
Mol. Wt.: 449.45  
b95; 
Yield 89%;  
Yellow solid;  
M.P.: 119°C;  
TLC: Rf = 0.49 cyclohexane/ethyl acetate (2:1);  
1H NMR (400 MHz, CDCl3): δ 11.30 (s, 1H), 8.00 (d, J = 12.0 Hz, 1H), 7.89 (d, J = 
12.0 Hz, 1H), 7.56 (t, J = 9.2 Hz, 1H), 7.42-7.39 (m, 1H), 7.27-7.18 (m, 3H), 7.06-6.99 
(m, 2H), 6.88-6.85 (m, 1H), 5.64 (d, J = 8.0 Hz, 1H), 5.01 (t, J = 8.0 Hz, 1H), 4.20 (q, J 
= 6.4 Hz, 2H), 4.00 (q, J = 6.4 Hz, 2H), 1.25 (t, J = 6.4 Hz, 3H), 0.93 (t, J = 6.4 Hz, 3H); 
13C NMR (100 MHz, CDCl3): δ 193.6, 173.6, 163.8, 158.0, 144.4, 135.01, 134.99, 
133.5, 130.8, 128.1, 127.42, 127.39, 125.42, 125.40, 119.4, 118.7, 118.6, 118.48, 
118.45, 66.1, 62.3, 61.0, 14.2, 13.7;  
HRMS (ESI): Calculated for C25H23O7N [M+H
+]: 450.1547, Found: 450.1542. 
 
 
General procedure for synthesis of benzopyrido-oxazine b91 from common precurosor 
and bis-nucleophile b31. 
 
To a solution of keton aldehyde (2 mmol) in anhydrous dichloromethane (15 
mL/mmol) was added (2-aminophenyl) methanol b31 (2.4 mmol), and the solution 
was stirred at room temperature for 3-6 h at argon atmosphere. The color of reaction 
turned straw yellow into deep yellow slowly. The reaction was monitored by TLC 
using cyclohexane/ethyl acetate (2:1) as eluent. Water was added to quench the 
reaction. The solution was extracted with DCM, and then washed with brine. The 
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organic layer was separated, dried over Na2SO4, evaporated, and purified by column 
chromatography on silica gel using cyclohexane/ethyl acetate (4:1) as eluant to afford 
yellow solid. Following is the spectroscopic data for the representative compounds. 
 
OH O
N O
CO2Me
C21H17NO5
Exact Mass: 363.11
Mol. Wt.: 363.36    
OH O
N
CO2Me
O
C21H17NO5
Exact Mass: 363.11
Mol. Wt.: 363.36  
b98; a;  +  b99; b; 
Yield 93%; (a+b) 
White solid;  
M.P.: 131-133°C;  
TLC: Rf = 0.41 cyclohexane/ethyl acetate (2:1);  
1H NMR (400 MHz, CDCl3): δ 11.39 (s, 1H), 7.98 (s, 1H), 7.97 (s, 1H), 7.58-7.55 (m, 
1H), 7.34-7.23 (m, 3H), 7.10 (t, J = 8.0 Hz, 1H), 7.02-6.99 (m, 1H), 6.94-6.86 (m, 1H), 
6.15 (s, 1H), 5.32 (d, J = 15.2 Hz, 1H), 4.96 (t, J = 15.2 Hz, 1H), 3.81 (s, 3H); 
13C NMR (100 MHz, CDCl3, a+b): δ 197.5, 193.8, 171.0, 165.7, 165.6, 161.9, 161.6, 
144.3, 141.7, 138.7, 138.6, 135.4, 135.3, 134.8, 134.3, 131.8, 130.8, 129.0, 128.7, 
127.8, 127.7, 126.7, 126.4, 125.73, 125.7, 118.8, 118.5, 118.3, 118.1, 118.0, 117.7, 
111.9, 109.0, 100.3, 81.3, 81.1, 68.3, 68.2, 50.3, 51.8, 51.5;  
HRMS (ESI): Calculated for C21H18O5N [M+H
+]: 364.1242, Found: 364.1240. 
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OH O
N O
CO2Me
Cl
C21H16ClNO5
Exact Mass: 397.07
Mol. Wt.: 397.81   
OH O
N
CO2Me
O
C21H17NO5
Exact Mass: 363.11
Mol. Wt.: 363.36
Cl
 
b100; a; + b101; b; 
 
Yield 89%; (a+b) 
White solid;  
M.P.: 142-144°C;  
TLC: Rf = 0.43 cyclohexane/ethyl acetate (2:1);  
1H NMR (400 MHz, CDCl3): δ 11.11 (bs, 1H), 7.93 (s, 1H), 7.89 (d, J = 1.6 Hz, 1H), 
7.61 (dd, J = 8.0, 1.6 Hz, 1H), 7.58 (dd, J = 8.0, 1.6 Hz, 1H), 7.37-7.34 (m, 1H), 
7.31-7.22 (m, 1H), 7.06 (t, J = 8.0 Hz, 1H), 6.91(d, J = 2.4 Hz, 1H), 6.41 (d, J = 0.8 Hz, 
1H), 3.77 (s, 3H);  
13C NMR (100 MHz, CDCl3, a+b): δ 197.5, 193.8, 171.0, 155.7, 165.6, 161.9, 161.6, 
144.3, 141.7, 138.7, 138.6, 135.4, 135.3, 134.8, 134.3, 131.8, 130.8, 129.0, 128.7, 
127.8, 127.7, 126.7, 126.4, 125.73, 125.69, 119.6, 119.5, 118.8, 118.5, 118.3, 118.0, 
117.7, 111.9, 109.0, 100.3, 81.3, 81.1, 68.3, 68.2, 51.8 ,51.5;  
HRMS (ESI): Calculated for C21H16O5NCl [M+H
+]: 397.1166, Found: 397.1165 
 
 
General procedure for synthesis of benzopyrido-oxazine b106 from common 
precurosor and bis-nucleophile b32. 
 
To a solution of keton ester b5 (2 mmol) in anhydrous dichloromethane (15 mL/mmol) 
was added 2-aminophenol b32 (2.4 mmol) and TEA (3.0 mmol), and the solution was 
stirred at room temperature for 3-6 h at argon atmosphere. The color of reaction 
turned straw yellow into deep yellow after about 1 hour. The reaction was monitored 
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by TLC using cyclohexane/ethyl acetate (2:1) as eluent. Water was added to quench 
the reaction. The solution was extracted with DCM, and then washed with brine. The 
organic layer was separated, dried over Na2SO4, evaporated, and purified by column 
chromatography on silica gel using cyclohexane/ethyl acetate (4:1) as eluant to afford 
yellow solid. Following is the spectroscopic data for the representative compounds. 
 
OOH
N
CO2Me
O
O
C21H15NO6
Exact Mass: 377.09
Mol. Wt.: 377.35  
b106; 
Yield 89%;  
White solid;  
M.P.: 151-153°C;  
TLC: Rf = 0.41 cyclohexane/ethyl acetate (2:1);  
1H NMR (400 MHz, CDCl3): δ 11.30 (bs, 1H), 8.65 (d, J = 2.8 Hz, 1H), 8.25 (d, J = 
2.8 Hz, 1H), 7.60 (d, J = 8.0 Hz, 1H), 7.53 (td, J = 8.0,1.6 Hz, 1H), 7.26-7.20 (m, 2H), 
7.06 (d, J = 8.0 Hz, 1H), 6.98-6.90 (m, 3H), 3.88(s, 3H);  
13C NMR (100 MHz, CDCl3): δ 193.9, 184.2, 164.9, 162.6, 160.7, 151.3, 150.0, 
144.7, 137.0, 131.6, 131.5, 127.3, 126.5, 123.1, 121.0, 119.5, 118.9, 118.4, 118.3, 
118.1, 53.0;  
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General procedure for synthesis of benzopyrido-oxazine b107 from common 
precurosor and bis-nucleophile b33. 
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To a solution of keton ester b5 (1 mmol) in anhydrous dichloromethane (15 mL/mmol) 
was added L-serine methyl ester b33 (1.2 mmol) and collidine (1.5 mmol), and the 
solution was stirred at room temperature for 3-6 h at argon atmosphere. The color of 
reaction turned straw yellow into deep yellow after about 1 hour. The reaction was 
monitored by TLC using cyclohexane/ethyl acetate (2:1) as eluent. Water was added to 
quench the reaction. The solution was extracted with DCM, and then washed with 
brine. The organic layer was separated, dried over Na2SO4, evaporated, and purified 
by column chromatography on silica gel using cyclohexane/ethyl acetate (4:1) as 
eluant to afford yellow solid. Following is the spectroscopic data for the representative 
compounds. 
 
N
O
O
COOMe
MeOOC OH
MeOOC
Chemical Formula: C21H21NO9
Exact Mass: 431,1216
Molecular Weight: 431,3927  
b111a; 
Yellow solid;  
M.P.: 112°C-114;  
TLC: Rf = 0.48 cyclohexane/ethyl acetate (2:1); 
1H NMR (400 MHz, CDCl3): δ 11.15 (s, 1H)，7,97 (d, J = 1.2 Hz, 1H), 7,54 (d, J = 
1.6 Hz, 1H), 7.33 (s, 1H), 7.25 (m, 1H), 6.92 (d, J = 8.4 Hz, 1H), 4,62 (m, 2H), 4.26 
(m, 1H), 3,84 (s, 3H), 3,79 (s, 3H), 3.75 (s, 3H), 2,30 (s, 3H);  
13C NMR (100 MHz, CDCl3): δ 193.1, 168.7, 167.9, 164.6, 159.4, 146.3, 136.03, 
135.98, 133.3, 130.9, 127.7, 119.3, 118.0, 113.8, 109.8, 91.5, 63.7, 62.2, 53.2, 52.0, 
20.6; 
HRMS (ESI): Calculated for C21H22O9N [M+H
+]: 432.1189, Found: 432.1190; 
Optical rotation: [α]D
25 = +53.3 (C = 0.05, MeOH). 
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N
O
O
COOMe
MeOOC OH
MeOOC
Chemical Formula: C21H21NO9
Exact Mass: 431,1216
Molecular Weight: 431,3927  
b111b; 
Yellow solid;  
M.P.: 112°C;  
TLC: Rf = 0.37 cyclohexane/ethyl acetate (2:1); 
1H NMR (400 MHz, CDCl3): δ 11.14 (s, 1H)，7,98 (d, J = 1.2 Hz, 1H), 7,66 (d, J = 
1.6 Hz, 1H), 7.33 (s, 1H), 7.25 (m, 1H), 6.93 (d, J = 8.4 Hz, 1H), 4,72 (m, 2H), 3,30 
(m, 1H), 3,80 (m, 9H), 2,30 (s, 3H);  
13C NMR (100 MHz, CDCl3): δ 193.2, 168.7, 167.9, 164.6, 161.7, 146.3, 136.1, 
133.3, 130.9, 119.6, 118.7, 118.3, 114.0, 109.8, 91.5, 63.7, 62.3, 53.3, 52.0, 29.6; 
HRMS (ESI): Calculated for C21H22O9N [M+H
+]: 432.1189, Found: 432.1192; 
Optical rotation: [α]D
25 = +33.0 (C = 0.14, MeOH). 
 
 
N
O
O
COOMe
MeOOC OH
MeOOC
Cl
Chemical Formula: C20H18ClNO9
Exact Mass: 451,0670
Molecular Weight: 451,8112  
b112a; 
Yellow solid;  
M.P.: 100-101°C;  
TLC: Rf = 0.32 cyclohexane/ethyl acetate (2:1); 
1H NMR (400 MHz, CDCl3): δ 7.92 (d, J = 1.4 Hz, 1H), 7.53 (m, 2H), 7.42 (m, 1H), 
6.97 (d, J = 8.4 Hz, 1H), 6.88 (m, 1H), 4.67 (dd, J = 5.1, 8.9 Hz, 1H), 4.56 (dd, J = 
5.1, 8.3 Hz, 1H), 4.23 (dd, J = 8.4, 8.9 Hz, 1H), 3.82 (s, 3H), 3.76 (s, 3H), 3.72 (s, 
  Experimental section  
 208 
3H);  
13C NMR (100 MHz, CDCl3): δ 193.1, 168.7, 167.8, 164.5,. 161.5, 146.5, 135.0, 
133.2, 130.9, 119.5, 118.6, 118.2, 113.9, 109.6, 91.4, 63.6, 62.2, 53.2, 51.9 ; 
HRMS (ESI): Calculated for C20H19ClO9N [M+H
+]: 452.0736, Found: 452.0736. 
Optical rotation: [α]D
25 = -20.7 (C = 0.04, MeOH). 
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N
O
O
COOMe
MeOOC OH
MeOOC
Cl
Chemical Formula: C20H18ClNO9
Exact Mass: 451,0670
Molecular Weight: 451,8112  
b112b; 
Yellow solid;  
M.P.: 158°C;  
TLC: Rf = 0.24 cyclohexane/ethyl acetate (2:1); 
1H NMR (400 MHz, CDCl3): δ 11.21 (bs, 1H), 7.88 (m, 1H), 7.52 (m, 1H), 7.44 (d, J 
= 2.6 Hz, 1H), 7.32 (dd, J = 2.6, 8.9 Hz, 1H), 6.90 (d, J = 8.9 Hz, 1H), 4.58 (m, 2H), 
4.22 (t, J = 8.2 Hz, 1H), 3.81 (s, 3H), 3.73 (s, 3H), 3.69 (s, 3H);  
13C NMR (100 MHz, CDCl3): δ 191.7, 168.5, 167.7, 164.4, 160.1, 146.6, 134.7, 
132.7, 130.0, 123.3, 120.4, 119.9, 114.2, 109.3, 91.4, 63.9, 62.0, 53.4, 52.0; 
HRMS (ESI): Calculated for C20H19ClO9N [M+H
+]: 452.0736, Found: 452.0738. 
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Optical rotation: [α]D
25 = +42.2 (C = 0.25, MeOH). 
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N
O
O
COOMe
MeOOC OH
MeOOC
Chemical Formula: C20H19NO9
Exact Mass: 417,1060
Molecular Weight: 417,3662  
b113a; 
Yellow solid;  
M.P.: 105°C;  
TLC: Rf = 0.35 cyclohexane/ethyl acetate (2:1); 
1H NMR (400 MHz, CDCl3): δ 7.96 (s, 1H), 7.56 (m, 2H), 7.44 (m, 1H), 7.16 (m, 
2H), 7.02 (d, J = 8.2 Hz, 1H), 6.90 (t, J = 7.6 Hz, 1H), 4.61 (m, 2H), 4.26 (t, J = 8.2 
Hz, 1H), 3.84 (s, 3H), 3.79 (s, 3H), 3.75 (s, 3H);  
13C NMR (100 MHz, CDCl3): δ 193.1, 168.7, 167.8, 164.5, 161.5, 146.5, 135.0, 
133.2, 130.9, 119.5, 118.6, 118.2, 113.9, 109.6, 91.4, 63.6, 62.2, 53.2, 51.9; 
HRMS (ESI): Calculated for C20H20O9N [M+H
+]: 417.3662, Found: 418.1129. 
Optical rotation: [α]D
25 = +32.4 (C = 0.09, MeOH). 
 
 
N
O
O
COOMe
MeOOC OH
MeOOC
Chemical Formula: C20H19NO9
Exact Mass: 417,1060
Molecular Weight: 417,3662  
b113b; 
Yellow solid;  
M.P.: 106°C;  
TLC: Rf = 0.28 cyclohexane/ethyl acetate (2:1); 
1H NMR (400 MHz, CDCl3): δ 7.95 (s, 1H), 7.56 (m, 2H), 7.44 (t, J = 7.7 Hz, 1H), 
6.99 (d, J = 8.4 Hz, 1H), 6.90 (t, J = 7.6 Hz, 1H), 4.61 (m, 2H), 4.25 (t, J = 8.4 Hz, 
1H), 3.84 (s, 3H), 3.78 (s, 3H), 3.74 (s, 3H);  
13C NMR (100 MHz, CDCl3): δ 193.2, 168.7, 167.8, 164.6, 161.3, 135.1, 133.3, 
130.9, 119.6, 118.6, 118.3, 114.0, 109.8, 91.5, 63.6, 62.3, 53.3, 52.0; 
HRMS (ESI): Calculated for C20H20O9N [M+H
+]: 417.3662, Found: 418.1133. 
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Optical rotation: [α]D
25 = +60.0 (C = 0.03, MeOH). 
 
 
N
O
O
COOEt
MeOOC OH
EtOOC
Chemical Formula: C22H23NO9
Exact Mass: 445,1373
Molecular Weight: 445,4193  
b114a; 
Yellow solid;  
M.P.: 109-110°C;  
TLC: Rf = 0.22 cyclohexane/ethyl acetate (2:1); 
1H NMR (400 MHz, CDCl3): δ 11.31 (bs, 1H), 7.93 (d, J = 1.4 Hz, 1H), 7.54 (m, 
2H), 7.42 (m, 1H), 6.97 (d, J = 8.4 Hz, 1H), 6.88 (t, J = 7,6 Hz, 1H), 4.60 (m, 2H), 
4.24-4,16 (m, 5H), 3.81 (s, 3H), 1,28 (t, J = 6,1 Hz, 3H), 1,25 ((t, J = 6,0 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ  193.2, 168.8, 167.4, 164.1, 161.6, 146.5, 135.0, 
132.7, 130.9, 121.4, 119.6, 118.6, 118.2, 114.6, 109.7, 91.5, 63.6, 62.1, 60.9, 53.2, 
14.2, 13.9; 
HRMS (ESI): Calculated for C22H24O9N [M+H
+]: 446.1437, Found: 446.1437. 
Optical rotation: [α]D
25 = +18.3 (C = 0.29, MeOH). 
 
 
N
O
O
COOEt
MeOOC OH
EtOOC
Chemical Formula: C22H23NO9
Exact Mass: 445,1373
Molecular Weight: 445,4193  
b114b; 
Yellow solid;  
M.P.: 122°C;  
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TLC: Rf = 0.14 cyclohexane/ethyl acetate (2:1); 
1H NMR (400 MHz, CDCl3): δ 11.36 (bs, 1H), 7.93 (d, J = 1.6 Hz, 1H), 7.54 (m, 
2H), 7.42 (m, 1H), 6.99 (d, J = 8.4 Hz, 1H), 6.88 (t, J = 8,0 Hz, 1H), 4.61 (m, 2H), 
4.24-4,16 (m, 5H), 3.81 (s, 3H), 1,28 (t, J = 7,2 Hz, 3H), 1,25 ((t, J = 7,2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ193.3, 168.8, 167.4, 164.2, 161.7, 146.3, 135.1, 
132.9, 131.0, 118.7, 118.6, 118.3, 114.7, 111.8, 109.9, 91.6, 63.7, 62.2, 60.9, 53.2, 
14.2, 13.9; 
HRMS (ESI): Calculated for C22H24O9N [M+H
+]: 446.1440, Found: 446.1442. 
Optical rotation: [α]D
25 = +15.0 (C = 0.06, MeOH). 
 
 
N
O
O
COOMe
MeOOC OH
MeOOC
Chemical Formula: C23H25NO9
Exact Mass: 459,1529
Molecular Weight: 459,4459  
b115a; 
Yellow solid;  
M.P.: 128°C;  
TLC: Rf = 0.41 cyclohexane/ethyl acetate (2:1); 
1H NMR (400 MHz, CDCl3): δ 11.08 (bs, 1H), 7.48 (d, J = 1.4 Hz, 1H), 7.32 (d, J = 
2.1 Hz, 1H), 7.26 (dd, J = 2.3, 8.5 Hz, 1H), 6.89 (d, J = 8.5 Hz, 1H), 4.56 (m, 2H), 
4.21 (t, J = 10.5 Hz, 1H), 3.77 (s, 3H), 3.73 (s, 3H), 3.70 (s, 3H), 2.81 (m, 1H), 1.17 
(d, J = 7.2 Hz, 6H);  
13C NMR (100 MHz, CDCl3): δ 193.4, 168.7, 167.9, 164.6, 159.6, 146.2, 138.9, 
133.7, 133.6, 128.4, 119.3, 118.0, 113.7, 110.0, 91.5, 63.7, 62.2, 53.3, 52.0, 33.1, 24.0, 
23.8; 
HRMS (ESI): Calculated for C23H26O9N [M+H
+]: 460.1600, Found: 460.1596. 
Optical rotation: [α]D
25 = -64.2 (C = 0.012, MeOH). 
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5.5.2.3 N, C; O, C; and C, C-bisnuleophilies 
 
General procedure for synthesis of benzoindolizine derivatives b118 from common 
precurosor and bis-nucleophile b57. 
 
To a solution of keton ester (2 mmol) in anhydrous ethanol (20 mL/mmol) was added 
di-tert-butyl 2-(2-aminophenyl)malonate (b57, 1.2 equiv.) and 2.6-lutidine (1.5 equiv.) 
followed by adding Silver triflate (10 mol%, 0.2mmol). The reaction mixture was 
stirred at preheated oil-bath at 60oC for 4-8 h under argon atmosphere because there 
was no reaction, and almost starts compounds left in the room temperature. The aim of 
the preheated oil-bath inspired the start compounds and avoided the side-reactions. The 
color of the solution turned colorless into red in this temperature quickly. The reaction 
was monitored by TLC using cyclohexane/ethyl acetate (4:1). The mixture was cooled 
to room temperature, and water was added to quench the reaction. The solution was 
evaporated under vacuum to remove the excess of ethanol. The solution was extracted 
with EtOAc, then washed with brine. The organic layer was separated, dried over 
Na2SO4, evaporated, and purified by column chromatography on silica gel using 
cyclohexane/ethyl acetate (10:1) as eluant to afford red solid. Following is the 
spectroscopic data for the representative compounds. 
 
O
N
OH
Me
ButO2C CO2tBu
CO2Me
CO2Me
C34H37NO10
Exact Mass: 619.24
Mol. Wt.: 619.66  
b119; 
Yield 83%;  
Red solid;  
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M.P.: 151°C;  
TLC: Rf = 0.45 cyclohexane/ethyl acetate (4:1); 
1H NMR (400 MHz, CDCl3): δ 7.55 (d, J = 2.0 Hz, 1H), 7.38 (d, J = 1.2 Hz, 1H), 
7.29-7.26 (m, 2H), 7.20 (dd, J = 7.6, 1.2 Hz, 1H), 7.19(d, J = 1.6 Hz, 1H), 7.02 (d, J = 
8.4 Hz, 1H), 6.91 (d, J = 8.4 Hz, 1H), 6.26 (d, J = 5.6 Hz, 1H), 4.00 (s, 3H), 3.71 (s, 3H), 
2.31 (s, 3H), 1.49 (s, 9H), 1.29 (s, 9H);  
13C NMR (100 MHz, CDCl3): δ 196.0, 167.4, 165.4, 164.9, 163.8, 159.7, 140.5, 
136.0, 134.6, 132.0, 131.6, 129.4, 127.7, 126.4, 126.3, 121.9, 119.0, 117.7, 113.6, 98.9, 
83.5, 82.8, 68.5, 53.4, 51.9, 27.8, 27.6, 20.5;  
HRMS (ESI): Calculated for C34H38O10N [M+H
+]: 620.2417, Found: 620.2487 
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O
N
OH
Cl
ButO2C CO2tBu
CO2MeCO2Me
C33H34ClNO10
Exact Mass: 639.19
Mol. Wt.: 640.08  
b120; 
Yield 79%;  
Red solid;  
M.P.: 143°C;  
TLC: Rf = 0.43 cyclohexane/ethyl acetate (4:1); 
1H NMR (400 MHz, CDCl3): δ 10.85 (s, 1H), 7.69 (s, 1H), 7.40-7.33 (m, 3H), 
7.19-7.16 (m, 2H), 7.00 (d, J = 8.0 Hz, 1H), 6.94 (d, J = 8.8 Hz, 1H), 6.25 (s, 1H), 3.99 
(s, 3H), 3.71 (s, 3H), 1.48 (s, 9H), 1.29 (s, 9H);  
13C NMR (100 MHz,CDCl3): δ 194.7, 168.4, 167.4, 164.7, 163.6, 160.1, 140.3, 135.1, 
  Experimental section  
 217 
134.79, 134.76, 131.5, 131.2, 129.4, 126.5, 126.3, 124.5, 123.5, 121.6, 120.2, 119.5, 
113.6, 83.7, 83.1, 68.5, 53.4, 51.9, 27.8, 27.6;  
HRMS (ESI): Calculated for C33H35ClO10N [M+H
+]: 641.1944, Found: 640.1935; 
 
 
O
N
OH
ButO2C CO2tBu
CO2MeCO2Me
C36H41NO10
Exact Mass: 647.27
Mol. Wt.: 647.71  
b121; 
Yield 87%;  
Red solid;  
M.P.: 156°C;  
TLC: Rf = 0.41 cyclohexane/ethyl acetate (4:1); 
1H NMR (400 MHz, CDCl3): δ 10.96 (s, 1H), 7.61 (s, 1H), 7.37 (s, 1H), 7.35 (s, 1H), 
7.32 (s, 1H), 7.30 (d, J = 1.6 Hz, 1H), 7.20 (d, J = 8.0 Hz, 1H), 7.01 (d, J = 8.0 Hz, 1H), 
6.92 (d, J = 8.4 Hz, 1H), 6.27 (s, 1H), 3.99 (s, 3H), 3.67 (s, 3H), 2.82-2.90 (m, 1H), 1.48 
(s, 9H), 1.28 (s, 9H), 1.21 (d, J = 5.2 Hz, 6H);  
13C NMR (100 MHz, CDCl3): δ 195.2, 168.3, 165.2, 164.8, 159.8, 138.7, 135.4, 
133.7, 129.5, 129,3, 128.8, 127.7, 126,5, 126.1, 121.2, 118.8, 117.6, 113.8, 109.8, 83.5, 
82.8, 68.7, 53.8, 53.4, 51.6, 33.4, 27.9, 27.6, 23.9; 
HRMS (ESI): Calculated for C36H42O10N [M+H
+]: 648.2803, Found: 648.2797; 
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O
N
OH
ButO2C CO2tBu
CO2Me
CO2Me
C33H35NO10
Exact Mass: 605.23
Mol. Wt.: 605.63  
b122; 
Yield 89%;  
Red solid;  
M.P.: 135°C;  
TLC: Rf = 0.68 cyclohexane/ethyl acetate (2:1);  
1H NMR (400 MHz, CDCl3): δ 7.78 (dd, J = 7.6, 2.0 Hz, 1H), 7.48-7.44 (m, 1H), 7.37 
(dd, J = 7.6, 0.8 Hz, 1H), 7.29-7.25 (m, 1H), 7.22-7.18 (m, 2H), 7.02 (d, J = 8.4 Hz, 2H), 
6.95 (dt, J = 7.6, 1.2 Hz, 1H), 6.27 (d, J = 1.6 Hz, 1H), 4.00 (s, 3H), 3.70 (s, 3H), 1.49 (s, 
9H), 1.28 (s, 9H); 
13C NMR (100 MHz, CDCl3): δ 193.5, 167.4, 165.2, 164.7, 163.7, 161.9, 140.5, 
135.1, 134.8, 132.1, 129.3, 126.4, 126.3, 121.9, 119.2, 118.6, 118.0, 113.6, 109.8, 98.9, 
95.9, 83.6, 82.8, 68.5, 53.4, 51.8, 27.8, 27.6;  
HRMS (ESI): Calculated for C33H36O10N [M+H
+]: 606.2334, Found: 606.2329; 
 
 
General procedure for synthesis of 8,13-dihydro-7H-benzo[2,3]azocino[4,5-b] 
indole-6-carboxylates and 10,14c-dihydroindolo[3,2-c]-pyrido[1,2-a] quinoline (b130) 
from common precursor  and bis-nucleophile b35.  
 
2-hydroxy-1,4-naphthoquinone (1,1 equiv.) was added to a degassed acetic 
anhydride/acetic acid(1:3) (4 mL) solution of ketone ester (30 mg, 1 equiv.). The 
reaction mixture was stirred at preheating oil-bath 150oC refluxing for 4min under 
argon. The color of solution turned straw yellow into red immediately. The reaction was 
monitored by TLC using cyclohexane/ethyl acetate (1:1) as eluent. The solution was 
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added 50mL water to quench the reaction and cooled down to room temperature under 
the argon protected for 2-3 hours. The excess of acetic anhydride combined with the 
water very slow, otherwise excess of acetic anhydride will interfere the following steps 
include difficult it in column. The saturation solution of Na2CO3 was added to remove 
acetic acid to PH near 7. After evaporation of the solvent, the solution was extracted 
with EtOAc, and then washed with brine. The organic layer was separated, dried over 
Na2SO4, evaporated, and purified by column chromatography on silica gel using 
cyclohexane/ethyl acetate (2:1) to offer the yellow solid. Following is the spectroscopic 
data for the representative compounds. 
 
 
O
O
O
CO2Et
CO2Et
OH
OO
Cl
C28H21ClO10
Exact Mass: 552.08
Mol. Wt.: 552.91  
b125; 
(Mixture of two diastereoisomers ~ 5:1);  
Yield 84%;  
Yellow solid;  
M.P.: 168.4°C;  
TLC: Rf = 0.44 cyclohexane/ethyl acetate (1:1);  
1H NMR (400 MHz, CDCl3): δ 8.30 (s, 1H), 8.04 (t, J = 2.8 Hz, 1H), 7.99 (s, 1H), 
7.84-7.83 (m, 1H), 7.62-7.60 (m, 2H), 7.55 (dt, J =8.8, 2.8 Hz, 1H), 7.41 (dd, J = 8.8, 
1.6 Hz, 1H), 5.24 (s, 1H), 4.42-4.36 (m, 2H), 4.31 (t, J = 7.2 Hz, 1H), 4.17-4.01 (m, 2H), 
3.97 (d, J = 10.8 Hz, 1H) , 1.38 (t, J = 7.2 Hz, 3H) , 1.15 (t, J = 7.2 Hz, 3H);  
13CNMR (100MHz, CDCl3): δ 183.4, 178.5, 175.3, 168.1, 168.0, 157.1, 154.4, 151.3, 
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133.9, 133.7, 133.2, 131.8, 131.0, 130.9, 126.2, 126.1, 125.0, 124.9, 122.3, 122.1, 
119.9, 94.6, 63.8, 61.7, 45.6, 31.2, 13.9, 13.7;  
HRMS (ESI): Calculated for C28H22O10 [M+H
+]:553.0896, Found: 553.0892; 
 
 
O
O
O
CO2Me
CO2Me
OH
OO
C29H24O10
Exact Mass: 532.14
Mol. Wt.: 532.49  
b126; 
Yield 85%;  
Yellow solid;  
M.P.: 155.7°C;  
TLC: Rf = 0.38 cyclohexane/ethyl acetate (1:1);  
1H NMR (400 MHz, CDCl3): δ 8.30 (s, 1H), 8.08 (d, J = 8.4 Hz, 1H), 7.91 (s, 1H), 
7.88-7.86 (m, 1H), 7.64-7.62 (m, 2H), 7.52 (d, J =8.4 Hz, 1H), 7.41 (d, J = 8.4 Hz, 1H), 
4.38 (d, J =10.8 Hz, 1H), 4.12 (d, J =10.8 Hz, 1H), 3.96 (s, 3H), 3.64 (s, 3H), 2.96 (m, 
1H) , 1.22 (d, J = 7.2 Hz, 6H);  
13CNMR (100MHz, CDCl3): δ 183.4, 178.6, 176.8, 168.69, 168.67, 157.1, 154.6, 
146.2, 135.4, 134.0, 133.3, 132.8, 132.0, 131.0, 126.4, 126.3, 126.2, 123.8, 122.8, 
122.1, 118.1, 94.7, 54.3, 52.6, 45.9, 33.8, 31.4, 23.9, 23.8;  
HRMS (ESI): Calculated for C29H24 O10 [M+H
+]:533.1442, Found: 533.1437; 
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O
O
O
CO2Me
CO2Me
OH
OO
Me
C27H20O10
Exact Mass: 504.11
Mol. Wt.: 504.44  
b127; 
Yield 88%;  
Yellow solid;  
M.P.: 163.4°C;  
TLC: Rf = 0.41 cyclohexane/ethyl acetate (1:1);  
1H NMR (400 MHz, CDCl3): δ 8.28 (s, 1H), 8.07 (d, J = 6.8 Hz, 1H), 7.97-7.84 (m, 
2H), 7.64-7.61 (m, 2H), 7.45 (d, J =8.8 Hz, 1H), 7.37 (d, J =8.8 Hz, 1H), 4.38 (d, J 
=10.8 Hz, 1H), 4.11 (d, J =10.8 Hz, 1H), 3.95 (s, 3H), 3.64 (s, 3H), 2.38 (s, 3H); 
13CNMR (100MHz, CDCl3): δ 183.4, 178.6, 176.6, 168.7, 168.6, 157.0, 154.4, 151.2, 
135.2, 134.9, 133.9, 133.3, 132.0, 131.0, 126.3, 126.2, 124.9, 123.7, 122.8, 121.4, 
118.0, 94.7, 54.2, 52.6, 45.9, 31.3, 20.9;  
HRMS (ESI): Calculated for C27H21 O10 [M+H
+]:505.1129, Found: 505.1123; 
O
O
O
OH
CO2Me
CO2Me
Ha
O
O
Hb nOe
Me
b127
O
O
O
CO2Me
CO2Me
OH
OO
Me
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O
O
O
CO2Me
CO2Me
OH
OO
C26H18O10
Exact Mass: 490.09
Mol. Wt.: 490.42  
b128; 
Yield 90%;  
Yellow solid;  
M.P.: 149.8°C;  
TLC: Rf = 0.22 cyclohexane/ethyl acetate (1:1);  
1H NMR (400 MHz, CDCl3): δ 7.92 (d, J = 7.6 Hz, 1H), 7.84-7.77 (m, 2H), 7.73 (d, J 
= 7.6 Hz, 1H), 7.57 (d, J = 6.8 Hz, 1H), 7.44 (dt, J =6.8, 1.6 Hz, 1H), 7.01 (dt, J =6.8, 
1.6 Hz, 1H), 6.89 (d, J =3.6 Hz, 1H), 6.55-6.53 (m, 1H), 5.85 (dd, J =9.6, 2.0 Hz, 1H), 
3.98 (d, J =11.6 Hz, 1H), 3.84 (d, J =11.6 Hz, 1H), 3.81 (s, 3H), 3.80 (s, 3H), 3.54 (d, J 
= 9.6 Hz, 1H);  
13CNMR (100MHz, CDCl3): δ 183.9, 179.3, 170.8, 169.0, 165.6, 160.5, 157.7, 148.8, 
137.8, 137.1, 136.7, 134.3, 131.6, 128.8, 127.9, 125.5, 124.9, 122.8, 121.6, 118.3, 
109.8, 83.6 62.3, 54.0, 53.2, 36.6;  
HRMS (ESI): Calculated for C26H19O10 [M+H
+]:491.0973, Found: 491.0968; 
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O
O
O
CO2Me
CO2Me
OH
OO
Cl
C27H19ClO10
Exact Mass: 538.07
Mol. Wt.: 538.89  
b129; 
Yield 86%;  
Yellow solid;  
M.P.: 163.7°C;  
TLC: Rf = 0.31 cyclohexane/ethyl acetate (1:1);  
1H NMR (400 MHz, CDCl3): δ 8.26 (s, 1H), 8.09-8.06 (m, 1H), 8.00 (s, 1H), 
7.87-7.85 (m, 1H), 7.65-7.62 (m, 2H), 7.36 (s, 1H), 4.37 (d, J =10.8 Hz, 1H), 4.06 (d, J 
=10.8 Hz, 1H), 3.96 (s, 3H), 3.88-3.86 (m, 1H), 3.65 (s, 3H);  
13CNMR (100MHz, CDCl3): δ 183.6, 179.2, 177.9, 170.1, 169.2, 157.0, 155.4, 151.5, 
134.0, 133.3, 132.0, 131.0, 126.41, 126.37, 126.2, 125.3, 123.1, 121.6, 120.00, 119.98, 
114.5, 94.6, 54.3, 52.7, 45.9, 31.3, 20.7;  
HRMS (ESI): Calculated for C27H20 O10Cl [M+H
+]:539.0740, Found: 539.0735; 
 
5.5.3 Mononucleophilic 
 
General procedure for stereoselective synthesis of substituted tricyclic benzopyrones 
(b138) from common precursor 1 and bisnucleophiles b40 and b41.  
 
N-phenylhydroxylamine (1.2 equiv.) was added to a degassed dichloromethane (15 mL) 
solution of keton ester/ keton aldehyde (30 mg, 1 equiv.). The reaction mixture was 
stirred at room temperature for 2-4 h under argon. The color of solution kept colorless 
in this process. The reaction was monitored by TLC using cyclohexane/ethyl acetate 
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(2:1) as eluent. After evaporation of the solvent, the crude product was purified by 
column chromatography on silica gel with cyclohexane/ethyl acetate as the eluent. 
Following is the spectroscopic data for the representative compounds. 
 
Triethylamine (1.5 equiv.) was added to a degassed dichloromethane (15 mL) solution 
of keton ester/ keton aldehyde (30 mg, 1 equiv.) and N-benzylhydroxylamine (1.2 
equiv.). The reaction mixture was stirred at room temperature for 2-4 h under argon. 
The color of the solution turned colorless to straw yellow. The reaction was monitored 
by TLC using cyclohexane/ethyl acetate (2:1) as eluent. After evaporation of the 
solvent, the crude product was purified by column chromatography on silica gel with 
cyclohexane/ethyl acetate (5:1) as the eluent. Following is the spectroscopic data for 
the representative compounds. 
 
O
O
H
H
MeO2C
O
O
O
O
NHPh
Chemical Formula: C23H21NO8
Exact Mass: 439,1267
Molecular Weight: 439,4147  
b134; 
Yield 93%;  
White solid;  
M.P.: 169°C;  
TLC: Rf = 0.41 cyclohexane/ethyl acetate (2:1);  
(Diastereomer ratio 84:16);  
1H NMR (400 MHz, CDCl3): 8.16 (s, 1H), 8.02 (s, 1H), 7.49 (dd, J = 8.4, 2.0 Hz, 
1H), 7.37 (d, J = 8.4Hz, 1H), 7.26-7.25 (m, 1H), 7.23-7.21 (m, 1H), 7.08 (s, 1H), 7.06 
(s, 1H), 6.96 (td, J =7.6, 0.8 Hz, 1H), 5.42 (d, J = 8.0 Hz, 1H), 4.37 (d, J = 8.0 Hz, 
1H), 3.91 (s, 3H). 3.73 (s, 3H), 2.45 (s, 3H);  
13CNMR (100MHz, CDCl3): 176.6, 168.0, 167.7, 154.6, 154.5, 151.3, 135.4, 135.1, 
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128.7, 128.6, 125.0, 123.5, 122.6, 121.5, 119.4, 117.9, 115.3, 101.6, 64.4, 60.2, 54.1, 
52.7, 20.9;  
HRMS (ESI): Calculated for C23H22O8N [M+H
+]:440.1332, Found: 440.1335; 
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O
O
H
H
H
O
O
O
O
NHBn
Chemical Formula: C22H21NO6
Exact Mass: 395,1369
Molecular Weight: 395,4052  
b135; 
Yield 87%;  
White solid;  
M.P.: 101-102°C;  
TLC: Rf = 0.33, cyclohexane/ethyl acetate (2:1);  
(Diastereomer ratio 91:9); 
1H NMR (400 MHz, CDCl3): 7.94 (s, 1H), 7.63 (s, 1H),7.42 (dd, J = 8.8, 2.4 Hz, 1H), 
7.25-7.23 (m, 3H), 7.12-7.05 (m, 3H), 5.55 (d, J = 8.8 Hz, 1H), 4.13 (d, J =14.0 Hz, 
1H), 3.94 (d, J =14.0 Hz, 1H), 4.04 (q, J =8.8 Hz, 1H), 3.84 (d, J=5.6 Hz, 1H), 3.67 (s, 
3H). 2.39 (s, 3H);  
13CNMR (100MHz, CDCl3): 177.0, 171.5, 155.1, 154.4, 136.5, 135.8, 135.5, 128.6, 
128.2, 127.3, 125.2, 123.6, 119.4, 117.7, 97.8, 66.1, 60.8, 52.6, 20.9;  
HRMS (ESI): Calculated for C22H22O6N [M+H
+]:396.1442, Found: 396.1439; 
 
 
O
O
H
H
EtOOC
O
O
O
O
NHPh
Cl
Chemical Formula: C24H22ClNO8
Exact Mass: 487,1034
Molecular Weight: 487,8864  
b136; 
Yield 90%;  
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White solid;  
M.P.: 135°C;  
TLC: Rf = 0.40 cyclohexane/ethyl acetate (2:1);  
(Diastereomer ratio 84:16);  
1H NMR (400 MHz, CDCl3): δ 8.12 (s, 2H), 7.54 (d, J = 9.2 Hz, 1H), 7.36 (d, J = 9.2 
Hz, 1H), 7.16 (t, J = 7.6 Hz, 2H), 7.00 (s, 1H), 6.98 (s, 1H), 6.89 (t, J = 7.2 Hz, 1H), 
5.34 (d, J = 7.6 Hz, 1H) 4.86 (s, 1H), 4.26 (q, J = 7.2 Hz, 2H), 4.12 (q, J = 7.2 Hz, 
2H), 1.27 (t, J = 7.2 Hz, 3H), 1.27 (q, J = 7.2 Hz, 3H);   
13C NMR (100 MHz, CDCl3): δ 175.3, 167.2, 154.9, 154.6, 151.3, 134.1, 131.4, 
128.7, 128.6, 125.2, 124.8, 122.6, 122.1, 119.9, 118.4, 115.3, 101.6, 63.9, 63.6, 61.7, 
60.3, 13.9, 13.8;  
HRMS (ESI): Calculated for C24H22Cl O8N [M+H
+]:488.1100, Found: 488.1103; 
 
 
O
O
H
H
H
O
O
O
O
NHBn
Chemical Formula: C24H25NO6
Exact Mass: 423,1682
Molecular Weight: 423,4584  
b137; 
Yield 86%;  
White solid;  
M.P. 109°C;  
TLC: Rf = 0.37 cyclohexane/ethyl acetate (2:1);  
(Diastereomer ratio 88:12);  
1H NMR (400 MHz, CDCl3): δ 8.08 (d, J = 2.0 Hz, 1H), 7.72 (s, 1H), 7.58 (dd, J = 8.4, 
2.4 Hz, 1H), 7.36 (t, J = 8.4 Hz, 1H), 7.33 (s, 1H), 7.31 (s, 1H), 7.21-7.14 (m, 3H), 5.63 
(d, J = 5.6 Hz, 1H), 4.19 (d, J =14.0 Hz, 1H), 4.03 (d, J =14.0 Hz, 1H), 3.92 (d, J = 5.6 
Hz, 1H), 3.76 (d, J = 5.6 Hz, 1H), 3.75 (s, 3H), 3.08-3.01 (m, 1H), 1.30 (d, J = 6.8 Hz, 
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6H);   
13C NMR (100 MHz, CDCl3): δ 177.6, 171.5, 155.1, 154.6, 146.8, 136.6, 133.3, 
128.6, 128.2, 127.3, 123.7, 122.6, 119.3, 117.9, 97.8, 66.2, 60.70, 60.68, 52.6, 33.8, 
23.88, 23.86;  
HRMS (ESI): Calculated for C24H25 O6N [M+H
+]:424.1755, Found: 424.1752; 
 
 
O
O
H
H
H
O
O
O
O
NHPh
Chemical Formula: C23H23NO6
Exact Mass: 409,1525
Molecular Weight: 409,4318  
b138; 
Yield 88%;  
White solid; 
M.P.: 114°C;  
TLC: Rf = 0.43 cyclohexane/ethyl acetate (2:1);  
(Diastereomer ratio 85/15); 
1H NMR (400 MHz, CDCl3): δ 8.07 (s, 1H), 7.87 (s, 1H), 7.55 (d, J = 8.4 Hz, 1H), 
7.38 (d, J = 8.4 Hz, 1H), 7.19 (s, 1H), 7.17 (s, 1H), 7.05-7.02 (m, 2H), 6.98 (t, J = 8.0 
Hz, 1H), 5.77 (br s, 1H), 4.35 (dd, J = 5.0; 1.4 Hz, 1H), 3.73 (d, J = 5.0 Hz, 1H), 3.68 (s, 
3H), 3.03-2.96 (m, 1H), 1.24 (d, J = 6.8 Hz, 6H);  
13C NMR (100 MHz, CDCl3): δ 177.1, 171.0, 155.7, 154.9, 149.4, 147.0, 133.5, 129.6, 
128.8, 126.3, 124.3, 122.7, 120.3, 118.6, 118.1, 97.8, 66.9, 61.2, 52.7, 33.8, 23.94, 
23.89;  
HRMS (ESI): Calculated for C23H24 O6N [M+H
+]:410.1598, Found: 410.1597. 
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O
O
H
H
H
O
O
O
O
NHPh
Cl
Chemical Formula: C21H18ClNO6
Exact Mass: 415,0823
Molecular Weight: 415,8237  
b139; 
Yield 89%;  
White solid;  
M.P.: 114°C;  
TLC: Rf = 0.38 cyclohexane/ethyl acetate (2:1);  
(Diastereomer ratio 81:19);  
1H NMR (400 MHz, CDCl3): δ 8.17 (s, 1H), 7.86 (s, 1H), 7.33 (s, 1H), 7.20-7.16 (m, 
3H), 7.03 (s, 1H), 7.01 (s, 1H), 6.98 (t, J = 7.2 Hz, 1H), 5.77 (br s, 1H), 4.39 (d, J = 4.8 
Hz, 1H), 3.75 (d, J = 1.0 Hz, 1H), 3.69 (d, J = 5.0 Hz, 1H), 3.68 (s, 3H), 2.46 (s, 3H); 
13C NMR (100 MHz, CDCl3): δ 175.8, 170.8, 155.7, 154.7, 144.0, 128.8, 125.6, 
125.4, 124.5, 120.6, 120.0, 119.9, 118.6, 113.9, 109.8, 97.8, 66.7, 61.1, 52.8, 20.9;  
HRMS (ESI): Calculated for C21H19Cl O6N [M+H
+]:416.0895, Found: 416.0893. 
 
 
O
O
H
H
MeOOC
O
O
O
O
NHBn
Chemical Formula: C23H21NO8
Exact Mass: 439,1267
Molecular Weight: 439,4147  
b140; 
Yield 94%;  
White solid;  
M.P.: 110-111°C;  
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TLC: Rf = 0.46 cyclohexane/ethyl acetate (2:1);  
(Diastereomer ratio 90:10) ;  
1H NMR (400 MHz, CDCl3): 8.17 (dd, J = 8.0, 1.6 Hz, 1H), 7.14 (s, 1H), 7.65 (td, J = 
8.0, 1.2 Hz, 1H), 7.44-7.42 (m, 3H), 7.38 (td, J =7.6, 1.2 Hz, 1H), 7.28-7.25 (m, 2H), 
7.22-7.18 (m, 1H), 5.00 (dd, J =6.0, 1.2 Hz, 1H), 4.87 (s, 1H), 4.57 (d, J =12.8 Hz, 1H), 
4.38 (d, J =12.8 Hz, 1H), 4.29 (d, J = 5.6 Hz, 1H), 3.81 (s, 3H), 3.79 (s, 3H);  
13C NMR (100 MHz, CDCl3): 176.8, 168.7, 168.6, 156.2, 154.4, 136.6, 133.6, 129.4, 
128.7, 128.3, 127.5, 125.6, 125.1, 123.8, 118.1, 103.1, 63.9, 63.8, 61.1, 54.0, 52.6; 
HRMS (ESI): Calculated for C23H22 O8N [M+H
+]:440.1340, Found: 440.1335; 
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O
O
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O
NHPh
Chemical Formula: C20H17NO6
Exact Mass: 367,1056
Molecular Weight: 367,3521  
b141; 
Yield 88%;  
White solid;  
M.P.: 115°C;  
TLC: Rf = 0.49 cyclohexane/ethyl acetate (2:1);  
(Diastereomer ratio 82:18);  
1H NMR (400 MHz, CDCl3): δ 8.28 (dd, J = 8.0, 1.6 Hz, 1H), 7.99 (s, 1H), 7.74 (dt, J 
= 7.2, 1.6 Hz, 1H), 7.52-7.47 (m, 2H), 7.26-7.22 (m, 1H), 7.11 (s, 1H), 7.09 (d, J = 0.8 
Hz, 1H), 7.07-7.03 (m, 2H), 5.85 (d, J = 6.8 Hz, 1H), 4.50 (d, J = 4.8 Hz, 1H), 3.78 (d, 
J = 4.8 Hz, 1H), 3.74 (s, 3H);  
13C NMR (100 MHz, CDCl3): δ 177.0, 170.9, 155.8, 149.4, 134.4, 128.7, 126.0, 125.8, 
124.3, 120.7, 118.4, 118.21, 118.19, 113.9, 97.8, 66.6, 61.1, 52.7;  
HRMS (ESI): Calculated for C20H18O6N [M+H
+]:368.1129, Found: 368.1130 
 
 
O
O
H
H
EtOOC
O
O
O
O
NHBn
Chemical Formula: C25H25NO8
Exact Mass: 467,1580
Molecular Weight: 467,4679  
b142; 
Yield 91%;  
White solid;  
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M.P.: 105°C;  
TLC: Rf = 0.40 cyclohexane/ethyl acetate (2:1);  
(Diastereomer ratio 87:13);  
1H NMR (400 MHz, CDCl3): δ 8.09 (d, J = 8.0 Hz, 1H), 8.05 (s, 1H), 7.58-7.54 (m, 
1H), 7.36-7.33 (m, 3H), 7.31-7.27 (m, 2H), 7.18 (t, J = 7.2 Hz, 1H), 7.11 (t, J = 7.2 Hz, 
1H), 4.93 (d, J = 5.9 Hz, 1H), 4.48 (d, J =13.2 Hz, 1H), 4.31 (d, J =12.8 Hz, 1H), 4.48 
(d, J = 13.0 Hz, 1H); 4.31 (d, J = 12.8 Hz, 1H); 4.20(d, J = 7.2 Hz, 1H), 4.21-4.16(m, 
4H), 1.19(t, J = 7.2 Hz, 3H), 1.09(t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 176.7, 168.3, 168.2, 156.2, 154.6, 136.7, 133.6, 
129.4, 128.5, 128.2, 128.1, 127.4, 125.6, 125.1, 118.0, 103.1, 63.7, 63.6, 63.4, 61.5, 
61.1, 14.0, 13.7;  
HRMS (ESI): Calculated for C25H26 O8N [M+H
+] : 468.1653, Found: 468.1646; 
 
 
O
O
H
H
EtOOC
O
O
O
O
NHPh
Chemical Formula: C24H23NO8
Exact Mass: 453,1424
Molecular Weight: 453,4413  
b143; 
Yield 93%;  
White solid;  
M.P.: 147°C;  
TLC: Rf = 0.39 cyclohexane/ethyl acetate (2:1);  
(Diastereomer ratio 87:13);  
1H NMR (400 MHz, CDCl3): δ 8.15 (d, J = 8.0 Hz, 1H), 8.11 (s, 1H), 7.58 (d, J = 7.2 
Hz, 1H), 7.38-7.30 (m, 2H), 7.14 (t, J = 7.2 Hz, 2H), 7.05-6.95 (m, 2H), 6.86 (t, J = 
7.2 Hz, 1H), 5.35 (t, J = 8.0 Hz, 1H), 4.98 (d, J = 7.2 Hz, 1H), 4.28 (q, J = 7.6 Hz, 
2H), 4.10 (q, J = 7.6 Hz, 2H), 1.24 (t, J = 7.6 Hz, 3H), 1.09 (t, J = 7.6 Hz, 3H);  
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13C NMR (100 MHz, CDCl3): δ 176.4, 167.3, 167.2, 156.2, 154.7, 151.3, 133.8, 
128.6, 128.5, 125.7, 125.3, 123.8, 122.4, 121.8, 118.5, 118.0, 115.3, 101.6, 64.1, 63.5, 
61.5, 60.2, 13.8, 13.7;  
HRMS (ESI): Calculated for C24H24 O8N [M+H
+]:454.1489, Found: 454.1491; 
 
 
O
O
H
H
MeOOC
O
O
O
O
NHPh
Chemical Formula: C22H19NO8
Exact Mass: 425,1111
Molecular Weight: 425,3882  
b144; 
Yield 95%;  
White solid;  
M.P.: 138°C;  
TLC: Rf = 0.61 cyclohexane/ethyl acetate (2:1);  
(Diastereomer ratio 82:18);  
1H NMR (400 MHz, CDCl3): δ 8.54 (d, J = 8.4 Hz, 1H), 8.48 (s, 1H), 7.99 (d, J = 8.0 
Hz, 1H), 7.77 (d, J = 8.8 Hz, 1H), 7.72 (t, J = 7.6 Hz, 1H), 7.56-7.52 (m, 2H), 7.38 (s, 
1H), 7.36 (s, 1H), 7.27 (t, J = 7.6 Hz, 1H), 5.72 (q, J = 8.0 Hz, 1H), 5.13(s, 1H), 
4.69(d, J = 8.0 Hz, 1H), 4.22(s, 3H), 4.03(s, 3H);  
13C NMR (100 MHz, CDCl3): δ 176.6, 168.0, 167.7, 156.4, 154.7, 151.3, 133.9, 
128.8, 128.7, 125.8, 125.7, 125.4, 123.9, 122.7, 121.8, 119.4, 118.2, 115.3, 101.6, 
64.4, 60.2, 54.2, 52.7;  
HRMS (ESI): Calculated for C22H20 O8N [M+H
+]:426.1186, Found: 426.1183; 
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NHPh
Chemical Formula: C21H19NO6
Exact Mass: 381,1212
Molecular Weight: 381,3787  
b145; 
Yield 88%;  
White solid;  
M.P.: 105°C;  
TLC: Rf = 0.40 cyclohexane/ethyl acetate (2:1);  
(Diastereomer ratio 81:19);  
1H NMR (400 MHz, CDCl3): δ 8.07 (s, 1H), 7.95 (s, 1H), 7.54 (d, J = 7.2 Hz, 1H), 
7.40 (d, J = 8.4Hz, 1H), 7.24 (t, J = 8.8Hz, 2H), 7.11 (s, 1H), 7.09 (s, 1H), 7.05 (t, J = 
7.2 Hz, 1H), 5.84 (s, 1H), 5.29 (s, 1H), 4.44 (d, J = 5.2 Hz, 1H), 3.79 (d, J =5.2 Hz, 
1H), 3.75(s, 3H), 2.48(s, 3H);  
13C NMR (100 MHz, CDCl3): δ 177.0, 171.0, 155.7, 154.7, 149.4, 136.0, 135.7, 
128.7, 125.2, 124.3, 123.7, 120.4, 118.5, 118.0, 117.9, 113.9, 97.8, 66.8, 61.1, 52.7, 
21.0;  
HRMS (ESI): Calculated for C21H20 O8N [M+H
+]: 382.1290, Found: 382.1285; 
 
 
O
O
H
H
H
O
O
O
O
NHBn
Chemical Formula: C21H19NO6
Exact Mass: 381,1212
Molecular Weight: 381,3787  
b146; 
Yield 89%;  
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White solid;  
M.P.: 132°C;  
TLC: Rf = 0.34 (cyclohexane/ethyl acetate 6:4);  
(Diastereomer ratio 88:12);  
1H NMR (400 MHz, CDCl3): 8.24 (dd, J =8.0, 1.6 Hz, 1H), 7.72 (s, 1H), 7.69 (td, J 
=8.0, 1.6 Hz, 1H), 7.46-7.41 (m, 2H), 7.33-7.30 (m, 2H), 7.19-7.13 (m, 3H), 7.04 (d, J 
= 10.8 Hz, 1H), 5.63 (d, J = 10.8 Hz, 1H), 4.22 (d, J =13.6 Hz, 1H), 4.02 (d, J =13.6 Hz, 
1H), 3.93 (d, J = 5.6 Hz, 1H), 3.75 (s, 3H), 3.94 (d, J = 5.6 Hz, 1H);  
13C NMR (100 MHz, CDCl3): 176.9, 171.4, 156.0, 155.1, 136.4, 134.2, 128.6, 128.1, 
127.3, 125.9, 125.6, 123.9, 119.6, 117.9, 97.8, 66.0, 60.8, 60.7, 52.6;  
HRMS (ESI): Calculated for C21H20O6N [M+H
+]: 382.1285, Found: 382.1287; 
 
 
O
O
H
H
MeOOC
O
O
O
O
NHBn
Chemical Formula: C24H23NO8
Exact Mass: 453,1424
Molecular Weight: 453,4413  
b147; 
Yield 94%;  
White solid;  
M.P.: 126°C;  
TLC: Rf = 0.35 cyclohexane/ethyl acetate (2:1);  
(Diastereomer ratio 86:14);  
1H NMR (400 MHz, CDCl3): 8.11 (s, 1H), 8.00 (s, 1H), 7.95 (s, 1H), 7.47 (d, J =1.6 
Hz, 1H), 7.44-7.39(m, 3H), 7.34-7.31 (m, 1H), 7.22-7.18(m, 1H), 5.06 (d, J = 2.4 Hz, 
1H), 5.01-4.99 (m, 1H), 4.58-4.36 (dd, J = 56.8, 12.8 Hz, 2H), 4.27 (dd, J = 6.0, 2.4 
Hz, 1H), 3.80 (s, 3H) , 3.79 (s, 3H) , 2.43 (s, 3H);  
13C NMR (100 MHz, CDCl3): 176.9, 168.8, 154.5, 154.3, 136.7, 134.9, 129.4, 128.3, 
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127.5, 124.9, 117.8, 103.1, 70.7, 64.0, 61.1, 54.0, 52.6, 20.9;  
HRMS (ESI): Calculated for C24H24O8N [M+H
+]: 454.1495, Found: 454.1493; 
 
 
O
O
H
H
MeOOC
O
O
O
O
NHPh
Chemical Formula: C22H18ClNO8
Exact Mass: 459,0721
Molecular Weight: 459,8332
Cl
 
b148; 
Yield 92%;  
White solid;  
M.P.: 138°C;  
TLC: Rf = 0.35 cyclohexane/ethyl acetate (2:1);  
(Diastereomer ratio 85:15);  
1H NMR (400 MHz, CDCl3): δ 8.13 (s, 2H), 7.56 (td, J = 9.2, 2.8 Hz, 1H), 7.37 (dd, 
J = 8.8, 2.8 Hz, 1H), 7.20-7.16 (m, 2H), 7.01-6.99 (m, 2H), 6.92 (t, J = 7.2 Hz, 1H), 
5.37 (d, J = 8.0 Hz, 1H), 4.77(s, 1H), 4.28 (d, J = 8.0 Hz, 1H), 3.87(s, 3H), 3.68(s, 
3H);  
13C NMR (100 MHz, CDCl3): δ 175.5, 167.8, 167.6, 154.8, 154.7, 151.2, 134.2, 
131.5, 128.8, 128.7, 125.2, 124.8, 122.8, 122.0, 119.9, 119.2, 115.3, 101.7, 64.2, 60.2, 
54.2, 52.8;  
HRMS (ESI): Calculated for C22H19ClO8N [M+H
+]:460.0795, Found: 460.0791; 
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O
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O
NHBn
Chemical Formula: C25H24ClNO8
Exact Mass: 501,1190
Molecular Weight: 501,9130
Cl
 
b149; 
Yield 88%;  
White solid; 
M.P.: 119°C;  
TLC: Rf = 0.49 cyclohexane/ethyl acetate (2:1);  
(Diastereomer ratio 86/14); 
1H NMR (400 MHz , CDCl3): δ 8.04 (d, J =6.8 Hz, 1H), 7.50 (d, J = 8.8 Hz, 1H), 
7.36-7.30 (m, 3H), 7.22 (d, J = 8.0 Hz, 1H), 7.18 (d, J =7.2 Hz, 2H), 7.12 (d, J = 7.2 Hz, 
1H), 4.91 (d, J = 5.9 Hz, 1H), 4.49 (d, J = 12.8 Hz, 1H), 4.30 (d, J = 12.8 Hz, 1H); 
4.21-4.12 (m, 5H), 1.20 (t, J = 7.2 Hz, 3H), 1.11 (t, J = 7.2 Hz, 3H);  
13CNMR (100MHz, CDCl3): δ 175.5, 168.14, 168.10, 154.8, 154.5, 136.6, 133.8, 
131.1, 129.4, 128.9, 128.3, 127.5, 125.0, 124.7, 119.8, 103.1, 63.7, 63.6, 63.4, 61.6, 
61.1, 14.0, 13.7;  
HRMS (ESI): Calculated for C25H25 ClO8N [M+H
+]: 502.1263, Found: 502.1256. 
 
 
Synthesis b154 with (Z)-methyl 3-oxo-2-((4-oxo-4H-chromen-3-yl)-methylene)- 
butanoate b150 and N-benzylhydroxylamine b40 
 
Triethylamine (1.5 equiv.) was added to a degassed dichloromethane (15 mL) solution 
of keton ester/ keton aldehyde (30 mg, 1 equiv.) and N-benzylhydroxylamine (1.2 
equiv.). The reaction mixture was stirred at room temperature for 2-4 h under argon. 
The color of the solution turned colorless to straw yellow. The reaction was monitored 
by TLC using cyclohexane/ethyl acetate (2:1) as eluent. After evaporation of the 
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solvent, the crude product was purified by column chromatography on silica gel with 
cyclohexane/ethyl acetate (5:1) as the eluent. Following is the spectroscopic data for 
the representative compounds. 
 
O
O
H
H
O
O
O
O
NHBn
Chemical Formula: C23H23NO6
Exact Mass: 409,1525
Molecular Weight: 409,4318  
b154; 
Yield 89%;  
White solid;  
M.P.: 129°C;  
TLC: Rf = 0.35 cyclohexane/ethyl acetate (2:1);  
(Diastereomer ratio 82:18);  
1H NMR (400 MHz, CDCl3): δ 8.23 (dd, J = 8.0, 1.6 Hz, 1H), 7.70 (td, J = 8.8, 2.0 
Hz, 1H), 7.65 (s, 1H), 7.45-7.38 (m, 3H), 7.33 (s, 1H), 7.31 (s, 1H), 7.17-7.09 (m, 2H), 
4.30-3.99 (dd, J = 107.6, 14.0 Hz, 2H), 4.25-4.13 (m, 2H), 4.06 (d, J = 6.0 Hz, 1H), 
3.77 (d, J = 6.0 Hz, 1H), 1.50(s, 3H), 1.28(t, J = 6.8 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 177.0, 171.6, 156.0, 122.0, 136.7, 134.2, 129.2, 
128.6, 128.3, 128.1, 127.2, 126.0, 125.6, 124.0, 119.7, 117.9, 102.7, 67.9, 62.9, 61.4, 
60.6, 20.7, 14.1;  
HRMS (ESI): Calculated for C23H24 O6N [M+H
+]:410.1600, Found: 410.1596; 
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Synthesis b158 with (Z)-methyl 3-oxo-2-((4-oxo-4H-chromen-3-yl)-methylene)- 
butanoate b150 and N-hydroxymethylamine b42 
  Experimental section  
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Triethylamine (1,5 equiv.) was added to a degassed dichloromethane (15 mL) solution 
of keton ester/ keton aldehyde (30 mg, 1 equiv.) and N-hydroxymethylamine (1.2 
equiv.). The reaction mixture was stirred at room temperature for 2-4 h under argon. 
The color of the solution turned colorless to straw yellow. The reaction was monitored 
by TLC using cyclohexane/ethyl acetate (2:1) as eluent. After evaporation of the 
solvent, the crude product was purified by column chromatography on silica gel with 
cyclohexane/ethyl acetate (5:1) as the eluent. Following is the spectroscopic data for 
the representative compounds. 
 
O
O
H
H
O
O
O
O
NHMe
Chemical Formula: C17H19NO6
Exact Mass: 333,1212
Molecular Weight: 333,3359  
b158; 
Yield 83%;  
White solid;  
M.P.: 142°C;  
TLC: Rf = 0.44 cyclohexane/ethyl acetate (2:1);  
(Diastereomer ratio 86:14);  
1H NMR (400 MHz, CDCl3): δ 8.25 (dd, J =8.0, 2.8 Hz, 1H), 7.93 (s, 1H), 7.72 (td, 
J =8.8, 2.0 Hz, 1H), 7.46 (t, J =8.4 Hz, 2H), 4.27-4.13 (m, 2H), 3.82 (s, 2H), 2.75 (s, 
3H), 1.51 (s, 3H), 1.28 (t, J = 7.2 Hz, 3H);  
13C NMR (100MHz, CDCl3): δ 177.3, 171.6, 158.3, 154.9, 134.4, 126.1, 125.8, 
124.1, 119.2, 118.1, 102.8, 70.1, 62.7, 61.4, 43.2, 20.7, 14.1;  
HRMS (ESI): Calculated for C17H20 O6N [M+H
+]:334.1300, Found: 334.1287; 
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5.5.4 Zwitterions 
 
General procedure for synthesis of substituted 3-(furan-3-yl)-4H-chromen-4-ones 
(b165) from common precursor and bisnucleophile b44.  
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Methyl isocyanoacetate (1.1 mmol.) was added to a anhydrous dichloromethane (15 
mL) solution of ketoester (1mmol). The color of solution kept color in this process.The 
reaction mixture was stirred at room temperature for 3-6 h under argon. The reaction 
was monitored by TLC using cyclohexane/ethyl acetate (2:1) as eluent. After 
evaporation of the solvent, the crude product was purified by column chromatography 
on silica gel with cyclohexane/ethyl acetate (4:1) as the eluent. Following is the 
spectroscopic data for the representative compounds. 
 
O
O
MeOOC
COOMe
HN
COOMe
O
Me
C21H19NO9
Exact Mass: 429.11
Mol. Wt.: 429.38  
b162; 
Yield 94%;  
White solid;  
M.P.: 163°C;  
TLC: Rf = 0.35 cyclohexane/ethyl acetate (2:1);  
1H NMR (400 MHz, CDCl3): δ 8.11 (s, 1H), 7.97 (s, 1H), 7.42 (d, J = 8.4 Hz, 1H), 
7.31 (d, J = 8.4 Hz, 1H), 6.29 (t, J = 5.2 Hz, 1H), 4.15 (d, J = 5.2 Hz, 2H), 3.80 (s, 3H), 
3.77 (s, 3H), 3.71 (s, 3H), 2.39 (s, 3H);  
13C NMR (100 MHz, CDCl3): δ 176.6, 170.3, 164.7, 157.9, 156.8, 154.22, 154.17, 
135.6, 135.3, 132.0, 128.7, 125.4, 123.2, 117.8, 116.4, 90.8, 52.8, 52.4, 51.7, 44.4, 
20.9;  
HRMS (ESI): Calculated for C21H20O9N [M+H
+]:430.1133, Found: 430.1130; 
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O
O
MeOOC
COOMe
HN
COOMe
O
Cl
C20H16ClNO9
Exact Mass: 449.05
Mol. Wt.: 449.8  
b163; 
Yield 91%;  
White solid;  
M.P.: 142°C;  
TLC: Rf = 0.28 cyclohexane/ethyl acetate (2:1);  
1H NMR (400 MHz, CDCl3): δ 8.23 (d, J = 2.4 Hz, 1H), 8.21 (s, 1H), 7.64 (dd, J = 9.2, 
2.8 Hz, 1H), 7.45 (d, J = 8.8 Hz, 1H), 6.23 (t, J = 5.6 Hz, 1H), 4.21 (d, J = 5.6 Hz, 2H), 
3.87 (s, 3H), 3.83 (s, 3H), 3.78 (s, 3H);  
13C NMR (100 MHz, CDCl3): δ 175.4, 170.3, 157.9, 156.8, 154.6, 154.52, 154.48, 
134.3, 134.2, 131.6, 125.7, 125.6, 124.4, 119.9, 119.8, 116.9, 52.9, 52.5, 51.8, 44.4; 
HRMS (ESI): Calculated for C20H17ClO9N [M+H
+]:450.0586, Found: 450.0585; 
 
 
O
O
MeOOC
COOMe
HN
COOMe
O
Me
Me
C23H23NO9
Exact Mass: 457.14
Mol. Wt.: 457.43  
b164; 
Yield 93%;  
White solid;  
M.P.: 157°C; 
TLC: Rf = 0.41 cyclohexane/ethyl acetate (2:1);  
1H NMR (400 MHz, CDCl3): δ 8.11(s, 1H), 8.05 (s, 1H), 7.52 (dd, J = 8.4, 1.2 Hz, 
1H), 7.35 (d, J = 8.4 Hz, 1H), 6.29 (t, J = 6.0 Hz, 1H), 4.15 (d, J = 6.4 Hz, 2H), 3.80 (s, 
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3H), 3.77 (s, 3H), 3.72 (s, 3H), 2.99 (m, J = 7.2 Hz, 1H), 1.24 (d, J = 7.2 Hz, 6H);  
13C NMR (100 MHz, CDCl3): δ 176.9, 170.4, 164.8, 157.9, 156.8, 154.4, 154.2, 
146.6, 133.1, 128.7, 126.2, 122.9, 118.0, 116.4, 109.8, 52.9, 52.5, 51.7, 44.5, 33.9, 23.9; 
HRMS (ESI): Calculated for C23H24O9N [M+H
+]:458.1446, Found: 458.1441; 
 
 
O
O
MeO2C
CO2Me
HN
CO2Me
O
C20H17NO9
Exact Mass: 415.09
Mol. Wt.: 415.35  
b165; 
Yield 95%;  
White solid;  
M.P.: 153°C;  
TLC: Rf = 0.16 cyclohexane/ethyl acetate (2:1);  
1H NMR (400 MHz, CDCl3): δ 8.27( dd, J = 8.0, 1.2 Hz, 1H), 8.19 (s, 1H), 7.69 (dt, J 
= 7.2, 1.6 Hz, 1H), 7.47 (d, J = 8.8 Hz, 1H), 7.42 (t, J = 8.0 Hz, 1H), 6.33 (t, J = 5.6 Hz, 
1H), 4.21 (d, J = 6.0 Hz, 2H), 3.86 (s, 3H), 3.82 (s, 3H), 3.77 (s, 3H);  
13C NMR (100 MHz, CDCl3): δ 175.7, 170.5, 163.8, 157.5 154.4 134.1, 134.0 126.39, 
126.37, 126.3, 125.9, 118.3, 118.1, 114.4, 109.8, 54.6, 52.9, 51.8, 44.6;  
HRMS (ESI): Calculated for C20H18O9N [M+H
+]:416.0976, Found: 416.0973; 
 
 
General procedure for synthesis of substituted (b193) from common precursor and b67. 
  
Methyl isocyanoacetate (1.1 mmol.) was added to an anhydrous dichloromethane (15 
mL) solution of ketoester (1mmol) with TEA (1.5mmol). The color of solution kept 
color in this process.The reaction mixture was stirred at room temperature for 3-6 h 
under argon. The reaction was monitored by TLC using cyclohexane/ethyl acetate (2:1) 
as eluent. After evaporation of the solvent, the crude product was purified by column 
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chromatography on silica gel with cyclohexane/ethyl acetate (4:1) as the eluent. 
Following is the spectroscopic data for the representative compounds. 
 
OH O
COOMe
COOMe
COOMe
Chemical Formula: C20H18O8
Exact Mass: 386,1002
Molecular Weight: 386,3521  
b170; 
Yield 93%;  
White solid;  
M.P.: 143°C;  
TLC: Rf = 0.22 cyclohexane/ethyl acetate (5:1); 
1H NMR (400 MHz, CDCl3): δ 11,54 (s, 1H), 8,46(s, 2H),7,39 (dd, J = 1,8 & 8,5 Hz, 
1H), 7,16 (s, 1H), 7,02 (d, J = 8,5 Hz, 1H), 4,05 (s, 3H), 3,94 (s, 6H), 2,25 (s, 3H);  
13C NMR (100 MHz, CDCl3): δ 198.7, 167.9, 164.3, 161.4, 138.9, 138.5, 134.1, 
132.5, 129.0, 128.5, 53.11, 53.08, 20.5; 
HRMS (ESI): Calculated for C20H17O8 [M-H
+]:385.0927, Found: 385.0924 
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OH O
COOMe
COOMe
COOMeCl
Chemical Formula: C19H15ClO8
Exact Mass: 406,0455
Molecular Weight: 406,7706  
b171; 
Yield 89%; 
White solid;  
M.P.: 148°C;  
TLC: Rf = 0.21 cyclohexane/ethyl acetate (5:1); 
1H NMR (400 MHz, CDCl3): δ 11,60 (s, 1H), 8,47(s, 2H),7,52 (d, J = 9,0 Hz, 1H), 
7,38 (m, 1H), 7,08 (dd, J = 1,1&8,9 Hz, 1H), 4,05 (s, 3H), 3,95 (s, 6H);  
13C NMR (100 MHz, CDCl3): δ 197.8, 167.7, 164.1, 161.9, 139.5, 138.0, 137.2, 
134.1, 131.7, 129.3, 124.1, 120.5, 119.1, 109.8, 53.17, 53.14; 
HRMS (ESI): Calculated for C19H14ClO8 [M-H
+]:405.0383, Found: 405.0380. 
 
 
OH O
COOMe
COOMe
COOMe
Chemical Formula: C22H22O8
Exact Mass: 414,1315
Molecular Weight: 414,4053  
b172; 
Yield 91%; 
White solid;  
M.P.: 154°C;  
TLC: Rf = 0.18 cyclohexane/ethyl acetate (5:1); 
1H NMR (400 MHz, CDCl3): δ 11,52 (s, 1H), 8,54(s, 2H),7,45 (dd, J = 8.6, 1.2Hz, 
1H), 7,28 (m, 1H), 7,05 (d, J = 8,6 Hz, 1H), 4,05 (s, 3H), 3,94 (s, 6H), 2,83 (m, 1H), 
1,19 (d, J = 6,9 Hz, 6H);  
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13C NMR (100 MHz, CDCl3): δ 193.8, 168.0, 164.2, 161.6, 139.6, 138.7, 136.0, 
134.7, 130.1, 129.0, 118.6, 118.1, 53.12, 53.04, 33.1, 23.9 ; 
HRMS (ESI): Calculated for C22H22O8 [M-H
+]:413.1240, Found: 413.1238 
 
 
OH O
COOMe
COOMe
COOMe
Chemical Formula: C19H16O8
Exact Mass: 372,0845
Molecular Weight: 372,3255  
b173; 
Yield 94%; 
White solid;  
M.P.: 140°C;  
TLC: Rf = 0.19 cyclohexane/ethyl acetate (5:1); 
1H NMR (400 MHz, CDCl3): δ 11,72 (s, 1H), 8,48(s, 2H),7,57 (m, 1H), 7,43 (dd, J = 
8.0, 1.7 Hz, 1H), 7,12 (dd, J = 0,7 & 8,4 Hz, 1H), 6,92 (m, 1H), 4,03 (s, 3H), 3,94 (s, 
6H);  
13C NMR (100 MHz, CDCl3): δ 198.6, 167.8, 164.2, 163.4, 138.7, 137.3, 134.3, 
132.9, 129.0, 119.3, 118,8. 118.5, 50.1; 
HRMS (ESI): Calculated for C19H15O8 [M-H
+]:371.0769, Found: 371.0769; 
 
 
General procedure for synthesis of diisopropyl 3-(4-oxo-4H-chromen-3-yl) 
-1H-pyrazole-1,2(3H)-dicarboxylates (b177) from common precursor and 
bisnucleophile b47.  
 
Triphenylphosphine (1.3 mmol.) was added to an anhydrous THF (15 mL) solution of 
keton ester (1 mmol.) and Diisopropyl azodicarboxylate (1.2 mmol.) at the argon 
atmosphere. The reaction mixture was stirred at room temperature for 2-5 h under argon. 
The color of solution turned straw yellow to deep yellow immediately, then tuned to 
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straw yellow slowly. The reaction was monitored by TLC using cyclohexane/ethyl 
acetate (2:1) as eluent. After evaporation of the solvent, the crude product was purified 
by column chromatography on silica gel with cyclohexane/ethyl acetate (4:1) as the 
eluent to offer yellow solid.  
 
O
O
N
N
CO2iPr
CO2iPr
MeOOC
COOMe
Cl
C24H25ClN2O10
Exact Mass: 536.12
Mol. Wt.: 536.92  
b177; 
Yield 86%;  
Yellow solid;  
M.P.: 121°C;  
TLC: Rf = 0.39 cyclohexane/ethyl acetate (2:1);  
1H NMR (400 MHz, CDCl3): δ 8.05 (d, J = 2.4 Hz, 1H), 7.93 (s, 1H), 7.50 (dd, J = 8.8, 
2.4 Hz, 1H), 7.33 (d, J = 8,8 Hz, 1H), 5.63 (s, 1H), 5.08 (d, J = 2.4 Hz, 1H), 4.94 (d, J = 
2.4 Hz, 1H), 3.89 (s, 3H), 3.60 (s, 3H), 1.34-1.25 (m, 12H);  
13C NMR (100 MHz, CDCl3): δ 173.5, 162.5, 162.0, 154.5, 154.4, 152.8, 146.5, 
133.9, 131.2, 125.6, 125.5, 120.9, 120.4, 119.8, 119.7, 109.8, 72.2, 71.7, 63.0, 53.2, 
52.1, 22.0, 21.9, 21.8;  
HRMS (ESI): Calculated for C24H26ClO10N2 [M+H
+]: 537.1271, Found: 537.1263; 
 
 
O
O
N
N
CO2iPr
CO2iPr
EtOOC
COOEt
Cl
C26H29ClN2O10
Exact Mass: 564.15
Mol. Wt.: 564.97  
b178; 
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Yield 84%;  
Yellow solid;  
M.P.: 130°C;  
TLC: Rf = 0.43 cyclohexane/ethyl acetate (2:1);  
1H NMR (400 MHz, CDCl3): δ 8.02 (d, J = 2.8 Hz, 1H), 7.92 (s, 1H), 7.49 (dd, J = 9.2 , 
2.4 Hz, 1H), 7.31 (d, J = 8.8 Hz, 1H), 5.64 (s, 1H), 5.08 (d, J = 2.4 Hz, 1H), 4.93 (d, J = 
2.4 Hz, 1H), 4.34(q, J = 7.2 Hz, 2H), 4.05(q, J = 7.2 Hz, 2H), 1.34 (t, J = 7.2 Hz, 3H), 
1.29-1.20 (m, 12H), 1.13 (t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 174.4, 161.5, 160.1, 156.6, 154.4, 154.3, 153.0,142.4, 
133.7, 131.1, 125.5, 125.3, 121.0, 119.7, 110.6, 72.0, 71.5, 62.9, 62.5, 60.9, 21.9, 21.8, 
21.7, 21.7, 13.9, 13.8;  
HRMS (ESI): Calculated for C26H30ClO10N2 [M+H
+]:565.1584, Found: 565.1579; 
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O
O
N
N
CO2iPr
CO2iPr
MeO2C
CO2Me
C24H26N2O10
Exact Mass: 502.16
Mol. Wt.: 502.47  
b179; 
Yield 91%;  
Yellow solid;  
M.P.: 156°C;  
TLC: Rf = 0.41 cyclohexane/ethyl acetate (2:1);  
1H NMR (400 MHz, CDCl3): δ 8.14 (d, J = 8.0 Hz, 1H), 7.99 (d, J = 2.0 Hz, 1H), 7.62 
(d, J = 8.0 Hz, 1H), 7.40 (d, J = 8.4 Hz, 1H), 7.34 (t, J = 8.0 Hz, 1H), 5.70 (s, 1H), 5.14 
(d, J = 2.4 Hz, 1H), 4.99 (d, J = 2.4 Hz, 1H), 3.95 (s, 3H), 3.65 (s, 3H), 1.34-1.25 (m, 
12H);  
13C NMR (100 MHz, CDCl3): δ 175.7, 162.0, 160.8, 156.6, 156.1, 154.3, 153.2, 
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142.6, 133.6, 126.0, 125.1, 124.6, 120.8, 117.9, 111.0, 72.0, 71.5, 63.1, 53.2, 52.0, 21.9, 
21.8, 21.74, 21.71;  
HRMS (ESI): Calculated for C24H27O10N2 [M+H
+]:503.1587, Found: 503.1654; 
 
 
O
O
N
N
CO2iPr
CO2iPr
EtO2C
CO2Et
C26H30N2O10
Exact Mass: 530.19
Mol. Wt.: 530.52  
b180; 
Yield 89%;  
Yellow solid;  
M.P.: 126°C;  
TLC: Rf = 0.36 cyclohexane/ethyl acetate (2:1);  
1H NMR (400 MHz, CDCl3): δ 8.11 (d, J = 8.0 Hz, 1H), 7.94 (s, 1H), 7.58 (d, J = 7.2 
Hz, 1H), 7.37 (dd, J = 8.0, 2.0 Hz, 1H), 7.30 (t, J = 8.0 Hz, 1H), 5.67 (s, 1H), 5.11 (d, J 
= 2.4 Hz, 1H), 4.97 (d, J = 2.4 Hz, 1H), 4.38 (t, J = 7.2 Hz, 2H), 4.08 (t, J = 7.2 Hz, 2H), 
1.36 (t, J = 7.2 Hz, 3H), 1.31-1.21 (m, 12H), 1.16 (t, J = 7.2 Hz, 3H);  
13C NMR (100 MHz, CDCl3): δ 175.5，161.6，160.3，156.7, 156.1，154.3，153.3, 
142.4，133.5，126.1，125.1，124.7，121.0，117.9，111.2，71.9，71.4，63.1，
62.6，60.9，22.0，21.9，21.79，21.76, 14.0，13.9;  
HRMS (ESI): Calculated for C26H31O10N2 [M+H
+]:531.1973, Found: 531.1965; 
 
 
General procedure for synthesis of (b184) from common precursor and bisnucleophile 
b47.  
Triphenylphosphine (1.3 mmol.) was added to a anhydrous THF (15 mL) solution of 
aldehyde (1 mmol.) and Diisopropyl azodicarboxylate (1.2 mmol.) at the argon 
atmosphere. The reaction mixture was stirred at room temperature for 2-5 h under argon. 
The color of solution turned straw yellow to deep yellow immediately, then tuned to 
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straw yellow slowly. The reaction was monitored by TLC using cyclohexane/ethyl 
acetate (2:1) as eluent. After evaporation of the solvent, the crude product was purified 
by column chromatography on silica gel with cyclohexane/ethyl acetate(4:1) as the 
eluent to offer yellow solid.  
 
O
O
N
N
CO2iPr
CO2iPr
MeO2C
H
C22H24N2O8
Exact Mass: 444.15
Mol. Wt.: 444.43  
b184; 
Yield 86%;  
Yellow solid;  
M.P.: 156°C;  
TLC: Rf = 0.45 cyclohexane/ethyl acetate (2:1);  
1H NMR (400 MHz, CDCl3): δ 8.00 (dd, J = 8.0, 1.6 Hz, 1H), 7.95 (s, 1H), 7.67 (s, 
1H), 7.52 (dt, J = 7.2, 1.6 Hz, 1H), 7.30 (d, J = 8.4 Hz, 1H), 7.24 (t, J = 7.2 Hz, 1H), 
5.63 (m, J = 1.2 Hz, 1H), 5.08 (m, J =2.4 Hz, 1H), 4.93 (d, J = 2.4 Hz, 1H), 3.56 (s, 3H), 
1.26-1.14 (m, 12H);  
13C NMR (100 MHz, CDCl3): δ 175.6, 162.7, 156.6, 156.1, 155.8, 154.1, 139.1, 
133.3, 125.4, 124.9, 124.3, 120.6, 117.7, 110.1, 71.3, 71.0, 62.9, 51.2, 21.64, 21.61, 
21.60, 21.5;  
HRMS (ESI): Calculated for C22H25O8N2 [M+H
+]:445.1605, Found: 445.1600; 
 
 
O N N
O COOMe
PriO2C
CO2iPr
C22H24N2O8
Exact Mass: 444.15
Mol. Wt.: 444.43  
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b185; 
Yield 13%;  
White solid;  
M.P.: 147°C;  
TLC: Rf = 0.50 hexane/EA (2:1);  
1H NMR (400 MHz, CDCl3): δ 8.86 (s, 1H), 8.06 (s, 1H), 8.03 (dd, J = 7.6, 1.6 Hz, 
1H), 7.54-7.51 (m, 1H), 7.11-7.03 (m, 2H), 5.74 (s, 1H), 5.03-4.97 (m, 1H), 4.77-4.71 
(m, 1H), 3.85 (s, 3H), 1.44-1.39 (m, 6H), 1.30-1.23 (m, 6H);  
13C NMR (100 MHz, CDCl3): δ 177.4, 166.3, 158.9, 143.1, 137.3, 135.9, 130.9, 
129.4, 127.1, 122.4, 121.9, 119.1, 117.3, 106.4, 89.7, 74.3, 72.3, 52.6, 21.72, 21.69, 
20.9, 20.7;  
HRMS (ESI): Calculated for C22H25O8N2 [M+H
+]: 445.1605, Found: 445.1602; 
 
 
O
O
N
N
CO2iPr
CO2iPr
MeOOC
C23H26N2O8
Exact Mass: 458.17
Mol. Wt.: 458.46  
b186; 
Yield 73%;  
White solid;  
M.P.: 156°C;  
TLC: Rf = 0.45 hexane/EA (2:1);  
1H NMR (400 MHz, CDCl3): δ 7.92 (s, 1H), 7.77 (s, 1H), 7.64 (s, 1H), 7.31 (dd, J = 
8.8, 2.0 Hz, 1H), 7.21 (dd, J = 8.8, 2.0 Hz, 1H), 5.61 (s, 1H), 5.07-5.04 (m, 1H), 
4.91-4.88 (m, 1H), 3.54 (s, 3H), 2.28 (s, 3H), 1.14 (d, J = 6.8 Hz, 6H), 1.13 (d, J = 6.8 
Hz, 6H);  
13C NMR (100 MHz, CDCl3): δ 175.7, 162.8, 156.6, 156.3, 154.1, 154.0, 139.0, 
134.8, 134.5, 124.7, 124.0, 120.3, 117.4, 110.1, 71.0, 62.9, 51.1, 21.60, 21.57, 21.51;  
HRMS (ESI): Calculated for C23H27O8N2 [M+H
+]: 459.1762, Found: 459.1761; 
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O N N
O COOMe
PriO2C
CO2iPr
C23H26N2O8
Exact Mass: 458.17
Mol. Wt.: 458.46  
b187; 
Yield 11%;  
White solid;  
M.P.: 142°C;  
TLC: Rf = 0.47 hexane/EA (2:1);  
1H NMR (400 MHz, CDCl3): δ 8.85 (s, 1H), 8.04 (s, 1H), 7.82 (s, 1H), 7.33 (d, J = 
8.4 Hz, 1H), 6.94 (d, J = 8.4 Hz, 1H), 5.70 (s, 1H), 5.17-5.15 (m, 1H), 4.74-4.73 (m, 
1H), 3.65 (s, 3H), 2.33 (s, 3H), 1.43-1.39 (m, 6H), 1.31-1.14 (m, 6H);  
13C NMR (100 MHz, CDCl3): δ 177.5, 157.1, 153.8, 143.0, 141.9, 137.0, 131.3, 
129.13, 129.12, 129.10, 126.5, 118.7, 117.2, 117.1, 89.7, 74.3, 72.3, 52.6, 21.73, 
21.70, 20.9, 20.7, 20.4;  
HRMS (ESI): Calculated for C23H27O8N2 [M+H
+]: 459.1762, Found: 459.1758; 
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